U.S. patent application number 17/409644 was filed with the patent office on 2022-07-21 for hydroxylated and methoxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors.
This patent application is currently assigned to Array BioPharma Inc.. The applicant listed for this patent is Array BioPharma Inc., Genentech, Inc.. Invention is credited to Josef R. Bencsik, James F. Blake, Christine Chabot, Steven Do, Nicholas C. Kallan, Anna L. Leivers, Jun Liang, Ian S. Mitchell, Brian Safina, Stephen T. Schlachter, Keith Lee Spencer, Eli M. Wallace, Dengming Xiao, Rui Xu, Birong Zhang.
Application Number | 20220226326 17/409644 |
Document ID | / |
Family ID | |
Filed Date | 2022-07-21 |
United States Patent
Application |
20220226326 |
Kind Code |
A1 |
Mitchell; Ian S. ; et
al. |
July 21, 2022 |
HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT
PROTEIN KINASE INHIBITORS
Abstract
The present invention provides compounds, including resolved
enantiomers, resolved diastereomers, solvates and pharmaceutically
acceptable salts thereof, comprising the Formula I: ##STR00001##
Also provided are methods of using the compounds of this invention
as AKT protein kinase inhibitors and for the treatment of
hyperproliferative diseases such as cancer.
Inventors: |
Mitchell; Ian S.; (Boulder,
CO) ; Blake; James F.; (Boulder, CO) ; Xu;
Rui; (Boulder, CO) ; Kallan; Nicholas C.;
(Boulder, CO) ; Xiao; Dengming; (Boulder, CO)
; Spencer; Keith Lee; (Boulder, CO) ; Bencsik;
Josef R.; (Boulder, CO) ; Wallace; Eli M.;
(Boulder, CO) ; Schlachter; Stephen T.; (Boulder,
CO) ; Leivers; Anna L.; (Boulder, CO) ; Liang;
Jun; (South San Francisco, CA) ; Safina; Brian;
(South San Francisco, CA) ; Zhang; Birong; (South
San Francisco, CA) ; Chabot; Christine; (South San
Francisco, CA) ; Do; Steven; (South San Francisco,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Array BioPharma Inc.
Genentech, Inc. |
Boulder
South San Francisco |
CO
CA |
US
US |
|
|
Assignee: |
Array BioPharma Inc.
Boulder
CO
Genentech, Inc.
South San Francisco
CA
|
Appl. No.: |
17/409644 |
Filed: |
August 23, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16736078 |
Jan 7, 2020 |
|
|
|
17409644 |
|
|
|
|
15670874 |
Aug 7, 2017 |
|
|
|
16736078 |
|
|
|
|
15140874 |
Apr 28, 2016 |
|
|
|
15670874 |
|
|
|
|
14458062 |
Aug 12, 2014 |
9359340 |
|
|
15140874 |
|
|
|
|
13272079 |
Oct 12, 2011 |
8853199 |
|
|
14458062 |
|
|
|
|
11773949 |
Jul 5, 2007 |
8063050 |
|
|
13272079 |
|
|
|
|
60818718 |
Jul 6, 2006 |
|
|
|
International
Class: |
A61K 31/517 20060101
A61K031/517; C07D 401/12 20060101 C07D401/12; C07D 403/12 20060101
C07D403/12; C07D 405/12 20060101 C07D405/12; C07D 409/12 20060101
C07D409/12; C07D 409/14 20060101 C07D409/14; C07D 239/70 20060101
C07D239/70; C07D 413/12 20060101 C07D413/12; C07D 407/12 20060101
C07D407/12 |
Claims
1. A compound of Formula I: ##STR00423## and tautomers, resolved
enantiomers, resolved diastereomers, solvates, metabolites, and
salts thereof, wherein: R.sup.1 is H, Me, Et, vinyl, CF.sub.3,
CHF.sub.2 or CH.sub.2F; R.sup.2 is H or Me; R.sup.5 is H, Me, Et,
or CF.sub.3; A is ##STR00424## G is phenyl optionally substituted
by one to four R.sup.9 groups or a 5-6 membered heteroaryl
optionally substituted by a halogen; R.sup.6 and R.sup.7 are
independently H, OCH.sub.3, (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2), (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2CH.sub.2), V--(CH.sub.2).sub.0-1 wherein V is
a 5-6 membered heteroaryl, W--(CH.sub.2).sub.1-2 wherein W is
phenyl optionally substituted with F, Cl, Br, I, OMe, CF.sub.3 or
Me, C.sub.3-C.sub.6-cycloalkyl optionally substituted with
C.sub.1-C.sub.3 alkyl or O(C.sub.1-C.sub.3 alkyl),
hydroxy-(C.sub.3-C.sub.6-cycloalkyl),
fluoro-(C.sub.3-C.sub.6-cycloalkyl), CH(CH.sub.3)CH(OH)phenyl, 4-6
membered heterocycle optionally substituted with F, OH,
C.sub.1-C.sub.3 alkyl, cyclopropylmethyl or
C(.dbd.O)(C.sub.1-C.sub.3 alkyl), or C.sub.1-C.sub.6-alkyl
optionally substituted with one or more groups independently
selected from OH, oxo, O(C.sub.1-C.sub.6-alkyl), CN, F, NH.sub.2,
NH(C.sub.1-C.sub.6-alkyl), N(C.sub.1-C.sub.6-alkyl).sub.2,
cyclopropyl, phenyl, imidazolyl, piperidinyl, pyrrolidinyl,
morpholinyl, tetrahydrofuranyl, oxetanyl or tetrahydropyranyl, or
R.sup.6 and R.sup.7 together with the nitrogen to which they are
attached form a 4-7 membered heterocyclic ring optionally
substituted with one or more groups independently selected from OH,
halogen, oxo, CF.sub.3, CH.sub.2CF.sub.3, CH.sub.2CH.sub.2OH,
O(C.sub.1-C.sub.3 alkyl), C(.dbd.O)CH.sub.3, NH.sub.2, NHMe,
N(Me).sub.2, S(O).sub.2CH.sub.3, cyclopropylmethyl and
C.sub.1-C.sub.3 alkyl; R.sup.a and R.sup.b are H, or R.sup.a is H,
and R.sup.b and R.sup.6 together with the atoms to which they are
attached form a 5-6 membered heterocyclic ring having one or two
ring nitrogen atoms; R.sup.c and R.sup.d are H or Me, or R.sup.c
and R.sup.d together with the atom to which they are attached form
a cyclopropyl ring; R.sup.8 is H, Me, F or OH, or R.sup.8 and
R.sup.6 together with the atoms to which they are attached form a
5-6 membered heterocyclic ring having one or two ring nitrogen
atoms; each R.sup.9 is independently halogen,
C.sub.1-C.sub.6-alkyl, C.sub.3-C.sub.6-cycloalkyl,
O--(C.sub.1-C.sub.6-alkyl), CF.sub.3, OCF.sub.3,
S(C.sub.1-C.sub.6-alkyl), CN, OCH.sub.2-phenyl, CH.sub.2O-phenyl,
NH.sub.2, NH--(C.sub.1-C.sub.6-alkyl),
N--(C.sub.1-C.sub.6-alkyl).sub.2, piperidine, pyrrolidine,
CH.sub.2F, CHF.sub.2, OCH.sub.2F, OCHF.sub.2, OH,
SO.sub.2(C.sub.1-C.sub.6-alkyl), C(O)NH.sub.2,
C(O)NH(C.sub.1-C.sub.6-alkyl), and
C(O)N(C.sub.1-C.sub.6-alkyl).sub.2; R.sup.10 is H or Me; and m, n
and p are independently 0 or 1.
2-76. (canceled)
77. A pharmaceutical composition comprising a compound as claimed
in claim 1.
78. A method of treating an AKT-mediated disease or disorder in a
mammal, said method comprising administering to said mammal a
therapeutically effective amount of a compound as claimed in claim
1.
79. The method of claim 76, wherein said disease or disorder is an
inflammatory, hyperproliferative, cardiovascular,
neurodegenerative, gynecological, or dermatological disease or
disease,
80. A method of inhibiting the production of AKT protein kinase in
a mammal, which comprises administering to said mammal an effective
amount of a compound as claimed in claim 1.
81. A method of inhibiting the activity of AKT protein kinase in a
mammal, which comprises contacting said kinase with a compound as
claimed in claim 1.
82. A kit for treating an AKT protein kinase-mediated condition,
wherein said kit comprises: a) a first pharmaceutical composition
comprising a compound as claimed in claim 1; and b) optionally
instructions for use.
83. A method of preparing a compound as claimed in claim 1, said
method comprising: reacting a compound having the formula:
##STR00425## with a compound having the formula ##STR00426##
84. A method of treating cancer in a mammal in need thereof, the
method comprising administering to the mammal an effective amount
of a compound selected from the group consisting of:
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
or a salt thereof;
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(methyl(tetrahydro-2H-pyran-4--
yl)amino)propan-1-one or a salt thereof;
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(3-hydroxyazetidin-1-yl)propan-
-1-one or a salt thereof;
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-((R)-pyrrolidin-3-ylamino)prop-
an-1-one or a salt thereof;
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-((S)-pyrrolidin-3-ylamino)prop-
an-1-one or a salt thereof;
(S)-3-(1-acetylpiperidin-4-ylamino)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hy-
droxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)p-
ropan-1-one or a salt thereof; and
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(tetrahydro-2H-pyran-4-ylamino-
)propan-1-one or a salt thereof.
85. The method of claim 84, comprising administering to the mammal
an effective amount of
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
or a salt thereof.
86. A method of treating an inflammatory, hyperproliferative,
cardiovascular, neurodegenerative, gynecological, or dermatological
disease in a mammal, the method comprising administering to the
mammal a therapeutically effective amount of the compound of
Formula (I), a tautomer thereof, a resolved enantiomer thereof, a
resolved diastereomer thereof, or a salt thereof; wherein the
compound of Formula (I) is: ##STR00427## wherein: R.sup.1 is H, Me,
Et, vinyl, CF.sub.3, CHF.sub.2 or CH.sub.2F; R.sup.2 is H or Me;
R.sup.5 is H, Me, Et, or CF.sub.3; A is ##STR00428## G is phenyl
optionally substituted by one to four R.sup.9 groups or a 5-6
membered heteroaryl optionally substituted by a halogen; R.sup.6
and R.sup.7 are independently H, OCH.sub.3, (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2), (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2CH.sub.2), V--(CH.sub.2).sub.0-1 wherein V is
a 5-6 membered heteroaryl, W--(CH.sub.2).sub.1-2 wherein W is
phenyl optionally substituted with F, Cl, Br, I, OMe, CF.sub.3 or
Me, C.sub.3-C.sub.6-cycloalkyl optionally substituted with
C.sub.1-C.sub.3 alkyl or O(C.sub.1-C.sub.3 alkyl),
hydroxy-(C.sub.3-C.sub.6-cycloalkyl),
fluoro-(C.sub.3-C.sub.6-cycloalkyl), CH(CH.sub.3)CH(OH)phenyl, 4-6
membered heterocycle optionally substituted with F, OH,
C.sub.1-C.sub.3 alkyl, cyclopropylmethyl or
C(.dbd.O)(C.sub.1-C.sub.3 alkyl), or C.sub.1-C.sub.6-alkyl
optionally substituted with one or more groups independently
selected from OH, oxo, O(C.sub.1-C.sub.6-alkyl), CN, F, NH.sub.2,
NH(C.sub.1-C.sub.6-alkyl), N(C.sub.1-C.sub.6-alkyl).sub.2,
cyclopropyl, phenyl, imidazolyl, piperidinyl, pyrrolidinyl,
morpholinyl, tetrahydrofuranyl, oxetanyl or tetrahydropyranyl, or
R.sup.6 and R.sup.7 together with the nitrogen to which they are
attached form a 4-7 membered heterocyclic ring optionally
substituted with one or more groups independently selected from OH,
halogen, oxo, CF.sub.3, CH.sub.2CF.sub.3, CH.sub.2CH.sub.2OH,
O(C.sub.1-C.sub.3 alkyl), C(.dbd.O)CH.sub.3, NH.sub.2, NHMe,
N(Me).sub.2, S(O).sub.2CH.sub.3, cyclopropylmethyl and
C.sub.1-C.sub.3 alkyl; R.sup.a and R.sup.b are H, or R.sup.a is H,
and R.sup.b and R.sup.6 together with the atoms to which they are
attached form a 5-6 membered heterocyclic ring having one or two
ring nitrogen atoms; R.sup.c and R.sup.d are H or Me, or R.sup.c
and R.sup.d together with the atom to which they are attached form
a cyclopropyl ring; R.sup.8 is H, Me, F or OH, or R.sup.8 and
R.sup.6 together with the atoms to which they are attached form a
5-6 membered heterocyclic ring having one or two ring nitrogen
atoms; each R.sup.9 is independently halogen,
C.sub.1-C.sub.6-alkyl, C.sub.3-C.sub.6-cycloalkyl,
O--(C.sub.1-C.sub.6-alkyl), CF.sub.3, OCF.sub.3,
S(C.sub.1-C.sub.6-alkyl), CN, OCH.sub.2-phenyl, CH.sub.2O-phenyl,
NH.sub.2, NH--(C.sub.1-C.sub.6-alkyl),
N--(C.sub.1-C.sub.6-alkyl).sub.2, piperidine, pyrrolidine,
CH.sub.2F, CHF.sub.2, OCH.sub.2F, OCHF.sub.2, OH,
SO.sub.2(C.sub.1-C.sub.6-alkyl), C(O)NH.sub.2,
C(O)NH(C.sub.1-C.sub.6-alkyl), and
C(O)N(C.sub.1-C.sub.6-alkyl).sub.2; R.sup.10 is H or Me; and m, n
and p are independently 0 or 1.
87. The method of claim 86, wherein: R.sup.1 is Me; A is
##STR00429## and R.sup.2, R.sup.5, R.sup.8, R.sup.c, and R.sup.d
are H.
88. The method of claim 86, wherein G is phenyl optionally
substituted with one or more groups independently selected from F,
Cl, Br, I, Me, ethyl, isopropyl, CN, CF.sub.3, OCF.sub.3, SMe, OMe
and OCH.sub.2Ph.
89. The method of claim 86, wherein G is 4-chlorophenyl,
2,4-dichlorophenyl, 3-chloro-4-fluorophenyl, 3,4-difluorophenyl,
4-chloro-3-fluorophenyl, 3-fluoro-4-bromophenyl,
3,4-dichlorophenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-bromophenyl,
4-cyanophenyl, 4-trifluoromethylphenyl, 4-thiomethylphenyl, or
4-methylphenyl.
90. The method of claim 86, wherein R.sup.6 and R.sup.7 are
independently selected from H, OCH.sub.3, (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2), (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2CH.sub.2), V--(CH.sub.2).sub.0-1 wherein V is
a 5-6 membered heteroaryl having from one to two ring heteroatoms
independently selected from N, O and S, W--(CH.sub.2).sub.1-2
wherein W is phenyl optionally substituted with F, Cl or Me,
C.sub.3-C.sub.6-cycloalkyl optionally substituted with OCH.sub.3,
hydroxy-(C.sub.3-C.sub.6-cycloalkyl),
fluoro-(C.sub.3-C.sub.6-cycloalkyl), CH(CH.sub.3)CH(OH)phenyl, 5-6
membered heterocycle optionally substituted with CH.sub.3 or
C(.dbd.O)CH.sub.3, or C.sub.1-C.sub.6-alkyl optionally substituted
with one or more groups independently selected from OH, oxo,
O(C.sub.1-C.sub.6-alkyl), CN, F, NH.sub.2,
NH(C.sub.1-C.sub.6-alkyl), N(C.sub.1-C.sub.6-alkyl).sub.2, phenyl,
imidazolyl, piperidinyl, pyrrolidinyl, morpholinyl, and
tetrahydropyranyl.
91. The method of claim 86, wherein R.sup.6 and R.sup.7 are
independently selected from H, methyl, ethyl, isopropyl, isobutyl,
tert-butyl, 3-pentyl, OCH.sub.3, CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2OMe, CH.sub.2CH.sub.2CF.sub.3,
CH.sub.2CH(CH.sub.3)OH, CH.sub.2CH(CF.sub.3)OH, CH.sub.2CF.sub.3,
CH.sub.2CH.sub.2F, CH.sub.2C(.dbd.O)NH.sub.2,
CH.sub.2C(.dbd.O)NH(CH.sub.3), CH.sub.2C(.dbd.O)N(CH.sub.3).sub.2,
CH.sub.2C(.dbd.O)NH(iPr), CH.sub.2CH.sub.2C(.dbd.O)NH.sub.2,
CH.sub.2-cyclopropyl, CH.sub.2-cyclopentyl, CH.sub.2-tBu
(neopentyl), cyclopropyl, cyclopentyl, cyclohexyl,
4-methoxycyclohexyl, 4,4-dimethylcyclohexyl,
3,3-dimethylcyclohexyl, CH.sub.2-(pyrid-3-yl),
4-hydroxycyclohex-1-yl, CH(CH.sub.3)CH(OH)phenyl,
CH(phenyl)CH.sub.2OH, CH(tetrahydropyranyl)CH.sub.2OH,
CH.sub.2CH.sub.2CH.sub.2(imidazolyl),
CH.sub.2CH.sub.2(morpholinyl), CH.sub.2(tetrahydropyranyl),
CH.sub.2CH.sub.2(tetrahydropyranyl), pyrrolidinyl, piperidinyl,
tetrahydropyranyl, tetrahydrofuranyl, ##STR00430##
92. The method of claim 86, wherein R.sup.6 and R.sup.7 together
with the nitrogen to which they are attached form a 4-7 membered
heterocyclic ring, wherein said heterocyclic ring is optionally
substituted with one or more groups independently selected from OH,
halogen, oxo, CF.sub.3, CH.sub.2CF.sub.3, CH.sub.2CH.sub.2OH,
OCH.sub.3, C(.dbd.O)CH.sub.3, NH.sub.2, NHMe, N(Me).sub.2,
S(O).sub.2CH.sub.3, and (C.sub.1-C.sub.3)alkyl.
93. The method of claim 86, wherein A is: ##STR00431##
94. The method of claim 86, wherein the compound of Formula (I) is
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
or a salt thereof;
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(methyl(tetrahydro-2H-pyran-Re-
sponse to Notice to File Missing Parts 4-yl)amino)propan-1-one or a
salt thereof;
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihy-
dro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(3-hydroxyazetidin-1--
yl)propan-1-one or a salt thereof;
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-((R)-pyrrolidin-3-ylamino)prop-
an-1-one or a salt thereof;
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-((S)-pyrrolidin-3-ylamino)prop-
an-1-one or a salt thereof;
(S)-3-(1-acetylpiperidin-4-ylamino)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hy-
droxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)p-
ropan-1-one or a salt thereof; or
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(tetrahydro-2H-pyran-4-ylamino-
)propan-1-one or a salt thereof.
95. The method of claim 86, wherein the compound of Formula (I) is
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
or a salt thereof.
Description
PRIORITY OF INVENTION
[0001] This application is a continuation of U.S. patent
application Ser. No. 15/140,874, filed Apr. 28, 2016 which is a
continuation of U.S. patent application Ser. No. 14/458,062, filed
Aug. 12, 2014, now issued as U.S. Pat. No. 9,359,340, which is a
division of U.S. patent application Ser. No. 13/272,079, filed Oct.
12, 2011, now issued as U.S. Pat. No. 8,853,199, which is a
division of U.S. patent application Ser. No. 11/773,949, filed Jul.
5, 2007, now issued as U.S. Pat. No. 8,063,050. This application
claims priority to U.S. Provisional Application No. 60/818,718 that
was filed on Jul. 6, 2006, the entire contents of which are herein
incorporated by reference.
BACKGROUND OF THE INVENTION
Field of the Invention
[0002] This invention relates to novel inhibitors of
serine/threonine protein kinases (e.g., AKT and related kinases),
pharmaceutical compositions containing the inhibitors, and methods
for preparing these inhibitors. The inhibitors are useful, for
example, for the treatment of hyperproliferative diseases, such as
cancer and inflammation, in mammals.
Description of the State of the Art
[0003] Protein kinases (PK) are enzymes that catalyze the
phosphorylation of hydroxy groups on tyrosine, serine and threonine
residues of proteins by transfer of the terminal (gamma) phosphate
from ATP. Through signal transduction pathways, these enzymes
modulate cell growth, differentiation and proliferation, i.e.,
virtually all aspects of cell life in one way or another depend on
PK activity (Hardie, G. and Hanks, S. (1995) The Protein Kinase
Facts Book. I and II, Academic Press, San Diego, Calif.).
Furthermore, abnormal PK activity has been related to a host of
disorders, ranging from relatively non-life threatening diseases
such as psoriasis to extremely virulent diseases such as
glioblastoma (brain cancer). Protein kinases are an important
target class for therapeutic modulation (Cohen, P. (2002) Nature
Rev. Drug Discovery 1:309).
[0004] Significantly, atypical protein phosphorylation and/or
expression is often reported to be one of the causative effects of
abnormal cellular proliferation, metastasis and cell survival in
cancer. The abnormal regulation and/or expression of various
kinases, including Akt, VEGF, ILK, ROCK, p70S6K, Bcl, PKA, PKC,
Raf, Src, PDK1, ErbB2, MEK, IKK, Cdk, EGFR, BAD, CHK1, CHK2 and
GSK3 amongst numerous others, has been specifically implicated in
cancer.
[0005] Protein kinases include two classes; protein tyrosine
kinases (PTK) and serine-threonine kinases (STK). The Protein
Kinase B/Akt enzymes are a group of serine/threonine kinases that
are overexpressed in a variety of human tumors. One of the
best-characterized targets of the PI3K lipid products is the 57 KD
serine/threonine protein kinase Akt, downstream of PI3K in the
signal transduction pathway (Hemmings, B. A. (1997) Science
275:628; Hay N. (2005) Cancer Cell 8:179-183). Akt is the human
homologue of the protooncogene v-akt of the acutely transforming
retrovirus AKT8. Due to its high sequence homology to protein
kinases A and C, Akt is also called Protein Kinase B (PKB) and
Related to A and C (RAC). Three isoforms of Akt are known to exist,
namely Akt1, Akt2 and Akt3, which exhibit an overall homology of
80% (Staal, S. P. (1987) Proc. Natl. Acad. Sci. 84:5034; Nakatani,
K. (1999) Biochem. Biophys. Res. Commun. 257:906; Li et al (2002)
Current Topics in Med. Chem. 2:939-971; WO 2005/113762). The Akt
isoforms share a common domain organization that consists of a
pleckstrin homology domain at the N-terminus, a kinase catalytic
domain, and a short regulatory region at the C-terminus. In
addition, both Akt2 and Akt3 exhibit splice variants. Upon
recruitment to the cell membrane by PtdInd(3,4,5)P.sub.3, Akt is
phosphorylated (activated) by PDK1 at T308, T309 and T305 for
isoforms Akt1 (PKB.alpha.), Akt2 (PKB.beta.) and Akt3 (PKB.gamma.),
respectively, and at S473, S474 and S472 for isoforms Akt1, Akt2
and Akt3, respectively. Such phosphorylation occurs by an as yet
unknown kinase (putatively named PDK2), although PDK1 (Balendran,
A., (1999) Curr. Biol. 9:393), autophosphorylation (Toker, A.
(2000) J. Biol. Chem. 275:8271) and integrin-linked kinase (ILK)
(Delcommenne, M. (1998) Proc. Natl. Acad. Sci. USA, 95:11211) have
been implicated in this process. Akt activation requires its
phosphorylation on residue Ser 473 in the C-terminal hydrophobic
motif (Brodbeck et al (1999) J. Biol. Chem. 274:9133-9136; Coffer
et al (1991) Eur. J. Biochem. 201:475-481; Alessi et al (1997)
Curr. Biol. 7:261-269). Although monophosphorylation of Akt
activates the kinase, bis(phosphorylation) is required for maximal
kinase activity.
[0006] Akt is believed to assert its effect on cancer by
suppressing apoptosis and enhancing both angiogenesis and
proliferation (Toker et al. (2006) Cancer Res. 66(8):3963-3966).
Akt is overexpressed in many forms of human cancer including, but
not limited to, colon (Zinda et al (2001) Clin. Cancer Res.
7:2475), ovarian (Cheng et al (1992) Proc. Natl. Acad. Sci. USA
89:9267), brain (Haas Kogan et al (1998) Curr. Biol. 8:1195), lung
(Brognard et al (2001) Cancer Res. 61:3986), pancreatic (Bellacosa
et al (1995) Int. J. Cancer 64:280-285; Cheng et al (1996) Proc.
Natl. Acad. Sci. 93:3636-3641), prostate (Graff et al (2000) J.
Biol. Chem. 275:24500) and gastric carcinomas (Staal et al (1987)
Proc. Natl. Acad. Sci. USA 84:5034-5037).
[0007] The PI3K/Akt/mammalian target of rapamycin (mTOR) pathway
has been explored for targeted small molecule inhibitor therapy
(Georgakis, G. and Younes, A. (2006) Expert Rev. Anticancer Ther.
6(1):131-140; Granville et al (2006) Clin. Cancer Res.
12(3):679-689). Inhibition of PI3K/Akt signaling induces apoptosis
and inhibits the growth of tumor cells that have elevated Akt
levels (Kim et al (2005) Current Opinion in Investig. Drugs
6(12):1250-1258; Luo et al (2005) Molecular Cancer Ther.
4(6):977-986).
[0008] The development of kinase inhibitors that target abnormally
regulated pathways and ultimately result in disease is of enormous
ethical and commercial interest to the medical and pharmaceutical
community. A compound that inhibits (1) recruitment of Akt to the
cell membrane, (2) activation by PDK1 or PDK2, (3) substrate
phosphorylation, or (4) one of the downstream targets of Akt could
be a valuable anticancer agent, either as a stand-alone therapy or
in conjunction with other accepted procedures.
[0009] United States Patent Application Publication 2005/0130954
discloses inter alia, a variety of compounds that act as AKT
inhibitors. The compounds are said to be useful in the treatment of
hyperproliferative diseases such as cancer.
SUMMARY OF THE INVENTION
[0010] This invention provides novel compounds that inhibit AKT
protein kinases. The compounds of the present invention have
utility as therapeutic agents for diseases and conditions that can
be treated by the inhibition of AKT protein kinases.
[0011] More specifically, the present invention includes compounds
having the general Formula I:
##STR00002##
and tautomers, resolved enantiomers, resolved diastereomers,
solvates, metabolites, salts and pharmaceutically acceptable
prodrugs thereof, wherein R.sup.1, R.sup.2, R.sup.5, R.sup.10 and A
are as defined herein.
[0012] The invention also provides pharmaceutical compositions
comprising a compound of Formula I, or an enantiomer, solvate,
metabolite, or pharmaceutically acceptable salt or prodrug
thereof.
[0013] In a further aspect, the present invention provides a method
of treating diseases or medical conditions in a mammal mediated by
AKT protein kinases, comprising administering to said mammal one or
more compounds of Formula I, or an enantiomer, solvate, metabolite,
or pharmaceutically acceptable salt or prodrug thereof, in an
amount effective to treat or prevent said disorder. AKT protein
kinase mediated conditions that can be treated according to the
methods of this invention include, but are not limited to,
inflammatory, hyperproliferative, cardiovascular,
neurodegenerative, gynecological, and dermatological diseases and
disorders.
[0014] In a further aspect, the present invention provides a method
of inhibiting the production of AKT protein kinases in a mammal,
which comprises administering to said mammal a compound of Formula
I, or an enantiomer, solvate, metabolite, or pharmaceutically
acceptable salt or prodrug thereof in an amount effective to
inhibit production of an AKT protein kinase.
[0015] In a further aspect, the present invention provides methods
of inhibiting the activity of AKT protein kinases, comprising
contacting said kinase with a compound of Formula I.
[0016] The inventive compounds may be used advantageously in
combination with other known therapeutic agents. Accordingly, this
invention also provides pharmaceutical compositions comprising a
compound of Formula I or an enantiomer, solvate, metabolite, or
pharmaceutically acceptable salt or prodrug thereof, in combination
with a second therapeutic agent.
[0017] This invention also provides compounds of Formula I and
enantiomers, solvates, metabolites, and pharmaceutically acceptable
salts and prodrugs thereof for use as medicaments in the treatment
of AKT protein kinase-mediated conditions.
[0018] An additional aspect of the invention is the use of a
compound of Formula I, or an enantiomer, solvate, metabolite, or
pharmaceutically acceptable salt or prodrug thereof, for therapy.
In one embodiment, the therapy comprises the treatment of an AKT
protein kinase-mediated condition.
[0019] This invention further provides kits for the treatment of an
AKT protein kinase-mediated disease or disorder, said kit
comprising a compound of Formula I, or an enantiomer, solvate,
metabolite, or pharmaceutically acceptable salt or prodrug thereof,
a container, and optionally a package insert or label indicating a
treatment. The kits may further comprise a second compound or
formulation comprising a second pharmaceutical agent useful for
treating said disease or disorder.
[0020] This invention further includes methods of preparing,
methods of separating, and methods of purifying of the compounds of
this invention.
[0021] Additional advantages and novel features of this invention
shall be set forth in part in the description that follows, and in
part will become apparent to those skilled in the art upon
examination of the following specification, or may be learned by
the practice of the invention. The advantages of the invention may
be realized and attained by means of the instrumentalities,
combinations, compositions, and methods particularly pointed out in
the appended claims.
DETAILED DESCRIPTION OF THE INVENTION
[0022] Reference will now be made in detail to certain embodiments
of the invention, examples of which are illustrated in the
accompanying structures and formulas. While the invention will be
described in conjunction with the enumerated embodiments, it will
be understood that they are not intended to limit the invention to
those embodiments. On the contrary, the invention is intended to
cover all alternatives, modifications, and equivalents which may be
included within the scope of the present invention as defined by
the claims. One skilled in the art will recognize many methods and
materials similar or equivalent to those described herein, which
could be used in the practice of the present invention. The present
invention is in no way limited to the methods and materials
described. In the event that one or more of the incorporated
literature and similar materials differs from or contradicts this
application, including but not limited to defined terms, tem usage,
described techniques, or the like, this application controls.
Definitions
[0023] The term "alkyl" as used herein refers to a saturated linear
or branched-chain monovalent hydrocarbon radical of one to twelve
carbon atoms, wherein the alkyl radical may be optionally
substituted independently with one or more substituents described
below. Examples of alkyl groups include, but are not limited to,
methyl(Me, --CH.sub.3), ethyl (Et, --CH.sub.2CH.sub.3), 1-propyl
(n-Pr, n-propyl, --CH.sub.2CH.sub.2CH.sub.3), 2-propyl (i-Pr,
i-propyl, --CH(CH.sub.3).sub.2), 1-butyl (n-Bu, n-butyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-methyl-1-propyl (i-Bu,
i-butyl, --CH.sub.2CH(CH.sub.3).sub.2), 2-butyl (s-Bu, s-butyl,
--CH(CH.sub.3)CH.sub.2CH.sub.3), 2-methyl-2-propyl (t-Bu, t-butyl,
--C(CH.sub.3).sub.3), 1-pentyl (n-pentyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-pentyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.3), 3-pentyl
(--CH(CH.sub.2CH.sub.3).sub.2), 2-methyl-2-butyl
(--C(CH.sub.3).sub.2CH.sub.2CH.sub.3), 3-methyl-2-butyl
(--CH(CH.sub.3)CH(CH.sub.3).sub.2), 3-methyl-1-butyl
(--CH.sub.2CH.sub.2 CH(CH.sub.3).sub.2), 2-methyl-1-butyl
(--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.3), 1-hexyl
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-hexyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 3-hexyl
(--CH(CH.sub.2CH.sub.3)(CH.sub.2CH.sub.2CH.sub.3)),
2-methyl-2-pentyl (--C(CH.sub.3).sub.2CH.sub.2CH.sub.2CH.sub.3),
3-methyl-2-pentyl (--CH(CH.sub.3)CH(CH.sub.3)CH.sub.2CH.sub.3),
4-methyl-2-pentyl (--CH(CH.sub.3)CH.sub.2CH(CH.sub.3).sub.2),
3-methyl-3-pentyl (--C(CH.sub.3)(CH.sub.2CH.sub.3).sub.2),
ethyl-3-pentyl (--CH(CH.sub.2CH.sub.3)CH(CH.sub.3).sub.2),
2,3-dimethyl-2-butyl (--C(CH.sub.3).sub.2CH(CH.sub.3).sub.2),
3,3-dimethyl-2-butyl (--CH(CH.sub.3)C(CH.sub.3).sub.3, 1-heptyl,
1-octyl, and the like.
[0024] The term "alkylene" as used herein refers to a linear or
branched saturated divalent hydrocarbon radical of one to twelve
carbon atoms, wherein the alkylene radical may be optionally
substituted independently with one or more substituents described
herein. Examples include, but are not limited to, methylene,
ethylene, propylene, 2-methylpropylene, pentylene, and the
like.
[0025] The term "alkenyl" as used herein refers to a linear or
branched-chain monovalent hydrocarbon radical of two to twelve
carbon atoms with at least one site of unsaturation, i.e., a
carbon-carbon, sp.sup.2 double bond, wherein the alkenyl radical
may be optionally substituted independently with one or more
substituents described herein, and includes radicals having "cis"
and "trans" orientations, or alternatively, "E" and "Z"
orientations. Examples include, but are not limited to, ethylenyl
or vinyl (--CH.dbd.CH.sub.2), allyl (--CH.sub.2CH.dbd.CH.sub.2),
1-propenyl, 1-buten-1-yl, 1-buten-2-yl, and the like.
[0026] The term "alkynyl" as used herein refers to a linear or
branched monovalent hydrocarbon radical of two to twelve carbon
atoms with at least one site of unsaturation, i.e., a
carbon-carbon, sp triple bond, wherein the alkynyl radical may be
optionally substituted independently with one or more substituents
described herein. Examples include, but are not limited to, ethynyl
(--CCH) and propynyl (propargyl, --CH.sub.2CCH).
[0027] The terms "cycloalkyl," "carbocycle," "carbocyclyl" and
"carbocyclic ring" as used herein are used interchangeably and
refer to saturated or partially unsaturated cyclic hydrocarbon
radical having from three to twelve carbon atoms. The term
"cycloalkyl" includes monocyclic and polycyclic (e.g., bicyclic and
tricyclic) cycloalkyl structures, wherein the polycyclic structures
optionally include a saturated or partially unsaturated cycloalkyl
ring fused to a saturated, partially unsaturated or aromatic
cycloalkyl or heterocyclic ring. Examples of cycloalkyl groups
include, but are not limited to, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, and the like. Bicyclic
carbocycles include those having 7 to 12 ring atoms arranged, for
example, as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or as
bridged systems such as bicyclo[2.2.1]heptane,
bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane. The cycloalkyl may
be optionally substituted independently with one or more
substituents described herein.
[0028] The term "(C.sub.3-C.sub.6-cycloalkyl)-(CH.sub.2)" includes
cyclopropyl-CH.sub.2, cyclopentyl-CH.sub.2, and
cyclohexyl-CH.sub.2.
[0029] "Aryl" as used herein means a monovalent aromatic
hydrocarbon radical of 6-20 carbon atoms derived by the removal of
one hydrogen atom from a single carbon atom of a parent aromatic
ring system. Aryl includes bicyclic radicals comprising an aromatic
ring fused to a saturated, partially unsaturated ring, or aromatic
carbocyclic or heterocyclic ring. Exemplary aryl groups include,
but are not limited to, radicals derived from benzene, naphthalene,
anthracene, biphenyl, indene, indane, 1,2-dihydronapthalene,
1,2,3,4-tetrahydronapthalene, and the like. Aryl groups may be
optionally substituted independently with one or more substituents
described herein.
[0030] The terms "heterocycle", "hetercyclyl" and "heterocyclic
ring" as used herein are used interchangeably and refer to a
saturated or partially unsaturated carbocyclic radical of 3 to 8
ring atoms in which at least one ring atom is a heteroatom
independently selected from nitrogen, oxygen and sulfur, the
remaining ring atoms being C, where one or more ring atoms may be
optionally substituted independently with one or more substituents
described below. The radical may be a carbon radical or heteroatom
radical. The term "heterocycle" includes heterocycloalkoxy.
"Heterocyclyl" also includes radicals where heterocycle radicals
are fused with a saturated, partially unsaturated, or aromatic
carbocyclic or heterocyclic ring. Examples of heterocyclic rings
include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl,
dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl,
dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino,
thiomorpholino, thioxanyl, piperazinyl, homopiperazinyl,
azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl,
thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-pyrrolinyl,
3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl,
1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl,
dihydropyranyl, dihydrothienyl, dihydrofuranyl,
pyrazolidinylimidazolinyl, imidazolidinyl,
3-azabicyco[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl,
azabicyclo[2.2.2]hexanyl, 3H-indolyl quinolizinyl and N-pyridyl
ureas. Spiro moieties are also included within the scope of this
definition. The heterocycle may be C-attached or N-attached where
such is possible. For instance, a group derived from pyrrole may be
pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a
group derived from imidazole may be imidazol-1-yl (N-attached) or
imidazol-3-yl (C-attached). Examples of heterocyclic groups wherein
2 ring carbon atoms are substituted with oxo (.dbd.O) moieties are
isoindoline-1,3-dionyl and 1,1-dioxo-thiomorpholinyl. The
heterocycle groups herein are optionally substituted independently
with one or more substituents described herein.
[0031] The term "heteroaryl" as used herein refers to a monovalent
aromatic radical of a 5-, 6-, or 7-membered ring and includes fused
ring systems (at least one of which is aromatic) of 5-10 atoms
containing at least one heteroatom independently selected from
nitrogen, oxygen, and sulfur. Examples of heteroaryl groups
include, but are not limited to, pyridinyl, imidazolyl,
imidazopyridinyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl,
tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl,
isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl,
benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl,
phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl,
purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl,
furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl,
benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and
furopyridinyl. Spiro moieties are also included within the scope of
this definition. Heteroaryl groups may be optionally substituted
independently with one or more substituents described herein.
[0032] By way of example and not limitation, carbon bonded
heterocycles and heteroaryls are bonded at position 2, 3, 4, 5, or
6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position
2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a
pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran,
thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4,
or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of
an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an
aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4,
5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of
an isoquinoline. Further examples of carbon bonded heterocycles
include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl,
3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl,
2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl,
2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl,
4-thiazolyl, or 5-thiazolyl.
[0033] By way of example and not limitation, nitrogen bonded
heterocycles and heteroaryls are bonded at position 1 of an
aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline,
3-pyrroline, imidazole, imidazolidine, 2-imidazoline,
3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline,
piperidine, piperazine, indole, indoline, 1H-indazole, position 2
of an isoindole, or isoindoline, position 4 of a morpholine, and
position 9 of a carbazole, or (3-carboline. Still more typically,
nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl,
1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
[0034] The term "halogen" as used herein means fluoro, chloro,
bromo or iodo.
[0035] The term "a" as used herein means one or more.
[0036] As used herein, the terms "compound of this invention,"
"compounds of the present invention" and "compounds of Formula I"
includes compounds of Formula I and tautomers, resolved
enantiomers, resolved diastereomers, racemic mixtures, solvates,
metabolites, salts (including pharmaceutically acceptable salts)
and pharmaceutically acceptable prodrugs thereof.
[0037] It is to be understood that in instances where two or more
radicals are used in succession to define a substituent attached to
a structure, the first named radical is considered to be terminal
and the last named radical is considered to be attached to the
structure in question. Thus, for example, an arylalkyl radical is
attached to the structure in question by the alkyl group.
AKT Inhibitors
[0038] The inventive compounds of Formula I are useful for
inhibiting AKT protein kinases. Such compounds have utility as
therapeutic agents for diseases that can be treated by the
inhibition of the AKT protein kinase signaling pathway and tyrosine
and serine/threonine kinase receptor pathways.
[0039] In particular, certain compounds of Formula I wherein Ole is
OH were found to be at least 50-fold more selective for AKT versus
protein kinase A (PKA). For example, at least 100-fold, and as a
further example, at least 150-fold more selective for AKT versus
PKA. Selectivity over PKA is desirable, since PKA is involved in
many cellular processes important for the normal function and
physiology of many cell types. Additionally, inhibition of PKA is
not believed to contribute to the anti-proliferative and
pro-apoptotic effects of AKT inhibition. Thus, inhibition of PKA
could lead to adverse events not associated with AKT inhibition
without contributing to the disease modifying benefits of AKT
inhibition.
[0040] The compounds of Formula I may also be useful as inhibitors
of tyrosine kinases as well as serine and threonine kinases in
addition to AKT.
[0041] In general, one aspect of the invention includes compounds
of the Formula I:
##STR00003##
and tautomers, resolved enantiomers, resolved diastereomers,
solvates, metabolites, salts and pharmaceutically acceptable
prodrugs thereof, wherein:
[0042] R.sup.1 is H, Me, Et, vinyl, CF.sub.3, CHF.sub.2 or
CH.sub.2F;
[0043] R.sup.2 is H or Me;
[0044] R.sup.5 is H, Me, Et, or CF.sub.3;
[0045] A is
##STR00004##
[0046] G is phenyl optionally substituted by one to four R.sup.9
groups or a 5-6 membered heteroaryl optionally substituted by a
halogen;
[0047] R.sup.6 and R.sup.7 are independently H, OCH.sub.3,
(C.sub.3-C.sub.6 cycloalkyl)-(CH.sub.2), (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2CH.sub.2), V--(CH.sub.2).sub.0-1 wherein V is
a 5-6 membered heteroaryl having from one to two ring heteroatoms
independently selected from N, O and S, W--(CH.sub.2).sub.1-2
wherein W is phenyl optionally substituted with F, Cl, Br, I, OMe,
CF.sub.3 or Me, C.sub.3-C.sub.6-cycloalkyl optionally substituted
with C.sub.1-C.sub.3 alkyl or O(C.sub.1-C.sub.3 alkyl),
hydroxy-(C.sub.3-C.sub.6-cycloalkyl),
fluoro-(C.sub.3-C.sub.6-cycloalkyl), CH(CH.sub.3)CH(OH)phenyl, 4-6
membered heterocycle optionally substituted with F, OH,
C.sub.1-C.sub.3-alkyl, cyclopropylmethyl or
C(.dbd.O)(C.sub.1-C.sub.3 alkyl), or C.sub.1-C.sub.6-alkyl
optionally substituted with one or more groups independently
selected from OH, oxo, O(C.sub.1-C.sub.6-alkyl), CN, F, NH.sub.2,
NH(C.sub.1-C.sub.6-alkyl), N(C.sub.1-C.sub.6-alkyl).sub.2,
cyclopropyl, phenyl, imidazolyl, piperidinyl, pyrrolidinyl,
morpholinyl, tetrahydrofuranyl, oxetanyl, or tetrahydropyranyl,
[0048] or R.sup.6 and R.sup.7 together with the nitrogen to which
they are attached form a 4-7 membered heterocyclic ring, wherein
said heterocyclic ring is optionally substituted with one or more
groups independently selected from OH, halogen, oxo, CF.sub.3,
CH.sub.2CF.sub.3, CH.sub.2CH.sub.2OH, O(C.sub.1-C.sub.3 alkyl),
C(.dbd.O)CH.sub.3, NH.sub.2, NHMe, N(Me).sub.2, S(O).sub.2CH.sub.3,
cyclopropylmethyl and C.sub.1-C.sub.3 alkyl;
[0049] R.sup.a and R.sup.b are H,
[0050] or R.sup.a is H, and R.sup.b and R.sup.6 together with the
atoms to which they are attached form a 5-6 membered heterocyclic
ring having one or two ring nitrogen atoms;
[0051] R.sup.c and R.sup.d are H or Me,
[0052] or R.sup.c and R.sup.d together with the atom to which they
are attached from a cyclopropyl ring;
[0053] R.sup.8 is H, Me, F or OH,
[0054] or R.sup.8 and R.sup.6 together with the atoms to which they
are attached form a 5-6 membered heterocyclic ring having one or
two ring nitrogen atoms;
[0055] each R.sup.9 is independently halogen,
C.sub.1-C.sub.6-alkyl, C.sub.3-C.sub.6-cycloalkyl, CF.sub.3,
OCF.sub.3, S(C.sub.1-C.sub.6-alkyl), CN, OCH.sub.2-phenyl,
CH.sub.2O-phenyl, NH.sub.2, NH--(C.sub.1-C.sub.6-alkyl),
N--(C.sub.1-C.sub.6-alkyl).sub.2, piperidine, pyrrolidine,
CH.sub.2F, CHF.sub.2, OCH.sub.2F, OCHF.sub.2, OH,
SO.sub.2(C.sub.1-C.sub.6-alkyl), C(O)NH.sub.2,
C(O)NH(C.sub.1-C.sub.6-alkyl), and
C(O)N(C.sub.1-C.sub.6-alkyl).sub.2;
[0056] R.sup.10 is H or Me; and
[0057] m, n and p are independently 0 or 1.
[0058] In a further embodiment, the compounds of Formula I include
compounds wherein G is phenyl optionally substituted by one to four
R.sup.9 groups; and
[0059] R.sup.6 and R.sup.7 are independently H, (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2), (C.sub.3-C.sub.6
cycloalkyl)-(CH.sub.2CH.sub.2), V--(CH.sub.2).sub.0-1 wherein V is
a 5-6 membered heteroaryl having from one to two ring heteroatoms
independently selected from N, O and S, W--(CH.sub.2).sub.1-2
wherein W is phenyl optionally substituted with F, Cl or Me,
C.sub.3-C.sub.6-cycloalkyl, hydroxy-(C.sub.3-C.sub.6-cycloalkyl),
fluoro-(C.sub.3-C.sub.6-cycloalkyl), CH(CH.sub.3)CH(OH)phenyl, or
C.sub.1-C.sub.6-alkyl optionally substituted with one or more
groups independently selected from OH, O(C.sub.1-C.sub.6-alkyl),
CN, F, NH.sub.2, NH(C.sub.1-C.sub.6-alkyl),
N(C.sub.1-C.sub.6-alkyl).sub.2, piperidinyl, and pyrrolidinyl,
[0060] or R.sup.6 and R.sup.7 together with the nitrogen to which
they are attached form a 4-6 membered heterocyclic ring, wherein
said heterocyclic ring is optionally substituted with one or more
groups independently selected from OH, halogen, oxo, CF.sub.3,
CH.sub.2CF.sub.3, and (C.sub.1-C.sub.3)alkyl;
[0061] R.sup.c and R.sup.d are H or Me;
[0062] R.sup.8 is H, Me, or OH; and
[0063] each R.sup.9 is independently halogen,
C.sub.1-C.sub.6-alkyl, C.sub.3-C.sub.6-cycloalkyl,
O--(C.sub.1-C.sub.6-alkyl), CF.sub.3, OCF.sub.3,
S(C.sub.1-C.sub.6-alkyl), CN, CH.sub.2O-phenyl, NH.sub.2,
NH--(C.sub.1-C.sub.6-alkyl), N--(C.sub.1-C.sub.6-alkyl).sub.2,
piperidine, pyrrolidine, CH.sub.2F, CHF.sub.2, OCH.sub.2F,
OCHF.sub.2, OH, SO.sub.2(C.sub.1-C.sub.6-alkyl), C(O)NH.sub.2,
C(O)NH(C.sub.1-C.sub.6-alkyl), and
C(O)N(C.sub.1-C.sub.6-alkyl).sub.2.
[0064] Referring to the G group of Formula I, examples include
phenyl optionally substituted with one or more R.sup.9 groups
independently selected from F, Cl, Br, CN, methyl, ethyl,
isopropyl, OCH.sub.3, OCH.sub.2CH.sub.3, CF.sub.3, OCF.sub.3,
SCH.sub.3, OCH.sub.2Ph and cyclopropyl. Exemplary embodiments
include, but are not limited to, phenyl, 2-chlorophenyl,
3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl,
4-fluorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl,
2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethyl phenyl,
3-ethylphenyl, 4-ethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl,
4-isopropylphenyl, 2-trifluoromethylphenyl,
3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-cyanophenyl,
3-cyanophenyl, 4-cyanophenyl, 2-methoxyphenyl, 3-methoxyphenyl,
4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl,
2-thiomethylphenyl, 3-thiomethyl phenyl, 4-thiomethylphenyl,
2-trifluoromethoxy-phenyl, 3-trifluoromethoxyphenyl,
4-trifluoromethoxyphenyl, 2-cyclopropyl phenyl, 3-cyclo-propyl
phenyl, 4-cyclopropyl phenyl, 4-chloro-3-fluorophenyl,
3,4-difluorophenyl, 4-bromo-3-fluorophenyl,
3-fluoro-4-methylphenyl, 3-fluoro-4-methoxyphenyl,
3-fluoro-4-trifluoromethylphenyl, 4-cyano-3-fluorophenyl,
3,4-dichlorophenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl,
2-chloro-4-fluorophenyl, 2-fluoro-4-chlorophenyl,
3,5-dichlorophenyl. 3,5-difluorophenyl, 3-chloro-5-fluorophenyl,
3-chloro-4-fluorophenyl, 3-bromo-4-fluorophenyl,
3,5-difluoro-4-chlorophenyl, 2,3-difluoro-4-chlorophenyl,
2,5-difluoro-4-chlorophenyl, 3,5-difluoro-4-bromophenyl,
2,3-difluoro-4-bromophenyl, 2,5-difluoro-4-bromophenyl and
4-(OCH.sub.2Ph)-phenyl.
[0065] A further example of the G group of Formula I includes when
R.sup.9 is I. An exemplary embodiment includes 4-iodophenyl.
[0066] Referring to the G group of Formula I, the phrase "5-6
membered heteroaryl optionally substituted by a halogen" includes
thiophenes and pyridines optionally substituted by halogens.
Particular examples include, but are not limited to, the
structures:
##STR00005##
[0067] Referring to the R.sup.6 and R.sup.7 groups of Formula I,
the term "(C.sub.3-C.sub.6-cycloalkyl)-(CH.sub.2)" includes
cyclopropyl-CH.sub.2, cyclobutyl-CH.sub.2, cyclopentyl-CH.sub.2,
and cyclohexyl-CH.sub.2.
[0068] Referring to the R.sup.6 and R.sup.7 groups of Formula I,
the term "V--(CH.sub.2).sub.0-1" includes, but is not limited to,
the following structures:
##STR00006##
[0069] Referring to the R.sup.6 and R.sup.7 groups of Formula I,
the term "hydroxy-(C.sub.3-C.sub.6-cycloalkyl)" includes, but is
not limited to, the following structures:
##STR00007##
[0070] Referring to the R.sup.6 and R.sup.7 groups of Formula I,
the term "fluoro-(C.sub.3-C.sub.6-cycloalkyl)" includes but is not
limited to, the following structures:
##STR00008##
[0071] Referring to the R.sup.6 and R.sup.7 groups of Formula I,
the phrase "C.sub.1-C.sub.6-alkyl optionally substituted with one
or more groups independently selected from OH, OMe, and CN"
includes, but is not limited to, CH.sub.2OH, CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2CH.sub.2OH, CH.sub.2CH(OH)CH.sub.2,
CH.sub.2CH.sub.2CH(OH)CH.sub.3, CH.sub.2C(OH)(CH.sub.3).sub.2,
CH.sub.2OMe, CH.sub.2CH.sub.2OMe, CH.sub.2CH.sub.2CH.sub.2OMe,
CH.sub.2CH(OMe)CH.sub.2, CH.sub.2CH.sub.2CH(OMe)CH.sub.3,
CH.sub.2C(OMe)(CH.sub.3).sub.2, CH.sub.2CN, CH.sub.2CH.sub.2CN,
CH.sub.2CH.sub.2CH.sub.2CN, CH.sub.2CH(CN)CH.sub.2,
CH.sub.2CH.sub.2CH(CN)CH.sub.3, CH.sub.2C(CN)(CH.sub.3).sub.2, and
the like.
[0072] Referring to the R.sup.6 and R.sup.7 groups of Formula I, in
certain embodiments the term "heteroaryl" refers to a 5-6 membered
heteroaryl having from one to two ring heteroatoms independently
selected from N, O and S.
[0073] Referring to the R.sup.6 and R.sup.7 groups of Formula I, in
certain embodiments the phrase "4-6 membered heterocycle optionally
substituted with F, OH, C.sub.1-C.sub.3-alkyl, cyclopropylmethyl or
C(.dbd.O)(C.sub.1-C.sub.3 alkyl)" refers to a 4-6 membered
heterocycle having from one to two ring heteroatoms independently
selected from N, O and S, and optionally substituted with a
CH.sub.3 or C(.dbd.O)CH.sub.3 substituent. Examples include, but
are not limited to, the structures:
##STR00009##
[0074] In one embodiment of Formula I, R.sup.10 is H.
[0075] In another embodiment of Formula I, R.sup.10 is methyl.
[0076] In one embodiment of Formula I, OR.sup.2 is in the (S) or
(R) configuration. In a particular embodiment, R.sup.2 is H.
[0077] In another embodiment of Formula I, R.sup.2 is methyl.
[0078] In one embodiment of Formula I, R.sup.5 is H. In another
embodiment, R.sup.5 is methyl, wherein said methyl is optionally in
the (S) configuration.
[0079] In one embodiment of Formula I, R.sup.1 is methyl, wherein
said methyl is optionally in the (R) configuration. In another
embodiment, R.sup.1 is H.
[0080] In one embodiment of Formula I, G is phenyl optionally
substituted with one or more groups independently selected from F,
Cl, Br, Me, Et, isopropyl, CN, CF.sub.3, OCF.sub.3, SMe, OMe and
CH.sub.2OPh. Exemplary embodiments of G include phenyl,
2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-fluorophenyl,
4-bromophenyl, 4-methylphenyl, 4-ethylphenyl, 4-isopropylphenyl,
4-trifluoromethylphenyl, 4-cyanophenyl, 4-methoxyphenyl,
4-ethoxyphenyl, 4-thiomethylphenyl, 4-trifluoromethoxyphenyl,
4-cyclopropylphenyl, 4-chloro-3-fluorophenyl, 3,4-difluorophenyl,
4-bromo-3-fluorophenyl, 3-fluoro-4-methylphenyl,
3-fluoro-4-methoxyphenyl, 3-fluoro-4-trifluoromethylphenyl,
4-cyano-3-fluorophenyl, 3,4-dichlorophenyl, 2,4-dichlorophenyl,
2,4-difluorophenyl, 2-chloro-4-fluorophenyl,
2-fluoro-4-chlorophenyl, 3,5-dichlorophenyl, 3,5-difluorophenyl,
3-chloro-5-fluorophenyl, 3-chloro-4-fluorophenyl,
3-bromo-4-fluorophenyl, 3,5-difluoro-4-chlorophenyl,
2,3-difluoro-4-chlorophenyl, 2,5-difluoro-4-chlorophenyl,
3,5-difluoro-4-bromophenyl, 2,3-difluoro-4-bromophenyl,
2,5-difluoro-4-bromophenyl or 4-(OCH.sub.2Ph)-phenyl.
[0081] In particular embodiments, G is 4-chlorophenyl,
2,4-dichlorophenyl, 3-chloro-4-fluorophenyl, 3,4-difluorophenyl,
4-chloro-3-fluorophenyl, 3,4-dichlorophenyl,
3-fluoro-4-bromophenyl, 4-methoxyphenyl, 4-fluorophenyl,
4-bromophenyl, 4-cyanophenyl, 4-trifluoromethylphenyl,
4-thiomethylpyhenyl, or 4-methylphenyl.
[0082] In additional embodiments, R.sup.9 may be I or
OCH.sub.2-phenyl.
[0083] Additionally, G may be 4-iodophenyl,
4-trifluoromethoxyphenyl, 3,5-difluorophenyl,
4-bromo-3-fluorophenyl, 3-fluoro-4-methoxyphenyl,
3-fluoro-4-trifluoromethylphenyl,
3-trifluoromethoxy-4-chlorophenyl,
3-fluoro-4-trifluoromethoxyphenyl,
3-trifluoromethyl-4-chlorophenyl,
3-trifluoromethoxy-4-fluorophenyl, 3,5-bis(trifluoromethyl)phenyl,
3-chloro-5-fluorophenyl, 3-bromo-4-methoxyphenyl,
2-fluoro-4-chlorophenyl, 2-fluoro-4-bromophenyl,
2-fluoro-4-trifluoromethyl phenyl, or
3-trifluoromethyl-4-fluorophenyl.
[0084] In one embodiment, G may be a 5-6 membered heteroaryl
optionally substituted by a halogen. In certain embodiments, G is a
thiophene or pyridine optionally substituted by a halogen.
Particular embodiments include:
##STR00010##
[0085] In one embodiment, R.sup.6 or R.sup.7 may be H.
[0086] In one embodiment, R.sup.6 or R.sup.7 may be OCH.sub.3.
[0087] In one embodiment, R.sup.6 or R.sup.7 may be
(C.sub.3-C.sub.6 cycloalkyl)-(CH.sub.2).
[0088] In one embodiment, R.sup.6 or R.sup.7 may be
(C.sub.3-C.sub.6 cycloalkyl)-(CH.sub.2CH.sub.2).
[0089] In one embodiment, R.sup.6 or R.sup.7 may be
V--(CH.sub.2).sub.0-1 wherein V is a 5-6 membered heteroaryl having
from one to two ring heteroatoms independently selected from N, O
and S.
[0090] In one embodiment, R.sup.6 or R.sup.7 may be
W--(CH.sub.2).sub.1-2 wherein W is phenyl optionally substituted
with F, Cl, Br, I, OMe, CF.sub.3 or Me.
[0091] In one embodiment, R.sup.6 or R.sup.7 may be
C.sub.3-C.sub.6-cycloalkyl optionally substituted with
C.sub.1-C.sub.3 alkyl or O(C.sub.1-C.sub.3 alkyl).
[0092] In one embodiment, R.sup.6 or R.sup.7 may be
hydroxy-(C.sub.3-C.sub.6-cycloalkyl).
[0093] In one embodiment, R.sup.6 or R.sup.7 may be
fluoro-(C.sub.3-C.sub.6-cycloalkyl).
[0094] In one embodiment, R.sup.6 or R.sup.7 may be
CH(CH.sub.3)CH(OH)phenyl.
[0095] In one embodiment, R.sup.6 or R.sup.7 may be 4-6 membered
heterocycle optionally substituted with F, OH, C.sub.1-C.sub.3
alkyl, cyclopropylmethyl or C(.dbd.O)CH.sub.3. In another
embodiment, R.sup.6 or R.sup.7 may be a 4-6 membered heterocycle
optionally substituted with C.sub.1-C.sub.3 alkyl or
C(.dbd.O)CH.sub.3
[0096] In one embodiment, R.sup.6 or R.sup.7 may be
C.sub.1-C.sub.6-alkyl optionally substituted with one or more
groups independently selected from OH, oxo,
O(C.sub.1-C.sub.6-alkyl), CN, F, NH.sub.2,
NH(C.sub.1-C.sub.6-alkyl), N(C.sub.1-C.sub.6-alkyl).sub.2,
cyclopropyl, phenyl, imidazolyl, piperidinyl, pyrrolidinyl,
morpholinyl, tetrahydrofuranyl, oxetanyl and tetrahydropyranyl. In
another embodiment, R.sup.6 or R.sup.7 may be C.sub.1-C.sub.6-alkyl
optionally substituted with one or more groups independently
selected from OH, oxo, O(C.sub.1-C.sub.6-alkyl), CN, F, NH.sub.2,
NH(C.sub.1-C.sub.6-alkyl), N(C.sub.1-C.sub.6-alkyl).sub.2,
cyclopropyl, phenyl, imidazolyl, piperidinyl, pyrrolidinyl,
morpholinyl, and tetrahydropyranyl.
[0097] In one embodiment, R.sup.6 or R.sup.7 may be H.
[0098] In another embodiment, R.sup.6 or R.sup.7 may be methyl,
ethyl, isopropyl, isobutyl, tert-butyl, 3-pentyl, or CH.sub.2-tBu
(neopentyl). In an additional embodiment, R.sup.6 or R.sup.7 may be
CH.sub.2CH.sub.2OH, CH.sub.2CH.sub.2OMe, CH.sub.2CH.sub.2CF.sub.3,
CH.sub.2CH(CH.sub.3)OH, CH.sub.2CH(CF.sub.3)OH, CH.sub.2CF.sub.3,
CH.sub.2CH.sub.2F, CH.sub.2C(.dbd.O)NH.sub.2,
CH.sub.2C(.dbd.O)NH(CH.sub.3), CH.sub.2C(.dbd.O)N(CH.sub.3).sub.2,
CH.sub.2C(.dbd.O)NH(iPr), CH.sub.2CH.sub.2C(.dbd.O)NH.sub.2,
CH(phenyl)CH.sub.2OH, CH(tetrahydropyranyl)CH.sub.2OH,
CH.sub.2CH.sub.2CH.sub.2(imidazolyl),
CH.sub.2CH.sub.2(morpholinyl), CH.sub.2(tetrahydropyranyl), or
CH.sub.2CH.sub.2(tetrahydropyranyl) or
##STR00011##
[0099] In an additional embodiment, R.sup.6 and R.sup.7 are
independently CH(isopropyl).sub.2, CH.sub.2CH.sub.2CH.sub.2OH,
CH(CH.sub.2CH.sub.2OH).sub.2, CH(CH.sub.2CH.sub.2OMe).sub.2,
CH.sub.2CH.sub.2CH.sub.2OMe, CH.sub.2CN, CH.sub.2-phenyl.
[0100] In another embodiment, R.sup.6 or R.sup.7 may be
OCH.sub.3.
[0101] In another embodiment, R.sup.6 or R.sup.7 may be
CH.sub.2-cyclopropyl, or CH.sub.2-cyclopentyl. In an additional
embodiment, R.sup.6 or R.sup.7 may be CH.sub.2-cyclobutyl.
[0102] In another embodiment, R.sup.6 or R.sup.7 may be
CH.sub.2-(pyrid-3-yl). In an additional embodiment, R.sup.6 or
R.sup.7 may be CH.sub.2-(pyrid-2-yl) or CH.sub.2-(pyrid-4-yl).
[0103] In another embodiment, R.sup.6 or R.sup.7 may be
cyclopropyl, cyclopentyl, cyclohexyl, 4-methoxycyclohexyl,
4,4-dimethylcyclohexyl, 3,3-dimethylcyclohexyl, or
4-hydroxycyclohex-1-yl.
[0104] In another embodiment, R.sup.6 or R.sup.7 may be
CH(CH.sub.3)CH(OH)phenyl.
[0105] In another embodiment, R.sup.6 or R.sup.7 may be
pyrrolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrofuranyl,
or
##STR00012##
[0106] In other embodiments, R.sup.6 and R.sup.7 together with the
nitrogen to which they are attached form a 4-7 membered
heterocyclic ring, wherein said heterocyclic ring is optionally
substituted with one or more groups independently selected from OH,
halogen, oxo, CF.sub.3, CH.sub.2CF.sub.3, CH.sub.2CH.sub.2OH,
OCH.sub.3, C(.dbd.O)CH.sub.3, NH.sub.2, NHMe, N(Me).sub.2,
S(O).sub.2CH.sub.3, and (C.sub.1-C.sub.3)alkyl.
[0107] In particular embodiments, NR.sup.6R.sup.7 is selected from
the structures:
##STR00013## ##STR00014##
[0108] In another embodiment, NR.sup.6R.sup.7 is selected from the
structures:
##STR00015##
[0109] In one embodiment, R.sup.8 and R.sup.6 together with the
atoms to which they are attached form a 5-6 membered heterocyclic
ring having one or two ring nitrogen atoms. In certain embodiments,
R.sup.7 is H.
[0110] In another embodiment, R.sup.8 and R.sup.6 together with the
atoms to which they are attached form a 5-6 membered heterocyclic
ring having one ring nitrogen atom. In certain embodiments, R.sup.7
is H.
[0111] In one embodiment, R.sup.a is H, and R.sup.b and R.sup.6
together with the atoms to which they are attached form a 5-6
membered heterocyclic ring having one or two ring nitrogen atoms.
In certain embodiments, R.sup.7 is H.
[0112] In another embodiment, R.sup.a is H, and R.sup.b and R.sup.6
together with the atoms to which they are attached form a 5-6
membered heterocyclic ring having one ring nitrogen atom. In
certain embodiments, R.sup.7 is H.
[0113] In one embodiment of Formula I, m is 1, n is 0, p is 0, such
that A is represented by the Formula 1:
##STR00016##
wherein G, R.sup.6, R.sup.7, R.sup.8, R.sup.c and R.sup.d are as
defined herein.
[0114] In certain embodiments of the group A having the Formula 1,
R.sup.8 is H or OH. In certain embodiments, R.sup.8 is H. In
particular embodiments, A has the configuration:
##STR00017##
[0115] In certain embodiments of the A group having the Formula 1,
R.sup.c and R.sup.d are H. In other embodiments, R.sup.c and
R.sup.d together with the atom to which they are attached form a
cyclopropyl ring.
[0116] In certain embodiments of the A group having the Formula 1,
R.sup.6 and R.sup.7 are independently H,
C.sub.3-C.sub.6-cycloalkyl, heteroaryl-(CH.sub.2),
hydroxy-(C.sub.3-C.sub.6-cycloalkyl), CH(CH.sub.3)CH(OH)phenyl, or
(C.sub.1-6)-alkyl optionally substituted with one or more groups
independently selected from OH, OMe, and CN. In particular
embodiments, R.sup.6 and R.sup.7 are independently H, methyl,
ethyl, isopropyl, isobutyl, tert-butyl, 3-pentyl,
CH(isopropyl).sub.2, CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2CH.sub.2OH, CH(CH.sub.2CH.sub.2OH).sub.2,
CH.sub.2CH.sub.2OMe, CH(CH.sub.2CH.sub.2OMe).sub.2,
CH.sub.2CH.sub.2CH.sub.2OMe, CH.sub.2CN, CH.sub.2-cyclopropyl,
CH.sub.2-cyclobutyl, CH.sub.2-tBu, cyclopentyl, cyclohexyl,
CH.sub.2-phenyl, CH.sub.2-(pyrid-2-yl), CH.sub.2-(pyrid-3-yl),
CH.sub.2-(pyrid-4-yl), 4-hydroxycyclohex-1-yl, or
CH(CH.sub.3)CH(OH)phenyl.
[0117] In additional embodiments of the A group having the Formula
1, R.sup.6 or R.sup.7 may be OCH.sub.3, C.sub.3-C.sub.6-cycloalkyl
optionally substituted with OCH.sub.3, 5-6 membered heterocycle
optionally substituted with CH.sub.3 or C(.dbd.O)CH.sub.3, or
C.sub.1-C.sub.6-alkyl optionally substituted with one or more
groups independently selected from OH, oxo,
O(C.sub.1-C.sub.6-alkyl), CN, F, NH.sub.2,
NH(C.sub.1-C.sub.6-alkyl), N(C.sub.1-C.sub.6-alkyl).sub.2,
cyclopropyl, phenyl, imidazolyl, piperidinyl, pyrrolidinyl,
morpholinyl, and tetrahydropyranyl.
[0118] In particular embodiments, R.sup.6 or R.sup.7 may
independently be CH.sub.2CF.sub.3, CH.sub.2CH.sub.2F,
CH.sub.2-cyclopentyl, 4-methoxycyclohexyl, 4,4-dimethylcyclohexyl,
3,3-dimethylcyclohexyl, pyrrolidinyl, piperidinyl,
tetrahydropyranyl, tetrahydrofuranyl,
##STR00018##
[0119] In particular embodiments of the A group having the Formula
1, NR.sup.6R.sup.7 is NH.sub.2, NHMe, NHEt, NHPr, NHiPr, NHtBu,
NH(CH.sub.2-tBu), NH(CH.sub.2-cyclopropyl),
NH(CH.sub.2-cyclobutyl), NH(cyclopentyl), NH(CH.sub.2-pyridyl),
NH(cyclohexyl), NH(3-pentyl), NHCH(isopropyl).sub.2,
NH(CH.sub.2CH.sub.2OH), NH(CH.sub.2CH.sub.2CH.sub.2OH),
NH(CH.sub.2CH.sub.2OMe), NH(CH.sub.2CH.sub.2CH.sub.2OMe),
NH(CH.sub.2CN), NMe.sub.2, NMeEt, NMePr, NMe(iPr),
NMe(CH.sub.2-cyclopropyl), NMe(CH.sub.2-cyclobutyl),
NMe(CH.sub.2CH.sub.2OH), NMe(CH.sub.2CH.sub.2CH.sub.2OH),
NMe(CH.sub.2CH.sub.2OMe), NMe(CH.sub.2CH.sub.2CH.sub.2OMe),
NEt.sub.2, NEtPr, NEt(iPr), NEt(CH.sub.2-cyclopropyl),
NEt(CH.sub.2-cyclobutyl), NEt(CH.sub.2CH.sub.2OH),
NEt(CH.sub.2CH.sub.2CH.sub.2OH),
##STR00019##
[0120] In other embodiments of the A group having the Formula 1,
R.sup.6 and R.sup.7 together with the N to which they are attached
form a 4-6 membered heterocyclic ring having a ring nitrogen atom
and optionally having a second ring heteroatom selected form N and
O, wherein said heterocyclic ring is optionally substituted with
one or more groups independently selected from OH, halogen, oxo,
CH.sub.2CF.sub.3, and (C.sub.1-C.sub.3)alkyl. For example, in
certain embodiments, R.sup.6 and R.sup.7 together with the N to
which they are attached form a pyrrolidinyl, piperidinyl,
azetidinyl, morpholinyl or piperizinyl ring, wherein said
pyrrolidinyl, piperidinyl, azetidinyl, morpholinyl and piperazinyl
rings are optionally substituted with one or more groups
independently selected from OH, F methyl, CH.sub.2CF.sub.3, and
oxo. In particular embodiments of the A group having the Formula 1,
NR.sup.6R.sup.7 is selected from the structures:
##STR00020## ##STR00021##
[0121] In additional embodiments, R.sup.6 and R.sup.7 together with
the nitrogen to which they are attached form a 4-6 membered
heterocyclic ring, wherein said heterocyclic ring is optionally
substituted with one or more groups independently selected from OH,
halogen, oxo, CF.sub.3, CH.sub.2CF.sub.3, CH.sub.2CH.sub.2OH,
OCH.sub.3, C(.dbd.O)CH.sub.3, NH.sub.2, NHMe, N(Me).sub.2,
S(O).sub.2CH.sub.3, and (C.sub.1-C.sub.3)alkyl. In a particular
embodiment, NR.sup.6R.sup.7 has the structure:
##STR00022##
[0122] In certain embodiments of the A group having the Formula 1,
R.sup.6 and R.sup.8 together with the atoms to which they are
attached form a 5-6 membered heterocyclic ring having one or two
ring nitrogen atoms. In other embodiments, R.sup.6 and R.sup.8
together with the atoms to which they are attached form a
pyrrolidinyl or piperidinyl ring.
[0123] In particular embodiments, the A group is selected from the
formulas:
##STR00023## ##STR00024## ##STR00025## ##STR00026##
[0124] In additional embodiments, the A group is selected from the
formulas:
##STR00027## ##STR00028## ##STR00029## ##STR00030## ##STR00031##
##STR00032## ##STR00033## ##STR00034## ##STR00035## ##STR00036##
##STR00037## ##STR00038## ##STR00039## ##STR00040## ##STR00041##
##STR00042## ##STR00043## ##STR00044## ##STR00045## ##STR00046##
##STR00047## ##STR00048##
[0125] In additional embodiments, the A group is selected from the
formulas:
##STR00049##
[0126] In certain embodiments, compounds of the present invention
are represented by Formula 1B:
##STR00050##
wherein G, R.sup.6 and R.sup.7 are as defined herein.
[0127] In another embodiment of Formula I, m is 1, n is 1, p is 0,
such that A is represented by the Formula 2:
##STR00051##
wherein G, R.sup.6, R.sup.7, R.sup.8, R.sup.c and R.sup.d are as
defined herein. In certain embodiments, A has the
configuration:
##STR00052##
[0128] In certain embodiments of the group A having the Formula 2,
R.sup.8 is H or Me.
[0129] In certain embodiments of the group A having the Formula 2,
R.sup.c and R.sup.d are methyl. In other embodiments, R.sup.c and
R.sup.d are H.
[0130] In certain embodiments, R.sup.c and R.sup.d together with
the atom to which they are attached form a cyclopropyl ring.
[0131] In certain embodiments of the group A having the Formula 2,
R.sup.6 and R.sup.7 are independently H, methyl, ethyl, propyl,
isopropyl, CH.sub.2-cyclopropyl, or CH.sub.2-cyclobutyl,
[0132] or R.sup.6 and R.sup.7 together with the nitrogen to which
they are attached form a pyrrolidinyl, piperidinyl, or azetidinyl
ring,
[0133] or R.sup.6 and R.sup.8 together with the atoms to which they
are attached form a piperidinyl or pyrrolidinyl ring.
[0134] In additional embodiments of the group A having the Formula
2, R.sup.6 or R.sup.7 may independently be isobutyl,
tetrahydropyranyl, CH(phenyl)CH.sub.2OH,
CH(tetrahydropyranyl)CH.sub.2OH, cyclohexyl, CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2OCH.sub.3, CH.sub.2CH(CH.sub.3)OH,
CH.sub.2CH(CF.sub.3)OH, CH.sub.2C(.dbd.O)N(CH.sub.3).sub.2,
CH.sub.2C(.dbd.O)NH.sub.2, CH.sub.2CH.sub.2CH.sub.2(imidazolyl)
or
##STR00053##
[0135] In certain embodiments of the group A having the Formula 2,
NR.sup.6R.sup.7 is NH.sub.2, NHMe, NHEt, NHPr, NH(iPr),
NH(CH.sub.2-cyclopropyl), NH(CH.sub.2-cyclobutyl), NMe.sup.2,
NMeEt, NMePr, NMe(iPr), NEt.sub.2, NEtPr, or NEt(iPr).
[0136] In certain embodiments of the group A having the Formula 2,
NR.sup.6R.sup.7 is NH(isobutyl), NH(CH.sub.2CH.sub.2OH),
NH(CH.sub.2CH.sub.2OCH.sub.3),
NH(CH.sub.2C(.dbd.)N(CH.sub.3).sub.2), NH(CH.sub.2CH(CH.sub.3) OH),
NH(cyclohexyl), NH(tetrahydropyranyl), NH(CH(phenyl)CH.sub.2OH),
NH(CH(tetrahydro-pyranyl)CH.sub.2OH), NMe(CH.sub.2CH.sub.2OMe),
NH(CH.sub.2C(.dbd.O)NH.sub.2),
NH(CH.sub.2CH.sub.2CH.sub.2(imidazolyl)) or
##STR00054##
[0137] In other embodiments, NR.sup.6R.sup.7 is selected from the
structures:
##STR00055##
[0138] In other embodiments, NR.sup.6R.sup.7 is selected from the
structures:
##STR00056##
[0139] In certain embodiments of the group A having the Formula 2,
R.sup.6 and R.sup.7 are H. In particular embodiments, A is selected
from:
##STR00057## ##STR00058##
[0140] In additional embodiments, A is selected from:
##STR00059## ##STR00060##
[0141] In certain embodiments, compounds of the present invention
are represented by Formula 2B:
##STR00061##
wherein G, R.sup.c, R.sup.d, R.sup.6 and R.sup.7 are as defined
herein.
[0142] In another embodiment of Formula I, m is 1, n is 0 and p is
1, such that A is represented by the Formula 3:
##STR00062##
wherein G, R.sup.6, R.sup.7, R.sup.8, R.sup.a, R.sup.b, R.sup.c and
R.sup.d are as defined herein. In certain embodiments, A has the
configuration:
##STR00063##
[0143] In certain embodiments of the group A having the Formula 3,
R.sup.8 is H.
[0144] In certain embodiments of the group A of Formula 3, R.sup.c
and R.sup.d are H. In other embodiments, R.sup.c and R.sup.d
together with the atom to which they are attached form a
cyclopropyl ring.
[0145] In certain embodiments of the group A of Formula 3, R.sup.6
and R.sup.7 are independently H, methyl, ethyl, propyl, isopropyl,
t-butyl, CH.sub.2-cyclopropyl, or CH.sub.2-cyclobutyl.
[0146] In certain embodiments, NR.sup.6R.sup.7 of Formula 3 is
NH.sub.2, NHMe, NHEt, NHPr, NH(iPr), NHtBu,
NH(CH.sub.2-cyclopropyl), or NH(CH.sub.2-cyclobutyl).
[0147] In certain embodiments of the group A having the Formula 3,
R.sup.6 and R.sup.7 are H. In particular embodiments, A is:
##STR00064##
[0148] In other embodiments of group A of Formula 3, R.sup.a and
R.sup.8 are H, and R.sup.b and R.sup.6 together with the atoms to
which they are attached form a 5 to 6 membered heterocyclic ring
wherein one of the ring atoms is nitrogen. In certain embodiments,
R.sup.b and R.sup.6 together with the atoms to which they are
attached form a pyrrolidinyl ring. In certain embodiments, R.sup.7
is H. In particular embodiments, A is selected from:
##STR00065##
[0149] In certain embodiments, compounds of the present invention
are represented by Formula 3B:
##STR00066##
wherein G, R.sup.6 and R.sup.7 are as defined herein.
[0150] In certain embodiments of Formula I, m is 0, n is 0 and p is
1, such that A is represented by the Formula 4:
##STR00067##
wherein G, R.sup.6, R.sup.7, and R.sup.8 are as defined herein. In
certain embodiments, A has the configuration:
##STR00068##
[0151] In certain embodiments of the group A having the Formula 4,
R.sup.8 is H. In certain embodiments, R.sup.6 and R.sup.7 are
independently H or Me. In particular embodiments, A is selected
from:
##STR00069##
[0152] In certain embodiments, R.sup.6 or R.sup.7 may be methyl,
iPr, piperidinyl, tetrahydrofuranyl, CH.sub.2CH.sub.2CF.sub.3,
CH.sub.2CH.sub.2(morpholinyl), CH.sub.2(tetrahydropyranyl),
CH.sub.2CH.sub.2(tetrahydropyranyl), CH.sub.2C(.dbd.O)NH(iPr),
CH.sub.2C(.dbd.O)N(Me).sub.2 or
##STR00070##
[0153] Additional embodiments of A include:
##STR00071## ##STR00072## ##STR00073##
[0154] In certain embodiments, compounds of the present invention
are represented by Formula 4B:
##STR00074##
wherein G and R.sup.5 are as defined herein.
[0155] In certain embodiments, compounds of the present invention
are represented by Formula 4C:
##STR00075##
wherein G and R.sup.5 are as defined herein.
[0156] The compounds of this invention may possess one or more
asymmetric centers; such compounds can therefore be produced as
individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless
indicated otherwise, the description or naming of a particular
compound in the specification and claims is intended to include
both individual enantiomers and diastereomers, and mixtures,
racemic or otherwise, thereof. Accordingly, this invention also
includes all such isomers, including diastereomeric mixtures, pure
diastereomers and pure enantiomers of the compounds of this
invention. The term "enantiomer" refers to two stereoisomers of a
compound which are non-superimposable mirror images of one another.
The term "diastereomer" refers to a pair of optical isomers which
are not mirror images of one another. Diastereomers have different
physical properties, e.g. melting points, boiling points, spectral
properties, and reactivities.
[0157] The compounds of the present invention may also exist in
different tautomeric forms, and all such forms are embraced within
the scope of the invention. The term "tautomer" or "tautomeric
form" refers to structural isomers of different energies which are
interconvertible via a low energy barrier. For example, proton
tautomers (also known as prototropic tautomers) include
interconversions via migration of a proton, such as keto-enol and
imine-enamine isomerizations. Valence tautomers include
interconversions by reorganization of some of the bonding
electrons.
[0158] In the structures shown herein, where the stereochemistry of
any particular chiral atom is not specified, then all stereoisomers
are contemplated and included as the compounds of the invention.
Where stereochemistry is specified by a solid wedge or dashed line
representing a particular configuration, then that stereoisomer is
so specified and defined.
[0159] The compounds of Formula I include solvates,
pharmaceutically acceptable prodrugs and salts (including
pharmaceutically acceptable salts) of such compounds.
[0160] The phrase "pharmaceutically acceptable" indicates that the
substance or composition is compatible chemically and/or
toxicologically with the other ingredients comprising a
formulation, and/or the mammal being treated therewith.
[0161] A "solvate" refers to an association or complex of one or
more solvent molecules and a compound of the invention. Examples of
solvents that form solvates include, but are not limited to, water,
isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid,
and ethanolamine. The term "hydrate" can also be used to refer to a
complex wherein the solvent molecule is water.
[0162] A "prodrug" is a compound that may be converted under
physiological conditions or by solvolysis to the specified compound
or to a salt of such compound. Prodrugs include compounds wherein
an amino acid residue, or a polypeptide chain of two or more (e.g.,
two, three or four) amino acid residues, is covalently joined
through an amide or ester bond to a free amino, hydroxy or
carboxylic acid group of a compound of the present invention. The
amino acid residues include but are not limited to the 20 naturally
occurring amino acids commonly designated by three letter symbols
and also includes phosphoserine, phosphothreonine, phosphotyrosine,
4-hydroxyproline, hydroxylysine, demosine, isodemosine,
gamma-carboxyglutamate, hippuric acid, octahydroindole-2-carboxylic
acid, statine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid,
penicillamine, ornithine, 3-methylhistidine, norvaline,
beta-alanine, gamma-aminobutyric acid, cirtulline, homocysteine,
homoserine, methyl-alanine, para-benzoylphenylalanine,
phenylglycine, propargylglycine, sarcosine, methionine sulfone and
tert-butylglycine.
[0163] Additional types of prodrugs are also encompassed. For
instance, a free carboxyl group of a compound of Formula I can be
derivatized as an amide or alkyl ester. As another example,
compounds of this invention comprising free hydroxy groups may be
derivatized as prodrugs by converting the hydroxy group into a
group such as, but not limited to, a phosphate ester,
hemisuccinate, dimethylaminoacetate, or
phosphoryloxymethyloxycarbonyl group, as outlined in Advanced Drug
Delivery Reviews, 1996, 19, 115. Carbamate prodrugs of hydroxy and
amino groups are also included, as are carbonate prodrugs,
sulfonate esters and sulfate esters of hydroxy groups.
Derivatization of hydroxy groups as (acyloxy)methyl and
(acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester
optionally substituted with groups including, but not limited to,
ether, amine and carboxylic acid functionalities, or where the acyl
group is an amino acid ester as described above, are also
encompassed. Prodrugs of this type are described in J. Med. Chem.,
1996, 39, 10. More specific examples include replacement of the
hydrogen atom of the alcohol group with a group such as
(C.sub.1-C.sub.6)alkanoyloxymethyl,
1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
1-methyl-1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
(C.sub.1-C.sub.6)alkoxycarbonyloxymethyl,
N--(C.sub.1-C.sub.6)alkoxy-carbonylaminomethyl, succinoyl,
(C.sub.1-C.sub.6)alkanoyl, .alpha.-amino(C.sub.1-C.sub.4)alkanoyl,
arylacyl and .alpha.-aminoacyl, or
.alpha.-aminoacyl-.alpha.-aminoacyl, where each .alpha.-aminoacyl
group is independently selected from the naturally occurring
L-amino acids, P(O)(OH).sub.2,
--P(O)(O(C.sub.1-C.sub.6)alkyl).sub.2 or glycosyl (the radical
resulting from the removal of a hydroxyl group of the hemiacetal
form of a carbohydrate).
[0164] Free amines of compounds of Formula I can also be
derivatized as amides, sulfonamides or phosphonamides. All of these
moieties may incorporate groups including, but not limited to,
ether, amine and carboxylic acid functionalities. For example, a
prodrug can be formed by the replacement of a hydrogen atom in the
amine group with a group such as R-carbonyl, RO-carbonyl,
NRR'-carbonyl, wherein R and R' are each independently
(C.sub.1-C.sub.10)alkyl, (C.sub.3-C.sub.7)cycloalkyl, or benzyl, or
R-carbonyl is a natural .alpha.-aminoacyl or natural
.alpha.-aminoacyl-natural .alpha.-aminoacyl, --C(OH)C(O)OY wherein
Y is H, (C.sub.1-C.sub.6)alkyl or benzyl, --C(OY.sub.0)Y.sub.1
wherein Y.sub.0 is (C.sub.1-C.sub.4) alkyl and Yi is
(C.sub.1-C.sub.6)alkyl, carboxy(C.sub.1-C.sub.6)alkyl,
amino(C.sub.1-C.sub.4)alkyl or mono-N- or
di-N,N--(C.sub.1-C.sub.6)alkylaminoalkyl, or --C(Y.sub.2)Y.sub.3
wherein Y.sub.2 is H or methyl and Y.sub.3 is mono-N- or
di-N,N--(C.sub.1-C.sub.6)alkylamino, morpholino, piperidin-1-yl or
pyrrolidin-1-yl.
[0165] For additional examples of prodrug derivatives, see, for
example, a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier,
1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K.
Widder, et al. (Academic Press, 1985); b) A Textbook of Drug Design
and Development, edited by Krogsgaard-Larsen and H. Bundgaard,
Chapter 5 "Design and Application of Prodrugs," by H. Bundgaard p.
113-191 (1991); c) H. Bundgaard, Advanced Drug Delivery Reviews,
8:1-38 (1992); d) H. Bundgaard, et al., Journal of Pharmaceutical
Sciences, 77:285 (1988); and e) N. Kakeya, et al., Chem. Pharm.
Bull., 32:692 (1984), each of which is specifically incorporated
herein by reference.
[0166] Alternatively or additionally, compound of the invention may
possess a sufficiently acidic group, a sufficiently basic group, or
both functional groups, and accordingly react with any of a number
of inorganic or organic bases or acids to form a salt. Examples of
salts include those salts prepared by reaction of the compounds of
the present invention with a mineral or organic acid or an
inorganic base, such salts including, but not limited to, sulfates,
pyrosulfates, bisulfates, sulfites, bisulfites, phosphates,
monohydrogenphosphates, dihydrogenphosphates, metaphosphates,
pyrophosphates, chlorides, bromides, iodides, acetates,
propionates, decanoates, caprylates, acrylates, formates,
isobutyrates, caproates, heptanoates, propiolates, oxalates,
malonates, succinates, suberates, sebacates, fumarates, maleates,
butyn-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates,
methylbenzoates, dinitrobenzoates, hydroxybenzoates,
methoxybenzoates, phthalates, sulfonates, xylenesulfonates,
phenylacetates, phenylpropionates, phenylbutyrates, citrates,
lactates, .gamma.-hydroxybutyrates, glycollates, tartrates,
methanesulfonates, propanesulfonates, naphthalene-1-sulfonates,
naphthalene-2-sulfonates, and mandelates. Since a single compound
of the present invention may include more than one acidic or basic
moiety, the compounds of the present invention may include mono, di
or tri-salts in a single compound.
[0167] If the inventive compound is a base, the desired salt may be
prepared by any suitable method available in the art, for example,
by treatment of the free base with an acidic compound, for example
an inorganic acid such as hydrochloric acid, hydrobromic acid,
sulfuric acid, nitric acid, phosphoric acid and the like, or with
an organic acid, such as acetic acid, maleic acid, succinic acid,
mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic
acid, glycolic acid, salicylic acid, a pyranosidyl acid such as
glucuronic acid or galacturonic acid, an alpha hydroxy acid such as
citric acid or tartaric acid, an amino acid such as aspartic acid
or glutamic acid, an aromatic acid such as benzoic acid or cinnamic
acid, a sulfonic acid such as p-toluenesulfonic acid or
ethanesulfonic acid, or the like.
[0168] If the inventive compound is an acid, the desired salt may
be prepared by any suitable method, for example, by treatment of
the free acid with an inorganic or organic base. Examples of
suitable inorganic salts include those formed with alkali and
alkaline earth metals such as lithium, sodium, potassium, barium
and calcium. Examples of suitable organic base salts include, for
example, ammonium, dibenzylammonium, benzylammonium, 2-hydroxyethyl
ammonium, bis(2-hydroxyethyl)ammonium, phenylethylbenzylamine,
dibenzylethylenediamine, and the like salts. Other salts of acidic
moieties may include, for example, those salts formed with
procaine, quinine and N-methylglucosamine, plus salts formed with
basic amino acids such as glycine, ornithine, histidine,
phenylglycine, lysine and arginine.
[0169] In certain embodiments, the salt is a "pharmaceutically
acceptable salt" which, unless otherwise indicated, includes salts
that retain the biological effectiveness of the corresponding free
acid or base of the specified compound and are not biologically or
otherwise undesirable.
[0170] The compounds of Formula I also include other salts of such
compounds which are not necessarily pharmaceutically acceptable
salts, and which may be useful as intermediates for preparing
and/or purifying compounds of Formula I and/or for separating
enantiomers of compounds of Formula I.
[0171] The present invention also embraces isotopically-labeled
compounds of the present invention which are identical to those
recited herein, but for the fact that one or more atoms are
replaced by an atom having an atomic mass or mass number different
from the atomic mass or mass number usually found in nature. All
isotopes of any particular atom or element as specified are
contemplated within the scope of the compounds of the invention,
and their uses. Exemplary isotopes that can be incorporated into
compounds of the invention include isotopes of hydrogen, carbon,
nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and
iodine, such as .sup.2H, .sup.3H, .sup.11C, .sup.13C, .sup.14C,
.sup.13N, .sup.15N, .sup.15O, .sup.17O, .sup.18O, .sup.32P,
.sup.33P, .sup.35S, .sup.18F, .sup.36Cl, .sup.123I and .sup.125I.
Certain isotopically-labeled compounds of the present invention
(e.g., those labeled with .sup.3H and .sup.14C) are useful in
compound and/or substrate tissue distribution assays. Tritiated
(i.e., .sup.3H) and carbon-14 (i.e., .sup.14C) isotopes are useful
for their ease of preparation and detectability. Further,
substitution with heavier isotopes such as deuterium (i.e.,
.sup.2H) may afford certain therapeutic advantages resulting from
greater metabolic stability (e.g., increased in vivo half-life or
reduced dosage requirements) and hence may be preferred in some
circumstances. Positron emitting isotopes such as .sup.15O,
.sup.13N, .sup.11C and .sup.18F are useful for positron emission
tomography (PET) studies to examine substrate receptor occupancy.
Isotopically labeled compounds of the present invention can
generally be prepared by following procedures analogous to those
disclosed in the Schemes and/or in the Examples herein below, by
substituting an isotopically labeled reagent for a non-isotopically
labeled reagent.
Metabolites of Compounds of Formula I
[0172] Also falling within the scope of this invention are the in
vivo metabolic products of compounds of Formula I described herein.
A "metabolite" is a pharmacologically active product produced
through metabolism in the body of a specified compound or salt
thereof. Such products may result, for example, from the oxidation,
reduction, hydrolysis, amidation, deamidation, esterification,
deesterification, enzymatic cleavage, and the like, of the
administered compound. Accordingly, the invention includes
metabolites of compounds of Formula I, including compounds produced
by a process comprising contacting a compound of this invention
with a mammal for a period of time sufficient to yield a metabolic
product thereof.
[0173] Metabolites are identified, for example, by preparing a
radiolabelled (e.g., .sup.14C or .sup.3H) isotope of a compound of
the invention, administering it parenterally in a detectable dose
(e.g., greater than about 0.5 mg/kg) to an animal such as rat,
mouse, guinea pig, monkey, or to a human, allowing sufficient time
for metabolism to occur (typically about 30 seconds to 30 hours)
and isolating its conversion products from the urine, blood or
other biological samples. These products are easily isolated since
they are labeled (others are isolated by the use of antibodies
capable of binding epitopes surviving in the metabolite). The
metabolite structures are determined in conventional fashion, e.g.,
by MS, LC/MS or NMR analysis. In general, analysis of metabolites
is done in the same way as conventional drug metabolism studies
well known to those skilled in the art. The metabolites, so long as
they are not otherwise found in vivo, are useful in diagnostic
assays for therapeutic dosing of the compounds of the
invention.
Synthesis of Compounds of Formula I
[0174] Compounds of this invention may be synthesized by synthetic
routes that include processes analogous to those well known in the
chemical arts, particularly in light of the description contained
herein. The starting materials are generally available from
commercial sources such as Aldrich Chemicals (Milwaukee, Wis.) or
are readily prepared using methods well known to those skilled in
the art (e.g., prepared by methods generally described in Louis F.
Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-19,
Wiley, N.Y. (1967-1999 ed.), or Beilsteins Handbuch der organischen
Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including
supplements).
[0175] Compounds of Formula I may be prepared singly or as compound
libraries comprising at least 2, for example 5 to 1,000 compounds,
or 10 to 100 compounds. Libraries of compounds of Formula I may be
prepared by a combinatorial `split and mix` approach or by multiple
parallel syntheses using either solution phase or solid phase
chemistry, by procedures known to those skilled in the art. Thus
according to a further aspect of the invention there is provided a
compound library comprising at least 2 compounds of Formula I, or
salts thereof.
[0176] For illustrative purposes, Schemes 1-4 and Schemes A-J shows
a general method for preparing the compounds of the present
invention as well as key intermediates. For a more detailed
description of the individual reaction steps, see the Examples
section below. Those skilled in the art will appreciate that other
synthetic routes may be used to synthesize the inventive compounds.
Although specific starting materials and reagents are depicted in
the Schemes and discussed below, other starting materials and
reagents can be easily substituted to provide a variety of
derivatives and/or reaction conditions. In addition, many of the
compounds prepared by the methods described below can be further
modified in light of this disclosure using conventional chemistry
well known to those skilled in the art.
##STR00076## ##STR00077##
[0177] Scheme 1 shows a method of preparing compound 10 of Formula
I wherein R.sup.1 is H, R.sup.2 is OH and R.sup.5 is H. Formation
of pyrimidine 2 can be accomplished by the reaction of the keto
ester 1 with thiourea in the presence of a base such as KOH in an
appropriate solvent, such as ethanol. After reduction of the
mercapto group of compound 2 under standard reducing conditions
(e.g., Raney Ni and NH.sub.4OH) to provide compound 3, the
hydroxypyrimidine 3 can be chlorinated under standard conditions
(e.g., POCl.sub.3 in DIEA/DCE) to provide compound 4. Compound 4 is
then oxidized under standard conditions (e.g., MCPBA in an
appropriate solvent such as CHCl.sub.3) to give the
pyrimidine-oxide 5. Treatment of the pyrimidine-oxide with acetic
anhydride gives the rearrangement product 6. Compound 7 is obtained
by reacting compound 6 with an appropriately substituted piperidine
under standard S.sub.NAr reaction conditions to provide compound 7.
Compound 7 is hydrolyzed to provide compound 8, which is then
deprotected to yield the intermediate 9. Acylation of the
piperazinyl cyclopenta[d]pyrimidine 9 with an appropriated amino
acid in the presence of a coupling reagent such as HBTU, followed
by deprotection if necessary, gives compound 10 of Formula I.
##STR00078## ##STR00079##
[0178] Scheme 2 shows a method of preparing compounds 22, 25 and 27
of Formula I wherein R.sup.1, R.sup.2 and R.sup.5 are methyl.
According to Scheme 2, bromination of (+)-pulegone 11 with bromine
gives the dibromide 12. The treatment of the dibromide 12 with a
base such as sodium ethoxide provides the pulegenate 13. Ozonolysis
of the pulegenate 13 gives the ketoester 14. Treatment of the keto
ester 14 with thiourea in the presence of a base such as KOH in
ethanol, followed by reduction of the mercapto group under standard
conditions (e.g. Raney Ni catalyst in ammonia) affords the
hydroxypyrimidine 16. Chlorination of the hydroxypyrimidine 16
under standard conditions (e.g., POCl.sub.3) provides the
4-chloropyrimidine 17. The oxidation of the 4-chloropyrimidine 17
with an oxidizing agent such as MCPBA or hydrogen peroxide provides
the N-oxide 18. Rearrangement of the N-oxide 18 with acetic
anhydride yields the intermediate 19. Compound 19 is reacted with
the desired piperazine according to the procedure described in
Scheme 1 to provide compound 20 where R.sup.5 is H and 23 where
R.sup.5 is Me. Compounds 20 and 23 are subjected to chiral
separation using HPLC with chiral stationary and then hydrolyzed
upon treatment with a base such as lithium hydroxide to provide
compounds 21 and 24, respectively. After deprotection, compounds 21
and 24 are then reacted with the appropriate amino acid to provide
compounds 22 and 25, respectively.
[0179] Alternatively, the 7-hydroxy group of compound 24 may be
alkylated with alkylation reagent such as alkyl halide in the
presence of a base such as NaH or KOH to provide compound 26 where
R.sup.2 is Me. After deprotection, compound 26 is then reacted with
the appropriate amino acid to provide compound 27.
##STR00080## ##STR00081## ##STR00082##
[0180] Scheme 3 shows an alternative method of preparing compounds
73 and 74. According to Scheme 3, amination of 14 using an ammonia
synthon gives 63. Pyrimidine formation using, for example, ammonium
formate in the presence of formamide at 50.degree. C.-250.degree.
C. and/or at high pressure gives the bicyclic unit 64. Activation
of 64 using, for example, POCl.sub.3 or SOCl.sub.2 gives the
activated pyrimidine 65. Displacement of this leaving group, using
a suitable protected/substituted piperidine at 0.degree. C. to
150.degree. C. gives the piperidine 66. Oxidation, using, for
example, m-chloroperoxybenzoic acid ("MCPBA" or "m-CPBA") or
Oxone.RTM. at -20.degree. C. to 50.degree. C. gives the N-oxide 67.
Treatment with an acylating agent (eg. acetic anhydride) followed
by heating (40.degree. C. to 200.degree. C.) causes rearrangement
to give 68. Hydrolysis, using, for example LiOH or NaOH at
0.degree. C. to 50.degree. C. gives the alcohol 69. Oxidation,
using for example, Swern conditions, MnO.sub.4 or pyridine-SO.sub.3
complex at appropriate temperatures gives the ketone 70. Asymmetric
reduction using, for example, a catalytic chiral catalyst in the
presence of hydrogen, the CBS catalyst or a borohydride reducing
agent in the presence of a chiral ligand gives rise to either the
(R) or the (S) stereochemistry at the alcohol 71 or 72.
Alternatively, a non-chiral reducing agent could be used (eg.
H.sub.2, Pd/C), allowing the methyl group on the cyclopentane unit
to provide facial selectivity and ultimately diastereoselectivity.
If the reduction gives a lower diastereoselctivity, the
diastereomers could be separated by (for example) chromatography,
crystallization or derivitization. Finally deprotection of the
Boc-group, using, for example, acid at 0.degree. C. to 50.degree.
C., acylation using an appropriately functionalized amino acid and
final functionalization of the amine of this amino acid (eg.
removal of any protecting group, alkylation, reductive amination or
acylation to introduce new substituents) gives rise to the final
compounds 73 and 74.
##STR00083##
[0181] Introduction of a chiral auxiliary (e.g. Evans
oxazolidinone, etc.) to compound 1 may be accomplished by standard
acylation procedures to give the conjugate 2. For example,
treatment of the acid with an activating agent (e.g. COCl.sub.2) or
mixed anhydride formation (e.g. 2,2-dimethylpropanoyl chloride) in
the presence of an amine base at -20.degree. C. to 100.degree. C.
followed by treatment with the appropriate chiral auxiliary (X)
gives compound 2. The stereochemistry and choice of the chiral
auxiliary may determine the stereochemistry of the newly created
chiral center and the diastereoselectivity. Treatment of compound 2
with a Lewis acid (eg. TiCl.sub.4) at low temperature (e.g.
-20.degree. C. to -100.degree. C.) and an amine base (e.g. Hunig's
base) followed by the use of an appropriately substituted imminium
ion precursor 3 at low temperature then gives rise to compound 4.
The temperature, Lewis acid and chiral auxiliary may all be
expected to influence the diastereoselectivity of the addition
adduct. Finally, saponification under mild conditions (e.g.
LiOH/H.sub.2O at -10.degree. C. to 30.degree. C.) gives rise to the
desired acid 5.
[0182] According, another aspect of this invention provides a
method of preparing a compound of Formula I, comprising:
[0183] reacting a compound having the formula:
##STR00084##
wherein R.sup.1, R.sup.2, R.sup.5 and R.sup.10 are as defined
herein, with an amino acid having the formula:
##STR00085##
wherein R.sup.6, R.sup.7, R.sup.a, R.sup.b, R.sup.c, R.sup.d, G, m,
n and p are as defined herein.
[0184] The amino acids used in the synthesis of compounds of
Formula I as illustrated in Schemes 1-4 and in the Examples are
either commercially available or may be prepared according to the
methods disclosed herein. For example, in certain embodiments the
amino acids used to prepare compounds of Formula I include
.beta.-phenylglycine amino acids having the Formula 1A,
.gamma.-phenylglycine amino acids having the Formula 2A,
.beta.-phenylalanine amino acids having the Formula 3A, and
.gamma.-phenylalanine amino acids having the Formula 4A.
##STR00086##
[0185] Methods of preparing amino acids of Formulas 1A-4A are shown
in Schemes A-J.
##STR00087##
[0186] Scheme A illustrates a method of preparing optionally
substituted .beta.-phenylglycine amino acids 25 and 26 of the
Formula 1A wherein R.sup.8 is H, and R.sup.6, and R.sup.9 and are
as defined herein, t is 0 to 4, and R.sup.7 is H or an amine
protecting group. According to Scheme A, the acid 20 is converted
to an ester 21 wherein R' is alkyl using standard conditions such
as treatment with an appropriate alcohol (e.g. MeOH) in the
presence of a catalytic amount of an acid such as concentrated
H.sub.2SO.sub.4 or a coupling agent such as DCC/DMAP; or
alternatively by treatment with an appropriate electrophile (e.g.,
Mel, EtBr, BnBr) in the presence of a base such as NEt.sub.3/DMAP
at an appropriate temperature (e.g., -20.degree. C. to 100.degree.
C.). The appropriate choice of ester is determined by the
conditions required to reform the acid at the end of the synthesis,
with many appropriate examples and conditions being listed in
`Protective Groups in Organic Synthesis` by Greene and Wuts,
Wiley-Interscience, third edition, Chapter 5. Introduction of the
hydroxymethyl group to provide compound 22 may be performed by
treatment with an appropriate aldehyde (e.g., formaldehyde) in the
presence of base such as NaOEt at an appropriate temperature (e.g.,
-20.degree. C. to room temperature). Activation of the alcohol
group of compound 22 to form a leaving group (e.g., a mesylate,
tosylate, halide) may be accomplished by treatment with, for
example, methanesulphonyl chloride in the presence of excess base
such as NEt.sub.3, DIPEA, or DBU at an appropriate temperature
(e.g., -20.degree. C. to room temperature). In many cases the
olefin 24 can be isolated directly from this procedure, in other
cases warming (30.degree. C. to 100.degree. C.) or additional base
(e.g. DBU in the case of halide) may be required to complete the
elimination to provide compound 24. The activated olefin 24 may be
treated with the desired primary amine (e.g., ethylamine) in a
suitable solvent, such as THF, at an appropriate temperature (e.g.,
-20.degree. C. to reflux) to generate the amino ester intermediate.
In the case wherein compound 24 has an electron rich aromatic ring
or electron poor/bulky primary amine, heating (e.g. 30-240.degree.
C. in a sealed tube) or microwave chemistry may be required.
Protection of the amine group (for example as Boc-group) may be
accomplished using Boc.sub.2O under standard conditions to provide
compound 23 wherein Pg is a protecting group. Alternative
protecting groups may be used, and many appropriate examples are
listed in `Protective Groups in Organic Synthesis` by Greene and
Wuts, Wiley-Interscience, third edition, Chapter 7. Saponification
of the ester 23 to form the protected amino acid 25 may be
accomplished using conditions appropriate for the ester (e.g.,
aqueous LiOH for methyl esters, hydrogenation for benzyl esters,
acid for t-butyl esters).
[0187] Alternatively, the activated olefin 24 may be treated with a
secondary amine (e.g., diethylamine) in a suitable solvent such as
THF at an appropriate temperature (e.g., -20.degree. C. to reflux)
to generate the aminoester intermediate (not shown). In the case
wherein compound 24 has an electron rich aromatic ring or electron
poor/bulky secondary amine, heating (e.g., 30-240.degree. C. in a
sealed tube) or microwave chemistry may be required. Saponification
of the ester to form the amino acid 26 may be accomplished using
conditions appropriate for the ester (e.g., aqueous LiOH for methyl
esters, hydrogenation for benzyl esters, acid for t-butyl esters,
etc.).
[0188] In an alternative to Scheme A, Pg may be substituted with
R.sup.7 in compounds 23 and 25.
##STR00088##
[0189] Scheme A1 shows an alternative to Scheme 1, wherein the
activated olefin 24 is reacted to form the amino acid 26A.
##STR00089##
[0190] Scheme B shows a method of preparing optionally substituted
.beta.-phenylglycine amino acids 30 and 31 of Formula 1A wherein
R.sup.8 is OH, and R.sup.6, and R.sup.9 are as defined herein, t is
0 to 4, and R.sup.7 is as defined herein or an amine protecting
group. Oxidation of the unsaturated ester 24 (prepared according to
Scheme A), wherein t is 0-4 and R' is alkyl, using a standard
oxidizing agent such as MCPBA at an appropriate temperature (room
temperature to reflux) provides the epoxide intermediate 28.
Intermediate 28 may be treated with an appropriate amine, typically
at high temperature (e.g., 50-300.degree. C.) and high pressure
(e.g., in a sealed tube or a bomb) to give the amino alcohol 29 or
30. If a secondary amine is used (such as in the preparation of
compound 30), then deprotection of the ester using conditions
listed in `Protective Groups in Organic Synthesis` by Greene and
Wuts, Wiley-Interscience, third edition, Chapter 5 may be used
(e.g., LiOH for a methyl ester, hydrogenation for a benzyl ester,
etc). When a primary amine is used (such as in the preparation of
compound 29), protection of the amine (e.g., as a Boc-group using
Boc anhydride) followed by deprotection of the ester (using the
above conditions) provide the hydroxylated amino acid 31.
##STR00090##
[0191] Scheme C shows a method of preparing optionally substituted
.beta.-phenylglycine amino acids 36 of the Formula 1A wherein
R.sup.8 is methyl, R.sup.6 is H, R.sup.7 is an amine protecting
group t is 0 to 4, and R.sup.9 is as defined herein. The ester 32,
wherein R''' is alkyl, can be treated with a base (e.g. NaOtBu) at
an appropriate temperature (e.g., 0.degree. C. to reflux) to form
the anion, followed by addition of an electrophile (e.g.,
tert-butyl 2-bromoacetate) at an appropriate temperature (e.g.,
-78.degree. C. to room temperature) to give the homologated ester
33. Saponification of the t-butyl ester of compound 33 using an
appropriate acid such as TFA or HCl at an appropriate temperature
(e.g., 0.degree. C. to reflux) provides compound 34. A Curtius
rearrangement of compound 34 using, for example, DPPA in the
presence of mild base such as NEt.sub.3 at an appropriate
temperature (e.g., 0.degree. C. to reflux), followed by treatment
of the reactive intermediate with an alcohol (e.g. t-BuOH),
optionally in the presence of a Lewis acid (e.g. SnCl.sub.2) at
higher temperature (e.g., 40-200.degree. C.) provides compound 35
wherein Pg is an amine protecting group. The choice of alcohol used
to prepare compound 35 determines the amine protecting group (e.g.
t-BuOH provides the Boc-amine). Deprotection of the ester group of
compound 35 using standard conditions (e.g., with LiOH when the
protecting group is a methyl ester, hydrogenation for a benzyl
ester, etc.) gives the acid compound 36.
[0192] In one alternative of Scheme C, R.sup.8 may be methyl, H or
F.
[0193] In another alternative of Scheme C, Pg may be substituted
with R.sup.7 in compounds 35 and 36.
##STR00091##
[0194] Scheme D shows a method of preparing optionally substituted
.gamma.-phenylglycine amino acids 40 of Formula 2A wherein R.sup.c,
R.sup.d, and R.sup.9 are as defined herein t is 0 to 4, R.sup.6 is
H, and R.sup.7 is an amine protecting group such as Boc. The
starting unsaturated ester 24, prepared according to Scheme A, can
be treated with a substituted nitromethane derivative (e.g.
nitroethane) in the presence of a base such as DBU at an
appropriate temperature (e.g., 0.degree. C. to room temperature) to
give the homologated adduct 37. The nitro group of compound 37 can
be reduced using standard conditions (e.g., hydrogenation, Zn/acid,
etc.) at an appropriate temperature (e.g., room temperature to
reflux), and the resulting intermediate can be cyclized to give the
lactam intermediate 38. Protection of the amine, for example with a
Boc-group to provide compound 39, may be accomplished using
Boc.sub.2O under standard conditions. Alternative protecting groups
may be used, and many appropriate examples are listed in
`Protective Groups in Organic Synthesis` by Greene and Wuts,
Wiley-Interscience, third edition, Chapter 7. Treatment of compound
39 with an aqueous base such as LiOH or KOH at an appropriate
temperature (e.g., 0 to 100.degree. C.) effects ring opening of the
lactam to give the appropriately substituted protected amino acid
compound 40.
[0195] In one alternative of Scheme D, Boc may be replaced with
R.sup.7 in compounds 39 and 40.
##STR00092##
[0196] Scheme D1 shows representative methods of forming the single
enantiomers of the gamma amino acids 40d and 40e, wherein R.sup.c,
R.sup.d, and R.sup.9 are as defined herein, t is 0 to 4, R.sup.6 is
H, and R.sup.7 is an amine protecting group such as Boc. In one
possible method, the racemic amino acid is subject to chiral
chromatographic separation using a chiral stationary phase.
Alternatively, a diastereomeric mixture may be prepared which could
be separated by conventional chromatographic techniques. For
example, activation of compound 40 (e.g. COCl.sub.2, base) and
introduction of a chiral auxiliary (e.g. an Evans' oxazolidinone)
in the presence of a basic amine (e.g. Hunig's base) at -20.degree.
C. to 50.degree. C. gives the diastereomeric mixture of compounds
40b and 40c. This mixture may be separated using standard
conditions (e.g. column chromatography, HPLC, SFC, etc.) to give
the individual diastereomers. These may be converted to the desired
acids by cleavage of the chiral auxiliary (in the case of an Evans'
auxiliary, by using (for example) LiOH/HOOH at -15.degree. C. to
room temperature) to give the compounds 40d and 40e. The
temperature may need to be kept low so as to prevent racemisation
of the newly separated chiral center.
##STR00093##
[0197] Scheme E shows a method of making optionally substituted
.gamma.-phenylglycine amino acids 44 of Formula 2A wherein R.sup.8
is methyl, R.sup.6 is H, R.sup.7 is an amine protecting group, t is
0 to 4, and R.sup.9 is as defined herein. The ester 32, wherein R'
is alkyl and t is 0-4, can be treated with a suitable base such as
KOtBu at an appropriate temperature (e.g., 0.degree. C. to reflux)
to form the anion, followed by addition of an acrylate unit (e.g.,
t-butylacrylate) at a temperature ranging from -78.degree. C. to
room temperature to give the homologated ester 41. Saponification
of the t-butyl ester of compound 41 by treatment with a suitable
acid such as TFA or HCl at an appropriate temperature (e.g.,
0.degree. C. to reflux) provides compound 42. A Curtius
rearrangement of compound 42 using, for example, DPPA in the
presence of mild base such as NEt.sub.3 at an appropriate
temperature (e.g., 0.degree. C. to reflux), followed by treatment
of the reactive intermediate with an appropriate alcohol (e.g.
tBuOH), optionally in the presence of a Lewis acid (e.g.
SnCl.sub.2) at elevated temperatures (e.g. 40-200.degree. C.)
provides compound 43. The choice of alcohol determines the amine
protecting group of compound 43 (e.g., tBuOH provides the
Boc-amine). Deprotection of the ester of compound 43 under standard
conditions (e.g., LiOH for a methyl ester, hydrogenation for a
benzyl ester, etc.) gives the acid 44.
[0198] In one alternative to Scheme E, Pg may be substituted with
R.sup.7 in compounds 43 and 44.
##STR00094##
[0199] Scheme F shows a method of preparing optionally substituted
.beta.-phenylalanine amino acids 48, 49 and 50 of Formula 3A
wherein R.sup.6 is H, R.sup.7 is an amine protecting group, t is 0
to 4, and R.sup.9 is as defined herein. An appropriately
substituted aldehyde 45 can be treated with a cyanoacetate of the
formula CN--CH.sub.2CO.sub.2R''' wherein R''' is alkyl (e.g., ethyl
2-cyanoacetate) in the presence of a suitable base such as
piperidine at an appropriate temperature (e.g., room temperature to
reflux) to give the unsaturated ester 46. Reduction of the olefin
and the nitrile groups of compound 46 to provide compound 47 may be
accomplished in a number of ways. For example, the olefin may be
reduced with any agent known to effect 1,4-reductions, such as
NaBH.sub.4. The nitrile may be reduced using agents such as
LiAlH.sub.4 or NaBH.sub.4 in the presence of a Lewis acid such as
BF.sub.3.OEt.sub.2 or TFA. A number of alternative reducing agents
may be used, such as those listed in `Reductions in Organic
Chemistry` by Hudlicky, ACS monograph, 2.sup.nd edition, Chapter
18. If desired, the primary amine 47 can be monoalkylated or
bisalkylated at this stage using standard conditions (e.g.,
reductive amination using an appropriate aldehyde, Lewis acid and
reducing agent) to provide intermediates (not shown) en route to
compounds 48 and 49. To prepare primary and secondary amines,
protection may be accomplished using any number of protecting
groups (e.g. `Protective Groups in Organic Synthesis` by Greene and
Wuts, Wiley-Interscience, third edition, Chapter 7), for example as
a Boc-group using Boc anhydride at 0.degree. C. to room
temperature. Cleavage of the ester group to form the amino acid 48,
49 or 50 may be accomplished using an aqueous bases such as LiOH or
KOH, or any of the alternative reagents listed in the
aforementioned `Protecting Groups` text (e.g., hydrogenation for a
benzyl ester).
[0200] In one alternative to Scheme F, Pg may be substituted with
R.sup.7 in compounds 49 or 50.
##STR00095##
[0201] Scheme G shows a method of preparing optionally substituted
.alpha.-phenylalanine amino acids 54 of Formula 4A, wherein R.sup.6
is H, R.sup.7 is an amine protecting group, t is 0 to 4, and
R.sup.9 is as defined herein. An appropriately substituted acid 51
may be reduced to the benzyl alcohol 52 using for example
LiAlH.sub.4 at a temperature ranging from room temperature to
reflux. The alcohol group of compound 52 can be activated as a
leaving group (e.g. halide, mesylate, etc.) using, for example,
PBr.sub.3, MsCl/NEt.sub.3, etc. Displacement of this leaving group
using a protected glycine derivative such as ethyl
2-(diphenylmethyleneamino)acetate in the presence of strong base
such as LDA, nBuLi provides the amino ester intermediate 53 wherein
R.sup.1 is alkyl and Pg is a protecting group. Appropriate
protecting groups are listed in `Protective Groups in Organic
Synthesis` by Greene and Wuts, Wiley-Interscience). The amine
protecting group may be changed at this stage, for example to
introduce a Boc-group. Subsequent deprotection of the ester 53
(e.g., using 3N HCl, LiOH, hydrogenation for a benzyl ester, etc.)
at an appropriate temperature (e.g., 0.degree. C. to reflux)
provides the desired N-protected amino acid 54.
[0202] In one alternative to Scheme G, Pg may be substituted with
R.sup.7 in compound 54 after the deprotection of compound 53.
##STR00096##
[0203] Scheme H shows a method of preparing optionally substituted
.gamma.-phenyl glycine amino acids 56 of Formula 2A wherein R.sup.6
and R.sup.8 together with the atoms to which they are attached form
a spirocyclic heterocyclic ring, R.sup.7 is an amine protecting
group, t is 0 to 4, and R.sup.9 is as defined herein. According to
Scheme H, the unsaturated ester 24 can be treated with a suitably
protected glycine derivative (e.g., benzylglycine) and formaldehyde
under dry conditions (e.g., with addition of molecular sieves) at
an appropriate temperature (e.g., room temperature to reflux) to
generate compound 55. Cleavage of the benzyl group using standard
conditions (e.g., via hydrogenation, 1-chloroethylformate, etc.)
followed by addition of an amine protecting group such as a
Boc-group and cleavage of the ester under standard conditions (e.g.
LiOH for a methyl ester, acid for a t-butyl ester, etc., at
0.degree. C. to reflux) provides the N-protected amino acid 56.
[0204] In one alternative to Scheme H, Pg may be substituted with
R.sup.7 in compound 56.
##STR00097##
[0205] Scheme I shows a method of preparing optionally substituted
.beta.-phenylalanine amino acids 61 and 62 of Formula 3A wherein
R.sup.6 and R.sup.b together with the atoms to which they are
attached form a heterocyclic ring, and R.sup.7 and R.sup.9 are as
defined herein and t is 0 to 4. The acid 57 is converted to an
ester 58 using standard conditions such as treatment with an
appropriate alcohol (e.g., MeOH) in the presence of either
catalytic acid (e.g. concentrated H.sub.2SO.sub.4 or TMSCl) or a
coupling agent (e.g. DCC/DMAP); or alternatively by treatment with
an appropriate electrophile (e.g. Mel, EtBr, BnBr) in the presence
of a suitable base such as NEt.sub.3/DMAP at appropriate
temperatures (e.g., -20.degree. C. to 100.degree. C.). The
appropriate choice of ester is determined by the conditions
required to reform the acid at the end of the synthesis, such as
described in `Protective Groups in Organic Synthesis` by Greene and
Wuts, Wiley-Interscience, third edition, Chapter 5. Cyclization of
compound 58 to provide compound 59 may be achieved using, for
example,
N-(methoxymethyl)(phenyl)-N-((trimethylsilyl)methyl)methanamine in
the presence of TFA. This particular set of reagents generates the
benzylamine, which can be cleaved to provide compound 60 under
standard conditions such as such as hydrogenation at -20.degree. C.
to 50.degree. C. or any other standard conditions such as those
listed in `Protective Groups in Organic Synthesis` by Greene and
Wuts, Wiley-Interscience, third edition, Chapter 7. Protection of
the free amine of compound 60 with an alternative protecting group
(e.g., Boc) using reagents listed in the aforementioned text, such
as Boc-anhydride, followed by cleavage of the ester using standard
conditions appropriate for the ester (e.g. aqueous LiOH for methyl
esters, hydrogenation for benzyl esters, acid for t-butyl esters)
provides the acid compound 61. Alternatively, the free amine can be
functionalized further (e.g. using alkylation, reductive amination,
or acylation conditions), followed by ester cleavage to generate
the tertiary amino acid compound 62.
##STR00098##
[0206] Either enantiomer of the b-amino acids may be prepared using
a procedure such as that shown in Scheme J. A 2-phenylacetate
coupled with an appropriate chiral auxiliary (R*) (for example, an
Evans' auxiliary or a Sultam) with the appropriate stereochemistry
to generate the desired chemistry at the b-position of the amino
acid may be treated with an imine or iminium ion synthon (e.g.
prepared in situ by the presence of a Lewis acid (eg. TiCl.sub.4)
and an appropriately substituted alkoxymethanamine or
N-(alkoxymethyl)amide/carbamate at -100.degree. C. to 50.degree.
C.). The asymmetric addition may require the presence of Lewis
acids (eg. TiCl.sub.4), amine bases (eg. Hunig's base) and lower
temperatures (e.g. -100.degree. C. to 0.degree. C.) to generate the
best levels of stereochemical induction. If the de is lower than
required, the separate diastereomers may be separated at this stage
by (for example) chromatography or crystallization. Cleavage of the
chiral auxiliary, using methods known to cleave the chosen
auxiliary (e.g. LiOH/H.sub.2O.sub.2 at -50.degree. C. to 50.degree.
C. for the Evans auxiliary) then leads to the desired N-protected
b-amino acid with the desired stereochemistry at the b-position.
Additionally, if R.sup.6 is also a protecting group (e.g.
2,4-dimethoxybenzyl), it may be removed in the presence of the
Boc-group (e.g. hydrogenation or DDQ, etc.) to give the Boc-amino
acid, which upon removal of the Boc-group would provide the primary
amine, which may be further functionalized by alkylation, acylation
or reductive amination (either prior to or after coupling with the
pyrimidine-piperazine unit).
[0207] In preparing compounds of Formula I, protection of remote
functionalities (e.g., primary or secondary amines, etc.) of
intermediates may be necessary. The need for such protection will
vary depending on the nature of the remote functionality and the
conditions of the preparation methods. Suitable amino-protecting
groups (NH-Pg) include acetyl, trifluoroacetyl, t-butoxycarbonyl
(BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethyleneoxycarbonyl
(Fmoc). The need for such protection is readily determined by one
skilled in the art. For a general description of protecting groups
and their use, see T. W. Greene, Protective Groups in Organic
Synthesis, John Wiley & Sons, New York, 1991.
Methods of Separation
[0208] In any of the synthetic methods for preparing compounds of
Formula I, it may be advantageous to separate reaction products
from one another and/or from starting materials. The desired
products of each step or series of steps is separated and/or
purified to the desired degree of homogeneity by the techniques
common in the art. Typically such separations involve multiphase
extraction, crystallization from a solvent or solvent mixture,
distillation, sublimation, or chromatography. Chromatography can
involve any number of methods including, for example: reverse-phase
and normal phase; size exclusion; ion exchange; high, medium and
low pressure liquid chromatography methods and apparatus; small
scale analytical; simulated moving bed (SMB) and preparative thin
or thick layer chromatography, as well as techniques of small scale
thin layer and flash chromatography.
[0209] Another class of separation methods involves treatment of a
reaction mixture with a reagent selected to bind to or render
otherwise separable a desired product, unreacted starting material,
reaction by product, or the like. Such reagents include adsorbents
or absorbents such as activated carbon, molecular sieves, ion
exchange media, or the like. Alternatively, the reagents can be
acids in the case of a basic material, bases in the case of an
acidic material, binding reagents such as antibodies, binding
proteins, selective chelators such as crown ethers, liquid/liquid
ion extraction reagents (LIX), or the like.
[0210] Selection of appropriate methods of separation depends on
the nature of the materials involved. For example, boiling point
and molecular weight in distillation and sublimation, presence or
absence of polar functional groups in chromatography, stability of
materials in acidic and basic media in multiphase extraction, and
the like. One skilled in the art will apply techniques most likely
to achieve the desired separation.
[0211] Diastereomeric mixtures can be separated into their
individual diastereomers on the basis of their physical chemical
differences by methods well known to those skilled in the art, such
as by chromatography and/or fractional crystallization. Enantiomers
can be separated by converting the enantiomeric mixture into a
diastereomeric mixture by reaction with an appropriate optically
active compound (e.g., chiral auxiliary such as a chiral alcohol or
Mosher's acid chloride), separating the diastereomers and
converting (e.g., hydrolyzing) the individual diastereoisomers to
the corresponding pure enantiomers. Also, some of the compounds of
the present invention may be atropisomers (e.g., substituted
biaryls) and are considered as part of this invention. Enantiomers
can also be separated by use of a chiral HPLC column.
[0212] A single stereoisomer, e.g., an enantiomer, substantially
free of its stereoisomer may be obtained by resolution of the
racemic mixture using a method such as formation of diastereomers
using optically active resolving agents (Eliel, E. and Wilen, S.
"Stereochemistry of Organic Compounds," John Wiley & Sons,
Inc., New York, 1994; Lochmuller, C. H., J. Chromatogr., (1975)
113(3):283-302). Racemic mixtures of chiral compounds of the
invention can be separated and isolated by any suitable method,
including: (1) formation of ionic, diastereomeric salts with chiral
compounds and separation by fractional crystallization or other
methods, (2) formation of diastereomeric compounds with chiral
derivatizing reagents, separation of the diastereomers, and
conversion to the pure stereoisomers, and (3) separation of the
substantially pure or enriched stereoisomers directly under chiral
conditions. See: "Drug Stereochemistry, Analytical Methods and
Pharmacology," Irving W. Wainer, Ed., Marcel Dekker, Inc., New York
(1993).
[0213] Under method (1), diastereomeric salts can be formed by
reaction of enantiomerically pure chiral bases such as brucine,
quinine, ephedrine, strychnine,
.alpha.-methyl-.beta.-phenylethylamine (amphetamine), and the like
with asymmetric compounds bearing acidic functionality, such as
carboxylic acid and sulfonic acid. The diastereomeric salts may be
induced to separate by fractional crystallization or ionic
chromatography. For separation of the optical isomers of amino
compounds, addition of chiral carboxylic or sulfonic acids, such as
camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid
can result in formation of the diastereomeric salts.
[0214] Alternatively, by method (2), the substrate to be resolved
is reacted with one enantiomer of a chiral compound to form a
diastereomeric pair (E. and Wilen, S. "Stereochemistry of Organic
Compounds", John Wiley & Sons, Inc., 1994, p. 322).
Diastereomeric compounds can be formed by reacting asymmetric
compounds with enantiomerically pure chiral derivatizing reagents,
such as menthyl derivatives, followed by separation of the
diastereomers and hydrolysis to yield the pure or enriched
enantiomer. A method of determining optical purity involves making
chiral esters, such as a menthyl ester, e.g., (-)menthyl
chloroformate in the presence of base, or Mosher ester,
.alpha.-methoxy-.alpha.-(trifluoromethyl)phenyl acetate (Jacob III.
J. Org. Chem., (1982) 47:4165), of the racemic mixture, and
analyzing the .sup.1H NMR spectrum for the presence of the two
atropisomeric enantiomers or diastereomers. Stable diastereomers of
atropisomeric compounds can be separated and isolated by normal-
and reverse-phase chromatography following methods for separation
of atropisomeric naphthyl-isoquinolines (WO 96/15111). By method
(3), a racemic mixture of two enantiomers can be separated by
chromatography using a chiral stationary phase ("Chiral Liquid
Chromatography" (1989) W. J. Lough, Ed., Chapman and Hall, New
York; Okamoto, J. of Chromatogr., (1990) 513:375-378). Enriched or
purified enantiomers can be distinguished by methods used to
distinguish other chiral molecules with asymmetric carbon atoms,
such as optical rotation and circular dichroism.
Methods of Treatment with Compounds of Formula I
[0215] The compounds of the present invention can be used as
prophylactics or therapeutic agents for treating diseases or
disorders mediated by modulation or regulation of AKT protein
kinases, tyrosine kinases, additional serine/threonine kinases,
and/or dual specificity kinases. AKT protein kinase mediated
conditions that can be treated according to the methods of this
invention include, but are not limited to, inflammatory,
hyperproliferative cardiovascular, neurodegenerative,
gynecological, and dermatological diseases and disorders.
[0216] In one embodiment, said pharmaceutical composition is for
the treatment of hyperproliferative disorders, including cancers of
the following categories: (1) Cardiac: sarcoma (angiosarcoma,
fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma,
fibroma, lipoma and teratoma; (2) Lung: bronchogenic carcinoma
(squamous cell, undifferentiated small cell, undifferentiated large
cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial
adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma,
non-small cell lung, small cell lung; (3) Gastrointestinal:
esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma,
lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas
(ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma,
carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma,
carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma,
neurofibroma, fibroma), large bowel (adenocarcinoma, tubular
adenoma, villous adenoma, hamartoma, leiomyoma); (4) Genitourinary
tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma],
lymphoma, leukemia), bladder and urethra (squamous cell carcinoma,
transitional cell carcinoma, adenocarcinoma), prostate
(adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal
carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial
cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma);
(5) Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma,
hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma;
(6) Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma,
malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma,
malignant lymphoma (reticulum cell sarcoma), multiple myeloma,
malignant giant cell tumor chordoma, osteochronfroma
(osteocartilaginous exostoses), benign chondroma, chondroblastoma,
chondromyxofibroma, osteoid osteoma and giant cell tumors; (7)
Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma,
osteitis deformans), meninges (meningioma, meningiosarcoma,
gliomatosis), brain (astrocytoma, medulloblastoma, glioma,
ependymoma, germinoma [pinealoma], glioblastoma multifonn
oligodendroglioma, schwannoma, retinoblastoma, congenital tumors),
spinal cord neurofibroma, meningioma, glioma, sarcoma); (8)
Gynecological: uterus (endometrial carcinoma), cervix (cervical
carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian
carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma,
unclassified carcinoma], granulosa-thecal cell tumors,
Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma),
vulva (squamous cell carcinoma, intraepithelial carcinoma,
adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell
carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal
rhabdomyosarcoma), fallopian tubes (carcinoma); (9) Hematologic:
blood (myeloid leukemia [acute and chronic], acute lymphoblastic
leukemia, chronic lymphocytic leukemia, myeloproliferative
diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's
disease, non-Hodgkin's lymphoma [malignant lymphoma]; (10) Skin:
advanced melanoma, malignant melanoma, basal cell carcinoma,
squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi,
lipoma, angioma, dermatofibroma, keloids, psoriasis; (11) Adrenal
glands: neuroblastoma; (12) Breast: metastatic breast; breast
adenocarcinoma; (13) Colon; (14) Oral cavity; (15) Hairy cell
leukemia; (16) Head and neck; (17) and others including refractory
metastatic disease; Kaposi's sarcoma; Bannayan-Zonana syndrome; and
Cowden disease or Lhermitte-Duclos disease, among other kinds of
hyperproliferative disorders.
[0217] Compounds and methods of this invention can be also used to
treat diseases and conditions such as rheumatoid arthritis,
osteoarthritis, Chron's disease, angiofibroma, ocular diseases
(e.g., retinal vascularisation, diabetic retinopathy, age-related
macular degeneration, macular degeneration, etc.), multiple
sclerosis, obesity, Alzheimer's disease, restenosis, autoimmune
diseases, allergy, asthma, endometriosis, atherosclerosis, vein
graft stenosis, peri-anastomatic prothetic graft stenosis, prostate
hyperplasia, chronic obstructive pulmonary disease, psoriasis,
inhibition of neurological damage due to tissue repair, scar tissue
formation (and can aid in wound healing), multiple sclerosis,
inflammatory bowel disease, infections, particularly bacterial,
viral, retroviral or parasitic infections (by increasing
apoptosis), pulmonary disease, neoplasm, Parkinson's disease,
transplant rejection (as an immunosupressant), septic shock,
etc.
[0218] Accordingly, another aspect of this invention provides a
method of treating diseases or medical conditions in a mammal
mediated by AKT protein kinases, comprising administering to said
mammal one or more compounds of Formula I or a pharmaceutically
acceptable salt or prodrug thereof in an amount effective to treat
or prevent said disorder.
[0219] The phrase "effective amount" means an amount of compound
that, when administered to a mammal in need of such treatment, is
sufficient to (i) treat or prevent a particular disease, condition,
or disorder mediated by the activity of one or more AKT protein
kinases, tyrosine kinases, additional serine/threonine kinases,
and/or dual specificity kinases, (ii) attenuate, ameliorate, or
eliminate one or more symptoms of the particular disease,
condition, or disorder, or (iii) prevent or delay the onset of one
or more symptoms of the particular disease, condition, or disorder
described herein. In the case of cancer, an effective amount of the
drug may reduce the number of cancer cells; reduce the tumor size;
inhibit (i.e., slow to some extent and preferably stop) cancer cell
infiltration into peripheral organs; inhibit (i.e., slow to some
extent and preferably stop) tumor metastasis; inhibit, to some
extent, tumor growth; and/or relieve to some extent one or more of
the symptoms associated with the cancer. To the extent the drug may
prevent growth and/or kill existing cancer cells, it may be
cytostatic and/or cytotoxic. For cancer therapy, efficacy can be
measured, for example, by assessing the time to disease progression
(TTP) and/or determining the response rate (RR).
[0220] The amount of a compound of Formula I that will correspond
to such an amount will vary depending upon factors such as the
particular compound, disease condition and its severity, the
identity (e.g., weight) of the mammal in need of treatment, but can
nevertheless be routinely determined by one skilled in the art.
[0221] "Treating" is intended to mean at least the mitigation of a
disease condition in a mammal, such as a human, that is affected,
at least in part, by the activity of one or more AKT protein
kinases, tyrosine kinases, additional serine/threonine kinases,
and/or dual specificity kinases. The terms "treat" and "treatment"
refer to both therapeutic treatment and prophylactic or
preventative measures, wherein the object is to prevent or slow
down (lessen) an undesired physiological change or disorder. For
purposes of this invention, beneficial or desired clinical results
include, but are not limited to, alleviation of symptoms,
diminishment of extent of disease, stabilized (i.e., not worsening)
state of disease, delay or slowing of disease progression,
amelioration or palliation of the disease state, and remission
(whether partial or total), whether detectable or undetectable.
"Treatment" can also mean prolonging survival as compared to
expected survival if not receiving treatment. Those in need of
treatment include those already with the condition or disorder as
well as those found to be predisposed to having the disease
condition but have not yet been diagnosed as having it; modulating
and/or inhibiting the disease condition. The terms "treating",
"treat", or "treatment" embrace both preventative, i.e.,
prophylactic, and palliative treatment.
[0222] As used herein, the term "mammal" refers to a warm-blooded
animal that has or is at risk of developing a disease described
herein and includes, but is not limited to, guinea pigs, dogs,
cats, rats, mice, hamsters, and primates, including humans.
[0223] This invention also provides compounds of Formula I for use
in the treatment of AKT protein kinase-mediated conditions.
[0224] An additional aspect of the invention is the use of a
compound of Formula I in the preparation of a medicament for
therapy, such as for the treatment or prevention of AKT protein
kinase-mediated conditions.
Combination Therapy
[0225] The compounds of the present invention can be used in
combination with one or more additional drugs such as described
below. The dose of the second drug can be appropriately selected
based on a clinically employed dose. The proportion of the compound
of the present invention and the second drug can be appropriately
determined according to the administration subject, the
administration route, the target disease, the clinical condition,
the combination, and other factors. In cases where the
administration subject is a human, for instance, the second drug
may be used in an amount of 0.01 to 100 parts by weight per part by
weight of the compound of the present invention.
[0226] The second compound of the pharmaceutical combination
formulation or dosing regimen preferably has complementary
activities to the compound of this invention such that they do not
adversely affect each other. Such drugs are suitably present in
combination in amounts that are effective for the purpose intended.
Accordingly, another aspect of the present invention provides a
composition comprising a compound of this invention in combination
with a second drug, such as described herein.
[0227] A compound of this invention and the additional
pharmaceutically active drug(s) may be administered together in a
unitary pharmaceutical composition or separately and, when
administered separately this may occur simultaneously or
sequentially in any order. Such sequential administration may be
close in time or remote in time. The amounts of the compound of
this invention and the second drug(s) and the relative timings of
administration will be selected in order to achieve the desired
combined therapeutic effect.
[0228] The combination therapy may provide "synergy" and prove
"synergistic", i.e., the effect achieved when the active
ingredients used together is greater than the sum of the effects
that results from using the compounds separately. A synergistic
effect may be attained when the active ingredients are: (1)
co-formulated and administered or delivered simultaneously in a
combined, unit dosage formulation; (2) delivered by alternation or
in parallel as separate formulations; or (3) by some other regimen.
When delivered in alternation therapy, a synergistic effect may be
attained when the compounds are administered or delivered
sequentially, e.g., by different injections in separate syringes.
In general, during alternation therapy, an effective dosage of each
active ingredient is administered sequentially, i.e., serially,
whereas in combination therapy, effective dosages of two or more
active ingredients are administered together.
[0229] A "chemotherapeutic agent" is a chemical compound useful in
the treatment of cancer, regardless of mechanism of action.
Chemotherapeutic agents include compounds used in "targeted
therapy" and conventional chemotherapy.
[0230] Examples of chemotherapeutic agents include Erlotinib
(TARCEVA.RTM., Genentech/OSI Pharm.), Bortezomib (VELCADE.RTM.,
Millennium Pharm.), Fulvestrant (FASLODEX.RTM., AstraZeneca),
Sutent (SU11248, Pfizer), Letrozole (FEMARA.RTM., Novartis),
Imatinib mesylate (GLEEVEC.RTM., Novartis), PTK787/ZK 222584
(Novartis), Oxaliplatin (Eloxatin.RTM., Sanofi), 5-FU
(5-fluorouracil), Leucovorin, Rapamycin (Sirolimus, RAPAMUNE.RTM.,
Wyeth), Lapatinib (TYKERB.RTM., GSK572016, Glaxo Smith Kline),
Lonafarnib (SCH 66336), Sorafenib (BAY43-9006, Bayer Labs),
Irinotecan (CAMPTOSAR.RTM., Pfizer) and Gefitinib (IRESSA.RTM.,
AstraZeneca), AG1478, AG1571 (SU 5271; Sugen), alkylating agents
such as thiotepa and CYTOXAN.RTM. cyclosphosphamide; alkyl
sulfonates such as busulfan, improsulfan and piposulfan; aziridines
such as benzodopa, carboquone, meturedopa, and uredopa;
ethylenimines and methylamelamines including altretamine,
triethylenemelamine, triethylenephosphoramide,
triethylenethiophosphoramide and trimethylomelamine; acetogenins
(especially bullatacin and bullatacinone); a camptothecin
(including the synthetic analog topotecan); bryostatin;
callystatin; CC-1065 (including its adozelesin, carzelesin and
bizelesin synthetic analogs); cryptophycins (particularly
cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin
(including the synthetic analogs, KW-2189 and CB1-TM1);
eleutherobin; pancratistatin; a sarcodictyin; spongistatin;
nitrogen mustards such as chlorambucil, chlornaphazine,
chlorophosphamide, estramustine, ifosfamide, mechlorethamine,
mechlorethamine oxide hydrochloride, melphalan, novembichin,
phenesterine, prednimustine, trofosfamide, uracil mustard;
nitrosureas such as carmustine, chlorozotocin, fotemustine,
lomustine, nimustine, and ranimnustine; antibiotics such as the
enediyne antibiotics (e.g., calicheamicin, especially calicheamicin
gamma1I and calicheamicin omegaI1 (Angew Chem. Intl. Ed. Engl.
(1994) 33:183-186); dynemicin, including dynemicin A;
bisphosphonates, such as clodronate; an esperamicin; as well as
neocarzinostatin chromophore and related chromoprotein enediyne
antibiotic chromophores), aclacinomysins, actinomycin, authramycin,
azaserine, bleomycins, cactinomycin, carabicin, carminomycin,
carzinophilin, chromomycinis, dactinomycin, daunorubicin,
detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN.RTM.
(doxorubicin), morpholino-doxorubicin, cyanomorpholino-doxorubicin,
2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin,
esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin
C, mycophenolic acid, nogalamycin, olivomycins, peplomycin,
porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin,
streptozocin, tubercidin, ubenimex, zinostatin, zorubicin;
anti-metabolites such as methotrexate and 5-fluorouracil (5-FU);
folic acid analogs such as denopterin, methotrexate, pteropterin,
trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine,
thiamiprine, thioguanine; pyrimidine analogs such as ancitabine,
azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine,
doxifluridine, enocitabine, floxuridine; androgens such as
calusterone, dromostanolone propionate, epitiostanol, mepitiostane,
testolactone; anti-adrenals such as aminoglutethimide, mitotane,
trilostane; folic acid replenisher such as frolinic acid;
aceglatone; aldophosphamide glycoside; aminolevulinic acid;
eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate;
defofamine; demecolcine; diaziquone; elfornithine; elliptinium
acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea;
lentinan; lonidainine; maytansinoids such as maytansine and
ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine;
pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic
acid; 2-ethylhydrazide; procarbazine; PSK.RTM. polysaccharide
complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin;
sizofiran; spirogermanium; tenuazonic acid; triaziquone;
2,2',2''-trichlorotriethylamine; trichothecenes (especially T-2
toxin, verracurin A, roridin A and anguidine); urethan; vindesine;
dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman;
gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa;
taxoids, e.g., TAXOL.RTM. (paclitaxel; Bristol-Myers Squibb
Oncology, Princeton, N.J.), ABRAXANE.TM. (Cremophor-free),
albumin-engineered nanoparticle formulations of paclitaxel
(American Pharmaceutical Partners, Schaumberg, Ill.), and
TAXOTERE.RTM. (doxetaxel; Rhone-Poulenc Rorer, Antony, France);
chloranmbucil; GEMZAR.RTM. (gemcitabine); 6-thioguanine;
mercaptopurine; methotrexate; platinum analogs such as cisplatin
and carboplatin; vinblastine; etoposide (VP-16); ifosfamide;
mitoxantrone; vincristine; NAVELBINE.RTM. (vinorelbine);
novantrone; teniposide; edatrexate; daunomycin; aminopterin;
capecitabine (XELODA.RTM.); ibandronate; CPT-11; topoisomerase
inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such
as retinoic acid; and pharmaceutically acceptable salts, acids and
derivatives of any of the above.
[0231] Also included in the definition of "chemotherapeutic agent"
are: (i) anti-hormonal agents that act to regulate or inhibit
hormone action on tumors such as anti-estrogens and selective
estrogen receptor modulators (SERMs), including, for example,
tamoxifen (including NOLVADEX.RTM.; tamoxifen citrate), raloxifene,
droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018,
onapristone, and FARESTON.RTM. (toremifine citrate); (ii) aromatase
inhibitors that inhibit the enzyme aromatase, which regulates
estrogen production in the adrenal glands, such as, for example,
4(5)-imidazoles, aminoglutethimide, MEGASE.RTM. (megestrol
acetate), AROMASIN.RTM. (exemestane; Pfizer), formestanie,
fadrozole, RIVISOR.RTM. (vorozole), FEMARA.RTM. (letrozole;
Novartis), and ARIMIDEX.RTM. (anastrozole; AstraZeneca); (iii)
anti-androgens such as flutamide, nilutamide, bicalutamide,
leuprolide, and goserelin; as well as troxacitabine (a
1,3-dioxolane nucleoside cytosine analog); (iv) protein kinase
inhibitors; (v) lipid kinase inhibitors; (vi) antisense
oligonucleotides, particularly those which inhibit expression of
genes in signaling pathways implicated in aberrant cell
proliferation, such as, for example, PKC-alpha, Ralf and H-Ras;
(vii) ribozymes such as VEGF expression inhibitors (e.g.,
ANGIOZYME.RTM.) and HER2 expression inhibitors; (viii) vaccines
such as gene therapy vaccines, for example, ALLOVECTIN.RTM.,
LEUVECTIN.RTM., and VAXID.RTM.; PROLEUKIN.RTM. rIL-2; a
topoisomerase 1 inhibitor such as LURTOTECAN.RTM.; ABARELIX.RTM.
rmRH; (ix) anti-angiogenic agents such as bevacizumab
(AVASTIN.RTM., Genentech); and (x) pharmaceutically acceptable
salts, acids and derivatives of any of the above.
[0232] Also included in the definition of "chemotherapeutic agent"
are therapeutic antibodies such as alemtuzumab (Campath),
bevacizumab (AVASTIN.RTM., Genentech); cetuximab (ERBITUX.RTM.,
Imclone); panitumumab (VECTIBIX.RTM., Amgen), rituximab
(RITUXAN.RTM., Genentech/Biogen Idec), pertuzumab (OMNITARG.RTM.,
2C4, Genentech), trastuzumab (HERCEPTIN.RTM., Genentech),
tositumomab (Bexxar, Corixia), and the antibody drug conjugate,
gemtuzumab ozogamicin (MYLOTARG.RTM., Wyeth).
[0233] Humanized monoclonal antibodies with therapeutic potential
as chemotherapeutic agents in combination with the PI3K inhibitors
of the invention include: alemtuzumab, apolizumab, aselizumab,
atlizumab, bapineuzumab, bevacizumab, bivatuzumab mertansine,
cantuzumab mertansine, cedelizumab, certolizumab pegol,
cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab,
epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab
ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab,
lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab,
natalizumab, nimotuzumab, nolovizumab, numavizumab, ocrelizumab,
omalizumab, palivizumab, pascolizumab, pecfusituzumab, pectuzumab,
pertuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab,
reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab,
siplizumab, sontuzumab, tacatuzumab tetraxetan, tadocizumab,
talizumab, tefibazumab, tocilizumab, toralizumab, trastuzumab,
tucotuzumab celmoleukin, tucusituzumab, umavizumab, urtoxazumab,
and visilizumab.
Routes of Administration
[0234] The compounds of the invention may be administered by any
route appropriate to the condition to be treated. Suitable routes
include oral, parenteral (including subcutaneous, intramuscular,
intravenous, intraarterial, intradermal, intrathecal and epidural),
transdermal, rectal, nasal, topical (including buccal and
sublingual), vaginal, intraperitoneal, intrapulmonary and
intranasal. It will be appreciated that the preferred route may
vary with for example the condition of the recipient. Where the
compound is administered orally, it may be formulated as a pill,
capsule, tablet, etc. with a pharmaceutically acceptable carrier or
excipient. Where the compound is administered parenterally, it may
be formulated with a pharmaceutically acceptable parenteral vehicle
and in a unit dosage injectable form, as detailed below.
Pharmaceutical Formulations
[0235] In order to use a compound of this invention for the
therapeutic treatment (including prophylactic treatment) of mammals
including humans, it is normally formulated in accordance with
standard pharmaceutical practice as a pharmaceutical composition.
According to this aspect of the invention there is provided a
pharmaceutical composition that comprises a compound of this
invention. In certain embodiments, the pharmaceutical composition
comprises a compound of Formula I in association with a
pharmaceutically acceptable diluent or carrier.
[0236] The pharmaceutical compositions of the invention are
formulated, dosed and administered in a fashion, i.e., amounts,
concentrations, schedules, course, vehicles and route of
administration, consistent with good medical practice. Factors for
consideration in this context include the particular disorder being
treated, the particular mammal being treated, the clinical
condition of the individual patient, the cause of the disorder, the
site of delivery of the agent, the method of administration, the
scheduling of administration, and other factors known to medical
practitioners. The therapeutically effective amount of the compound
to be administered will be governed by such considerations, and is
the minimum amount necessary to prevent, ameliorate, or treat the
disorder. The compound of the present invention is typically
formulated into pharmaceutical dosage forms to provide an easily
controllable dosage of the drug and to enable patient compliance
with the prescribed regimen.
[0237] The composition for use herein is preferably sterile. In
particular, formulations to be used for in vivo administration must
be sterile. Such sterilization is readily accomplished, for
example, by filtration through sterile filtration membranes. The
compound ordinarily can be stored as a solid composition, a
lyophilized formulation or as an aqueous solution.
[0238] Pharmaceutical formulations of the compounds of the present
invention may be prepared for various routes and types of
administration. For example, a compound of this invention having
the desired degree of purity may optionally be mixed with
pharmaceutically acceptable diluents, carriers, excipients or
stabilizers (Remington's Pharmaceutical Sciences (1980) 16th
edition, Osol, A. Ed.), in the form of a lyophilized formulation, a
milled powder, or an aqueous solution. Formulation may be conducted
by mixing at ambient temperature at the appropriate pH, and at the
desired degree of purity, with physiologically acceptable carriers,
i.e., carriers that are non-toxic to recipients at the dosages and
concentrations employed. The pH of the formulation depends mainly
on the particular use and the concentration of compound, but may
range from about 3 to about 8. Formulation in an acetate buffer at
pH 5 is a suitable embodiment. The formulations may be prepared
using conventional dissolution and mixing procedures. For example,
the bulk drug substance (i.e., compound of the present invention or
stabilized form of the compound (e.g., complex with a cyclodextrin
derivative or other known complexation agent) is dissolved in a
suitable solvent in the presence of one or more excipients.
[0239] The particular carrier, diluent or excipient used will
depend upon the means and purpose for which the compound of the
present invention is being applied. Solvents are generally selected
based on solvents recognized by persons skilled in the art as safe
(GRAS) to be administered to a mammal. In general, safe solvents
are non-toxic aqueous solvents such as water and other non-toxic
solvents that are soluble or miscible in water. Suitable aqueous
solvents include water, ethanol, propylene glycol, polyethylene
glycols (e.g., PEG 400, PEG 300), etc. and mixtures thereof.
Acceptable diluents, carriers, excipients and stabilizers are
nontoxic to recipients at the dosages and concentrations employed,
and include buffers such as phosphate, citrate and other organic
acids; antioxidants including ascorbic acid and methionine;
preservatives (such as octadecyldimethylbenzyl ammonium chloride;
hexamethonium chloride; benzalkonium chloride, benzethonium
chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as
methyl or propyl paraben; catechol; resorcinol; cyclohexanol;
3-pentanol; and m-cresol); low molecular weight (less than about 10
residues) polypeptides; proteins, such as serum albumin, gelatin,
or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine, histidine, arginine, or lysine; monosaccharides,
disaccharides and other carbohydrates including glucose, mannose,
or dextrins; chelating agents such as EDTA; sugars such as sucrose,
mannitol, trehalose or sorbitol; salt-forming counter-ions such as
sodium; metal complexes (e.g., Zn-protein complexes); and/or
non-ionic surfactants such as TWEEN.TM., PLURONICS.TM. or
polyethylene glycol (PEG). The formulations may also include one or
more stabilizing agents, surfactants, wetting agents, lubricating
agents, emulsifiers, suspending agents, preservatives,
antioxidants, opaquing agents, glidants, processing aids,
colorants, sweeteners, perfuming agents, flavoring agents and other
known additives to provide an elegant presentation of the drug
(i.e., a compound of the present invention or pharmaceutical
composition thereof) or aid in the manufacturing of the
pharmaceutical product (i.e., medicament). The active
pharmaceutical ingredients may also be entrapped in microcapsules
prepared, for example, by coacervation techniques or by interfacial
polymerization, for example, hydroxymethylcellulose or
gelatin-microcapsules and poly-(methylmethacrylate) microcapsules,
respectively, in colloidal drug delivery systems (for example,
liposomes, albumin microspheres, microemulsions, nanoparticles and
nanocapsules) or in macroemulsions. Such techniques are disclosed
in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed.
(1980). A "liposome" is a small vesicle composed of various types
of lipids, phospholipids and/or surfactant which is useful for
delivery of a drug (such as a compound of Formula I and,
optionally, an additional therapeutic agent) to a mammal. The
components of the liposome are commonly arranged in a bilayer
formation, similar to the lipid arrangement of biological
membranes.
[0240] Sustained-release preparations of compounds of this
invention may be prepared. Suitable examples of sustained-release
preparations include semipermeable matrices of solid hydrophobic
polymers containing a compound of Formula 1, which matrices are in
the form of shaped articles, e.g., films, or microcapsules.
Examples of sustained-release matrices include polyesters,
hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or
poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919),
copolymers of L-glutamic acid and gamma-ethyl-L-glutamate,
non-degradable ethylene-vinyl acetate, degradable lactic
acid-glycolic acid copolymers such as the LUPRON DEPOT.TM.
(injectable microspheres composed of lactic acid-glycolic acid
copolymer and leuprolide acetate) and poly-D-(-)-3-hydroxybutyric
acid.
[0241] The pharmaceutical compositions of compounds of this
invention may be in the form of a sterile injectable preparation,
such as a sterile injectable aqueous or oleaginous suspension. This
suspension may be formulated according to the known art using those
suitable dispersing or wetting agents and suspending agents which
have been mentioned above. The sterile injectable preparation may
also be a sterile injectable solution or suspension in a non-toxic
parenterally acceptable diluent or solvent, such as a solution in
1,3-butanediol or prepared as a lyophilized powder. Among the
acceptable vehicles and solvents that may be employed are water,
Ringer's solution and isotonic sodium chloride solution. In
addition, sterile fixed oils may conventionally be employed as a
solvent or suspending medium. For this purpose any bland fixed oil
may be employed including synthetic mono- or diglycerides. In
addition, fatty acids such as oleic acid may likewise be used in
the preparation of injectables.
[0242] Formulations suitable for parenteral administration include
aqueous and non-aqueous sterile injection solutions which may
contain anti-oxidants, buffers, bacteriostats and solutes which
render the formulation isotonic with the blood of the intended
recipient; and aqueous and non-aqueous sterile suspensions which
may include suspending agents and thickening agents.
[0243] The compositions of the invention may also be in a form
suitable for oral use (for example as tablets, lozenges, hard or
soft capsules, aqueous or oily suspensions, emulsions, dispersible
powders or granules, syrups or elixirs), for topical use (for
example as creams, ointments, gels, or aqueous or oily solutions or
suspensions), for administration by inhalation (for example as a
finely divided powder or a liquid aerosol), for administration by
insufflation (for example as a finely divided powder)
[0244] Suitable pharmaceutically-acceptable excipients for a tablet
formulation include, for example, inert diluents such as lactose,
sodium carbonate, calcium phosphate or calcium carbonate,
granulating and disintegrating agents such as corn starch or
algenic acid; binding agents such as starch; lubricating agents
such as magnesium stearate, stearic acid or talc; preservative
agents such as ethyl or propyl p-hydroxybenzoate, and
anti-oxidants, such as ascorbic acid. Tablet formulations may be
uncoated or coated either to modify their disintegration and the
subsequent absorption of the active ingredient within the
gastrointestinal tract, or to improve their stability and/or
appearance, in either case, using conventional coating agents and
procedures well known in the art.
[0245] Compositions for oral use may be in the form of hard gelatin
capsules in which the active ingredient is mixed with an inert
solid diluent, for example, calcium carbonate, calcium phosphate or
kaolin, or as soft gelatin capsules in which the active ingredient
is mixed with water or an oil such as peanut oil, liquid paraffin,
or olive oil.
[0246] Aqueous suspensions generally contain the active ingredient
in finely powdered form together with one or more suspending
agents, such as sodium carboxymethylcellulose, methylcellulose,
hydroxypropylmethylcellulose, sodium alginate,
polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or
wetting agents such as lecithin or condensation products of an
alkylene oxide with fatty acids (for example polyoxethylene
stearate), or condensation products of ethylene oxide with long
chain aliphatic alcohols, for example heptadecaethyleneoxycetanol,
or condensation products of ethylene oxide with partial esters
derived from fatty acids and a hexitol such as polyoxyethylene
sorbitol monooleate, or condensation products of ethylene oxide
with partial esters derived from fatty acids and hexitol
anhydrides, for example polyethylene sorbitan monooleate. The
aqueous suspensions may also contain one or more preservatives
(such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as
ascorbic acid), coloring agents, flavoring agents, and/or
sweetening agents (such as sucrose, saccharine or aspartame).
[0247] Oily suspensions may be formulated by suspending the active
ingredient in a vegetable oil (such as arachis oil, olive oil,
sesame oil or coconut oil) or in a mineral oil (such as liquid
paraffin). The oily suspensions may also contain a thickening agent
such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents
such as those set out above, and flavoring agents may be added to
provide a palatable oral preparation. These compositions may be
preserved by the addition of an anti-oxidant such as ascorbic
acid.
[0248] Dispersible powders and granules suitable for preparation of
an aqueous suspension by the addition of water generally contain
the active ingredient together with a dispersing or wetting agent,
suspending agent and one or more preservatives. Suitable dispersing
or wetting agents and suspending agents are exemplified by those
already mentioned above. Additional excipients such as sweetening,
flavoring and coloring agents, may also be present.
[0249] The pharmaceutical compositions of the invention may also be
in the form of oil-in-water emulsions. The oily phase may be a
vegetable oil, such as olive oil or arachis oil, or a mineral oil,
such as for example liquid paraffin or a mixture of any of these.
Suitable emulsifying agents may be, for example,
naturally-occurring gums such as gum acacia or gum tragacanth,
naturally-occurring phosphatides such as soya bean, lecithin,
esters or partial esters derived from fatty acids and hexitol
anhydrides (for example sorbitan monooleate) and condensation
products of the said partial esters with ethylene oxide such as
polyoxyethylene sorbitan monooleate. The emulsions may also contain
sweetening, flavoring and preservative agents.
[0250] Syrups and elixirs may be formulated with sweetening agents
such as glycerol, propylene glycol, sorbitol, aspartame or sucrose,
and may also contain a demulcent, preservative, flavoring and/or
coloring agent.
[0251] Suppository formulations may be prepared by mixing the
active ingredient with a suitable non-irritating excipient that is
solid at ordinary temperatures but liquid at the rectal temperature
and will therefore melt in the rectum to release the drug. Suitable
excipients include, for example, cocoa butter and polyethylene
glycols. Formulations suitable for vaginal administration may be
presented as pessaries, tampons, creams, gels, pastes, foams or
spray formulations containing in addition to the active ingredient
such carriers as are known in the art to be appropriate.
[0252] Topical formulations, such as creams, ointments, gels and
aqueous or oily solutions or suspensions, may generally be obtained
by formulating an active ingredient with a conventional, topically
acceptable, vehicle or diluent using conventional procedures well
known in the art.
[0253] Compositions for transdermal administration may be in the
form of those transdermal skin patches that are well known to those
of ordinary skill in the art.
[0254] Formulations suitable for intrapulmonary or nasal
administration have a particle size for example in the range of 0.1
to 500 microns (including particle sizes in a range between 0.1 and
500 microns in increments microns such as 0.5, 1, 30 microns, 35
microns, etc.), which is administered by rapid inhalation through
the nasal passage or by inhalation through the mouth so as to reach
the alveolar sacs. Suitable formulations include aqueous or oily
solutions of the active ingredient. Formulations suitable for
aerosol or dry powder administration may be prepared according to
conventional methods and may be delivered with other therapeutic
agents such as compounds heretofore used in the treatment or
prophylaxis disorders as described below.
[0255] The pharmaceutical composition (or formulation) for
application may be packaged in a variety of ways depending upon the
method used for administering the drug. For example, an article for
distribution can include a container having deposited therein the
pharmaceutical formulation in an appropriate form. Suitable
containers are well known to those skilled in the art and include
materials such as bottles (plastic and glass), sachets, ampoules,
plastic bags, metal cylinders, and the like. The container may also
include a tamper-proof assemblage to prevent indiscreet access to
the contents of the package. In addition, the container has
deposited thereon a label that describes the contents of the
container. The label may also include appropriate warnings. The
formulations may also be packaged in unit-dose or multi-dose
containers, for example sealed ampoules and vials, and may be
stored in a freeze-dried (lyophilized) condition requiring only the
addition of the sterile liquid carrier, for example water, for
injection immediately prior to use. Extemporaneous injection
solutions and suspensions are prepared from sterile powders,
granules and tablets of the kind previously described. Preferred
unit dosage formulations are those containing a daily dose or unit
daily sub-dose, as herein above recited, or an appropriate fraction
thereof, of the active ingredient.
[0256] The invention further provides veterinary compositions
comprising at least one active ingredient as above defined together
with a veterinary carrier therefore. Veterinary carriers are
materials useful for the purpose of administering the composition
and may be solid, liquid or gaseous materials which are otherwise
inert or acceptable in the veterinary art and are compatible with
the active ingredient. These veterinary compositions may be
administered parenterally, orally or by any other desired
route.
[0257] The amount of a compound of this invention that is combined
with one or more excipients to produce a single dosage form will
necessarily vary depending upon the subject treated, the severity
of the disorder or condition, the rate of administration, the
disposition of the compound and the discretion of the prescribing
physician. In one embodiment, a suitable amount of a compound of
this invention is administered to a mammal in need thereof.
Administration in one embodiment occurs in an amount between about
0.001 mg/kg of body weight to about 60 mg/kg of body weight per
day. In another embodiment, administration occurs in an amount
between 0.5 mg/kg of body weight to about 40 mg/kg of body weight
per day. In some instances, dosage levels below the lower limit of
the aforesaid range may be more than adequate, while in other cases
still larger doses may be employed without causing any harmful side
effect, provided that such larger doses are first divided into
several small doses for administration throughout the day. For
further information on routes of administration and dosage regimes,
see Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry
(Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990,
which is specifically incorporated herein by reference.
Articles of Manufacture
[0258] In another embodiment of the invention, an article of
manufacture, or "kit", containing materials useful for the
treatment of the disorders described above is provided. In one
embodiment, the kit comprises a container comprising a compound of
this invention. Suitable containers include, for example, bottles,
vials, syringes, blister pack, etc. The container may be formed
from a variety of materials such as glass or plastic. The container
may hold a compound of this invention or a formulation thereof
which is effective for treating the condition and may have a
sterile access port (for example, the container may be an
intravenous solution bag or a vial having a stopper pierceable by a
hypodermic injection needle).
[0259] The kit may further comprise a label or package insert on or
associated with the container. The term "package insert" is used to
refer to instructions customarily included in commercial packages
of therapeutic products, that contain information about the
indications, usage, dosage, administration, contraindications
and/or warnings concerning the use of such therapeutic products. In
one embodiment, the label or package inserts indicates that the
composition comprising a compound of this invention can be used to
treat a disorder mediated, for example, by AKT kinase. The label or
package insert may also indicate that the composition can be used
to treat other disorders.
[0260] In certain embodiments, the kits are suitable for the
delivery of solid oral forms of a compound of this invention, such
as tablets or capsules. Such a kit preferably includes a number of
unit dosages. Such kits can include a card having the dosages
oriented in the order of their intended use. An example of such a
kit is a "blister pack". Blister packs are well known in the
packaging industry and are widely used for packaging pharmaceutical
unit dosage forms. If desired, a memory aid can be provided, for
example in the form of numbers, letters, or other markings or with
a calendar insert, designating the days in the treatment schedule
in which the dosages can be administered.
[0261] According to another embodiment, a kit may comprise (a) a
first container with a compound of this invention contained
therein; and (b) a second container with a second pharmaceutical
formulation contained therein, wherein the second pharmaceutical
formulation comprises a second compound useful for treating a
disorder mediated by AKT kinase. Alternatively, or additionally,
the kit may further comprise a third container comprising a
pharmaceutically-acceptable buffer, such as bacteriostatic water
for injection (BWFI), phosphate-buffered saline, Ringer's solution
and dextrose solution. It may further include other materials
desirable from a commercial and user standpoint, including other
buffers, diluents, filters, needles, and syringes.
[0262] The kit may further comprise directions for the
administration of the compound of this invention and, if present,
the second pharmaceutical formulation. For example, if the kit
comprises a first composition comprising a compound of this
invention and a second pharmaceutical formulation, the kit may
further comprise directions for the simultaneous, sequential or
separate administration of the first and second pharmaceutical
compositions to a patient in need thereof.
[0263] In certain other embodiments wherein the kit comprises a
composition of this invention and a second therapeutic agent, the
kit may comprise a container for containing the separate
compositions such as a divided bottle or a divided foil packet,
however, the separate compositions may also be contained within a
single, undivided container. In certain embodiments, the kit
comprises directions for the administration of the separate
components. The kit form is particularly advantageous when the
separate components are preferably administered in different dosage
forms (e.g., oral and parenteral), are administered at different
dosage intervals, or when titration of the individual components of
the combination is desired by the prescribing physician.
[0264] Accordingly, a further aspect of this invention provides a
kit for treating a disorder or disease mediated by Akt kinase,
wherein said kit comprises a) a first pharmaceutical composition
comprising a compound of this invention or a pharmaceutically
acceptable salt thereof; and b) instructions for use.
[0265] In certain embodiments, the kit further comprises (c) a
second pharmaceutical composition, wherein the second
pharmaceutical composition comprises a second compound suitable for
treating a disorder or disease mediated by Akt kinase. In certain
embodiment comprising a second pharmaceutical composition, the kit
further comprises instructions for the simultaneous, sequential or
separate administration of said first and second pharmaceutical
compositions to a patient in need thereof. In certain embodiments,
said first and second pharmaceutical compositions are contained in
separate containers. In other embodiments, said first and second
pharmaceutical compositions are contained in the same
container.
[0266] Although the compounds of Formula I are primarily of value
as therapeutic agents for use in mammals, they are also useful
whenever it is required to control AKT protein kinases, tyrosine
kinases, additional serine/threonine kinases, and/or dual
specificity kinases. Thus, they are useful as pharmacological
standards for use in the development of new biological tests and in
the search for new pharmacological agents.
[0267] The activity of the compounds of this invention may be
assayed for AKT protein kinases, tyrosine kinases, additional
serine/threonine kinases, and/or dual specificity kinases in vitro,
in vivo, or in a cell line. In vitro assays include assays that
determine inhibition of the kinase activity. Alternate in vitro
assays quantitate the ability of the inhibitor to bind to kinases
and may be measured either by radiolabelling the inhibitor prior to
binding, isolating the inhibitor/kinase complex and determining the
amount of radiolabel bound, or by running a competition experiment
where new inhibitors are incubated with known radioligands. These
and other useful in vitro and cell culture assays are well known to
those of skill in the art.
[0268] Although the invention has been described and illustrated
with a certain degree of particularity, it is understood that the
present disclosure has been made only by way of example, and that
numerous changes in the combination and arrangement of parts can be
resorted to by those skilled in the art without departing from the
spirit and scope of the invention, as hereinafter claimed.
BIOLOGICAL EXAMPLES
AKT-1 Kinase Assay
[0269] The activity of the compounds described in the present
invention may be determined by the following kinase assay, which
measures the phosphorylation of a fluorescently-labeled peptide by
full-length human recombinant active AKT-1 by fluorescent
polarization using a commercially available IMAP kit.
[0270] The assay materials are obtained from an IMAP AKT Assay Bulk
Kit, product #R8059, from Molecular Devices, Sunnyvale, Calif. The
kit materials include an IMAP Reaction Buffer (5.times.). The
diluted 1.times. IMAP Reaction Buffer contained 10 mM Tris-HCl, pH
7.2, 10 mM MgCl.sub.2, 0.1% BSA, 0.05% NaN.sub.3. DTT is routinely
added to a final concentration of 1 mM immediately prior to use.
Also included is IMAP Binding Buffer (5.times.), and IMAP Binding
Reagent. The Binding Solution is prepared as a 1:400 dilution of
IMAP Binding Reagent into 1.times. IMAP Binding Buffer.
[0271] The fluorescein-labeled AKT Substrate (Crosstide) has the
sequence (Fl)-GRPRTSSFAEG. A stock solution of 20 .mu.M is made up
in 1.times. IMAP Reaction Buffer.
[0272] The plates used include a Costar 3657 (382-well made of
polypropylene and having a white, v-bottom) that is used for
compound dilution and for preparing the compound-ATP mixture. The
assay plate is a Packard ProxyPlate.TM.-384 F.
[0273] The AKT-1 used is made from full-length, human recombinant
AKT-1 that is activated with PDK1 and MAP kinase 2.
[0274] To perform the assay, stock solutions of compounds at 10 mM
in DMSO are prepared. The stock solutions and the control compound
are serially diluted 1:2 nine times into DMSO (10 .mu.L of
compound+10 .mu.L of DMSO) to give 50.times. dilution series over
the desired dosing range. Next, 2.1-.mu.L aliquots of the compounds
in DMSO are transferred to a Costar 3657 plate containing 50 .mu.L
of 10.4 .mu.M ATP in 1.times. IMAP Reaction Buffer containing 1 mM
DTT. After thorough mixing, 2.5-.mu.L aliquots are transferred to a
ProxyPlate.TM.-384 F plate.
[0275] The assay is initiated by the addition of 2.5-.mu.L aliquots
of a solution containing 200 nM of fluorescently-labeled peptide
substrate and 4 nM AKT-1. The plate is centrifuged for 1 minute at
1000 g and incubated for 60 minute at ambient temperature. The
reaction is then quenched by the addition of 15 tit of Binding
Solution, centrifuged again and incubated for an additional 30
minutes at ambient temperature prior to reading on a Victor 1420
Multilabel HTS Counter configured to measure fluorescence
polarization.
[0276] The compounds of Examples 1-324 were tested in the above
assay and found to have an IC.sub.50 of less than <10 .mu.M.
Preparative Examples
[0277] In order to illustrate the invention, the following examples
are included. However, it is to be understood that these examples
do not limit the invention and are only meant to suggest a method
of practicing the invention. Persons skilled in the art will
recognize that the chemical reactions described may be readily
adapted to prepare a number of other compounds of Formula I, and
alternative methods for preparing the compounds of this invention
are deemed to be within the scope of this invention. For example,
the synthesis of non-exemplified compounds according to the
invention may be successfully performed by modifications apparent
to those skilled in the art, e.g., by appropriately protecting
interfering groups, by utilizing other suitable reagents known in
the art other than those described, and/or by making routine
modifications of reaction conditions. Alternatively, other
reactions disclosed herein or known in the art will be recognized
as having applicability for preparing other compounds of the
invention.
[0278] In the examples described below, unless otherwise indicated
all temperatures are set forth in degrees Celsius. Reagents were
purchased from commercial suppliers such as Aldrich Chemical
Company, Lancaster, TCI or Maybridge, and were used without further
purification unless otherwise indicated. Tetrahydrofuran (THF),
dichloromethane (DCM), toluene, and dioxane were purchased from
Aldrich in Sure seal bottles and used as received.
[0279] The reactions set forth below were done generally under a
positive pressure of nitrogen or argon or with a drying tube
(unless otherwise stated) in anhydrous solvents, and the reaction
flasks were typically fitted with rubber septa for the introduction
of substrates and reagents via syringe. Glassware was oven dried
and/or heat dried.
[0280] .sup.1H NMR spectra were recorded on a Varian instrument
operating at 400 MHz. .sup.1H-NMR spectra were obtained as
CDCl.sub.3, CD.sub.3OD, D.sub.2O or d.sub.6-DMSO solutions
(reported in ppm), using tetramethylsilane (0.00 ppm) or residual
solvent (CDCl.sub.3: 7.25 ppm; CD.sub.3OD: 3.31 ppm; D.sub.2O: 4.79
ppm; d.sub.6-DMSO: 2.50 ppm) as the reference standard. When peak
multiplicities are reported, the following abbreviations are used:
s (singlet), d (doublet), t (triplet), m (multiplet), br
(broadened), dd (doublet of doublets), dt (doublet of triplets).
Coupling constants, when given, are reported in Hertz (Hz).
Example 1
##STR00099##
[0281] Preparation of
2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclop-
enta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
dihydrochloride
[0282] Step 1: To a 1 L round-bottom flask were added
(R)-(+)-Pulegone (76.12 g, 0.5 mmol), anhydrous NaHCO.sub.3 (12.5
g) and anhydrous ether (500 mL). The reaction mixture was cooled
with ice-bath under nitrogen. The bromine (25.62 mL, 0.5 mmol) was
added dropwise over 30 minutes. The mixture was filtered and
carefully added to NaOEt (21%, 412 mL, 1.11 mmol) in an ice-cooled
bath. The mixture was stirred at room temperature overnight and
then 1 L of 5% HCl and 300 mL of ether were added. The aqueous
phase was extracted with ether (2.times.300 mL). The combined
organic phase was washed with water, dried and concentrated. The
residue was added to a warmed solution of semicarbazide
hydrochloride (37.5 g) and NaOAc (37.5 g) in water (300 mL), and
then boiling ethanol (300 mL) was added to give a clear solution.
The mixture was refluxed for 2.5 hours and then stirred at room
temperature overnight. The mixture was treated with 1 L of water
and 300 mL of ether. The aqueous phase was extracted with ether
(2.times.300 mL). The combined organic phase was washed with water,
dried and concentrated. The residue was purified by vacuum
distillation (73-76.degree. C. at 0.8 mm Hg) to give (2R)-ethyl
2-methyl-5-(propan-2-ylidene)cyclopentanecarboxylate (63 g, 64%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 4.13 (m, 2H), 3.38 (d,
J=16 Hz, 0.5H), 2.93 (m, 0.5H), 2.50-2.17 (m, 2H), 1.98 (m, 1H),
1.76 (m, 1H), 1.23 (m, 6H), 1.05 (m, 6H).
[0283] Step 2: (2R)-Ethyl
2-methyl-5-(propan-2-ylidene)cyclopentanecarboxylate (24 g, 0.122
mol) in ethyl acetate (100 mL) was cooled to -68.degree. C. with
dry ice/isopropanol. Ozonized oxygen (5-7 ft.sup.3h.sup.-1 of
O.sub.2) was bubbled through the solution for 3.5 hours. The
reaction mixture was flushed with nitrogen at room temperature
until the color disappeared. The ethyl acetate was removed under
vacuum and the residue was dissolved in 150 mL of acetic acid and
cooled by ice water. Then 45 g of zinc powder were added. The
solution was stirred for 30 minutes and then filtered. The filtrate
was neutralized with 2N NaOH (1.3 L) and NaHCO.sub.3. The aqueous
phase was extracted with ether (3.times.200 mL). The organic phase
was combined, washed with water, dried and concentrated to afford
(2R)-ethyl 2-methyl-5-oxocyclopentanecarboxylate (20 g, 96%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 4.21 (m, 2H), 2.77 (d,
J=11.2 Hz, 1H), 2.60 (m, 1H), 2.50-2.10 (m, 3H), 1.42 (m, 1H), 1.33
(m, 3H), 1.23 (m, 3H).
[0284] Step 3: To a solution of a mixture of (2R)-ethyl
2-methyl-5-oxocyclopentanecarboxylate (20 g, 117.5 mmol) and
thiourea (9.2 g, 120.9 mmol) in ethanol (100 mL) was added KOH (8.3
g, 147.9 mmol) in water (60 mL). The mixture was refluxed for 10
hours. After cooling, the solvent was removed and the residue was
neutralized with concentrated HCl (12 mL) at 0.degree. C. and then
extracted with DCM (3.times.150 mL). The solvent was removed and
the residue was purified by silica gel chromatography, eluting with
Hexane/ethyl acetate (2:1) to give
(R)-2-mercapto-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol
(12 g, 56%). MS (APCI+) [M+H].sup.+ 183.
[0285] Step 4: To a suspension of
(R)-2-mercapto-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol
(12 g, 65.8 mmol) in distilled water (100 mL) was added Raney
Nickel (15 g) and NH.sub.4OH (20 mL). The mixture was refluxed for
3 hours then filtered, and the filtrate was concentrated to afford
(R)-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol (9.89 g,
99%). MS (APCI+) [M+H].sup.+ 151.
[0286] Step 5: A mixture of
(R)-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol (5.8 g,
38.62 mmol) in POCl.sub.3 (20 mL) was refluxed for 5 minutes.
Excess POCl.sub.3 was removed under vacuum and the residue was
dissolved in DCM (50 mL). The mixture was then added to saturated
NaHCO.sub.3 (200 mL). The aqueous phase was extracted with DCM
(3.times.100 mL), and the combined organic phases were dried and
concentrated. The residue was purified by silica gel
chromatography, eluting with ethyl acetate to give
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine (3.18
g, 49%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.81 (s, 1H),
3.47 (m, 1H), 3.20 (m, 1H), 3.05 (m, 1H), 2.41 (m, 1H), 1.86 (m,
3H), 1.47 (m, 3H).
[0287] Step 6: To a solution of
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine (2.5
g, 14.8 mmol) in CHCl.sub.3 (60 mL) was added MCPBA (8.30 g, 37.0
mmol) in three portions. The mixture was stirred at room
temperature for 2 days. The mixture was cooled to 0.degree. C. and
to this was added dropwise Na.sub.2S.sub.2O.sub.3 (10 g) in water
(60 mL), followed by Na.sub.2CO.sub.3 (6 g) in water (20 mL). The
reaction mixture was stirred for 20 minutes. The aqueous phase was
extracted with CHCl.sub.3 (2.times.200 mL), and the combined
organic phases were concentrated at low temperature (<25.degree.
C.). The residue was purified by silica gel chromatography, eluting
with ethyl acetate-DCM/MeOH (20:1) to give
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-oxide
(1.45 g, 53%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.66 (s,
1H), 3.50 (m, 1H), 3.20 (m, 2H), 2.44 (m, 1H), 1.90 (m, 1H), 1.37
(d, J=7.2 Hz, 3H).
[0288] Step 7: A solution of
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-oxide
(1.45 g, 7.85 mmol) in acetic anhydride (20 mL) was heated to
110.degree. C. for 2 hours. After cooling, excess solvent was
removed under vacuum. The residue was purified by silica gel
chromatography, eluting with Hexane/ethyl acetate (3:1) to give
(5R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-yl
acetate (1.25 g, 70%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta.
8.92 (m, 1H), 6.30-6.03 (m, 1H), 3.60-3.30 (m, 1H), 2.84 (m, 1H),
2.40-2.20 (m, 1H), 2.15 (d, J=6 Hz, 2H), 1.75 (m, 2H), 1.47 (d,
J=6.8, 2H), 1.38 (d, J=7.2, 1H). MS (APCI+) [M+H].sup.+ 227.
[0289] Step 8: To a solution of
(5R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-yl
acetate (0.5 g, 2.2 mmol) in NMP (10 mL) was added 1-Boc-piperazine
(0.9 g, 4.8 mmol). The reaction mixture was heated to 110.degree.
C. for 12 hours. After cooling, the reaction mixture was diluted
with ethyl acetate (200 mL) and washed with water (6.times.100 mL).
The organic phase was dried and concentrated. The residue was
purified by silica gel chromatography, eluting with ethyl acetate
to give tert-butyl
4-05R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pipe-
razine-1-carboxylate (0.6 g, 72%). .sup.1H NMR (CDCl.sub.3, 400
MHz) .delta. 8.60 (d, 1H), 6.05-5.90 (m, 1H), 3.80-3.30 (m, 9H),
2.84 (m, 1H), 2.20 (m, 1H), 1.49 (s, 9H), 1.29-1.20 (m, 3H). MS
(APCI+) [M+H].sup.+ 377. The resulting mixture of the diastereomers
was purified by chiral separation HPLC (Chiralcel ODH column,
250.times.20 mm, Hexane/EtOH 60:40, 21 mL/min). The first peak
(RT=3.73 min) gave the tert-butyl
4-((5R,7R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate (0.144 g, 24%). The second peak (RT=5.66
min) gave the tert-butyl
4-((5R,7S)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate (0.172 g, 29%). MS (APCI+) [M+H].sup.+
377.
[0290] Step 9: To a solution of tert-butyl
4-((5R,7R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate (0.144 g, 0.383 mmol) in THF (4 mL) was
added LiOH (3M, 2 mL). The mixture was stirred at room temperature
for 6 hours and then quenched with 2N HCl (3 mL). The solvent was
removed and the residue was purified by silica gel chromatography,
eluting with ethyl acetate to give tert-butyl
4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate (89 mg, 70%). %). .sup.1H NMR (CDCl.sub.3,
400 MHz) .delta. 8.52 (s, 1H), 5.48 (br, 1H), 5.14 (m, 1H),
3.82-3.40 (m, 9H), 2.20 (m, 2H), 1.49 (s, 9H), 1.19 (d, J=6.8 Hz,
3H). MS (APCI+) [M+H].sup.+ 335.
[0291] Step 10: tert-Butyl
4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate was treated with HCl (4M in dioxane, 2 mL)
in DCM (5 mL) for 6 hours to give
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride. MS (APCI+) [M+H].sup.+ 235.
[0292] Step 11: Methyl 2-(4-chlorophenyl)acrylate (1.00 g, 5.09
mmol) was added as a solution in 2.5 mL of THF to a stirring
solution of i-PrNH.sub.2 (650 uL, 7.63 mmol) in 10 mL of THF. The
reaction was allowed to stir at room temperature overnight to
completion by LCMS analysis. The solvent was removed under reduced
pressure to give methyl
2-(4-chlorophenyl)-3-(isopropylamino)propanoate (LCMS (APCI.sup.+)
[M-Boc+H].sup.+ 256.1, Rt: 1.97 min), which was re-dissolved in 15
mL of DCM at room temperature. The Boc2O (1.29 mL, 5.59 mmol) was
added to the stirring amine via pipette followed by a catalytic
amount (1 mg) of DMAP. The reaction was allowed to stir overnight
to completion by LCMS and TLC analysis of the mixture. The solution
was concentrated in vacuo to afford methyl
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoa-
te as an oily residue (LCMS (APCI.sup.+) [M-Boc+H].sup.+ 256.1, Rt:
4.13 min) which was re-dissolved in 12.0 mL of THF and 4.0 mL of
water. The solution was treated with LiOH--H.sub.2O (1.07 g, 25.4
mmol) and allowed to stir for 4 hours to completion by LCMS
analysis. The solution was diluted with water and washed with
diethyl ether (discarded). The aqueous was treated with 1M HCl
solution until pH 2-3 and extracted with ethyl acetate several
times. The organics were combined, washed with brine, separated,
dried over MgSO.sub.4, filtered, and concentrated in vacuo to
afford
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoi-
c acid as a colorless oil (1.04 g, 60%). LCMS (APCI.sup.+)
[M-Boc+H].sup.+242.0.
[0293] Step 12: To a solution of
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride (41 mg, 0.13 mmol) and
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoic
acid (46 mg, 0.13 mmol) in DCM (10 mL) and triethylamine (1 mL) was
added HBTU (51 mg, 0.13 mmol). The reaction mixture was stirred at
room temperature for 1 hour. The solvent was removed and the
residue was purified by silica gel chromatography, eluting with
ethyl acetate-DCM/MeOH (20:1) to give tert-butyl
2-(4-chlorophenyl)-3-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclop-
enta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate
(58 mg, 78%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.49 (s,
1H), 7.30-7.22 (m, 4H), 5.11 (m, 1H), 3.80-3.40 (m, 13H), 2.20-2.10
(m, 2H), 1.48 (s, 9H), 1.14 (m, 3H), 1.03 (m, 3H), 0.68 (m, 3H). MS
(APCI+) [M+H].sup.+559.
[0294] Step 13: Treatment of tert-butyl
2-(4-chlorophenyl)-3-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclop-
enta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate
with HCl (4M in dioxane, 2 mL) in DCM (5 mL) for 6 hours to give
2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclop-
enta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
dihydrochloride. .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.36-8.35
(m, 1H), 7.36-7.35 (d, J=8.0 Hz, 2H), 7.22-7.20 (d, J=8.0 Hz, 2H),
5.23-5.10 (m, 1H), 4.36-4.33 (m, 1H), 3.96-3.00 (m, 12H), 2.17-2.13
(m, 1H), 2.06-2.00 (m, 1H), 1.20-1.17 (m, 6H), 1.08-0.97 (m, 3H).
MS (APCI+) [M+H].sup.+ 459.
Example 2
##STR00100##
[0295] Preparation of
(R)-2-amino-3-(4-chlorophenyl)-1-((S)-4-((5R,7R)-7-hydroxy-5-methyl-6,7-d-
ihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)propan-1-one
dihydrochloride
[0296] Step 1: To a solution of
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine (2.5
g, 14.8 mmol) in CHCl.sub.3 (60 mL) was added MCPBA (8.30 g, 37.0
mmol) in three portions. The mixture was stirred at room
temperature for 2 days. The mixture was cooled to 0.degree. C. and
to this was added dropwise Na.sub.2S.sub.2O.sub.3 (10 g) in water
(60 mL), followed by Na.sub.2CO.sub.3 (6 g) in water (20 mL). The
reaction mixture was stirred for 20 minutes. The aqueous phase was
extracted with CHCl.sub.3 (2.times.200 mL), and the combined
organic phases were concentrated at low temperature (<25.degree.
C.). The residue was purified by silica gel chromatography, eluting
with ethyl acetate-DCM/MeOH (20:1) to give
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-oxide
(1.45 g, 53%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.66 (s,
1H), 3.50 (m, 1H), 3.20 (m, 2H), 2.44 (m, 1H), 1.90 (m, 1H), 1.37
(d, J=7.2 Hz, 3H).
[0297] Step 2: A solution of
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-oxide
(1.45 g, 7.85 mmol) in acetic anhydride (20 mL) was heated to
110.degree. C. for 2 hours. After cooling, excess solvent was
removed under vacuum. The residue was purified by silica gel
chromatography, eluting with Hexane/ethyl acetate (3:1) to give
(5R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-yl
acetate (1.25 g, 70%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta.
8.92 (m, 1H), 6.30-6.03 (m, 1H), 3.60-3.30 (m, 1H), 2.84 (m, 1H),
2.40-2.20 (m, 1H), 2.15 (d, J=6 Hz, 2H), 1.75 (m, 2H), 1.47 (d,
J=6.8, 2H), 1.38 (d, J=7.2, 1H). MS (APCI+) [M+H].sup.+ 227.
[0298] Step 3: To a solution of
(5R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-yl
acetate (0.75 g, 3.3 mmol) in NMP (10 mL) was added (S)-tert-butyl
3-methylpiperazine-1-carboxylate (1.0 g, 5.0 mmol). The mixture was
heated to 125.degree. C. for 60 hours. After cooling, the mixture
was diluted with ethyl acetate (200 mL) and washed with water
(6.times.100 mL). The organic phase was dried and concentrated. The
residue was purified by silica gel chromatography, eluting with
ethyl acetate to give (5)-tert-butyl
4-((5R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3--
methylpiperazine-1-carboxylate (0.775 g, 60%). .sup.1H NMR
(CDCl.sub.3, 400 MHz) .delta. 8.60-8.59 (d, 1H), 6.07-5.89 (m, 1H),
4.73-4.60 (m, 1H), 4.30-3.80 (m, 3H), 3.60-3.35 (m, 1H), 3.22 (m,
1H), 3.02 (br, 1H), 2.78 (m, 1H), 2.35-1.60 (m, 5H), 1.49 (s, 9H),
1.32-1.20 (m, 6H). MS (APCI+) [M+H].sup.+ 391. The resulting
mixture of diastereomers was purified by chiral separation by HPLC
(Chiralcel ODH column, 250.times.20 mm, 15 mL/min, Hexane/EtOH
50:50). The first peak (RT=3.864 min) gave (5)-tert-butyl
4-((5R,7R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
-3-methylpiperazine-1-carboxylate (0.281 g, 36%) and the second
peak (RT=5.064 min) gave (S)-tert-butyl
4-((5R,7S)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
-3-methylpiperazine-1-carboxylate (0.389 g, 50%).
[0299] Step 4: To a solution of the (S)-tert-butyl
4-((5R,7R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
-3-methylpiperazine-1-carboxylate (0.281 g, 0.72 mmol) in THF (5
mL) was added LiOH (3M, 2 mL). The mixture was stirred at room
temperature for 6 hours and then quenched with 2N HCl (3 mL). The
solvent was removed and the residue was purified by silica gel
chromatography, eluting with ethyl acetate to give (S)-tert-butyl
4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
-3-methylpiperazine-1-carboxylate (0.206 g, 82%). .sup.1H NMR
(CDCl.sub.3, 400 MHz) .delta. 8.52 (s, 1H), 5.12 (m, 1H), 4.76 (br,
1H), 4.30-3.80 (m, 3H), 3.52 (m, 1H), 3.26 (m, 1H), 3.03 (br, 1H),
2.20 (m, 1H), 1.49 (s, 9H), 1.30-1.10 (m, 6H). MS (APCI+)
[M+H].sup.+ 349.
[0300] Step 5: T a solution of the (S)-tert-butyl
4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
-3-methylpiperazine-1-carboxylate (0.106 g, 0.304 mmol) in DCM (20
mL) was added HCl (4M in dioxane, 4 mL). The mixture was stirred at
room temperature overnight. The solvent was removed to afford
(5R,7R)-5-methyl-4-((S)-2-methylpiperazin-1-yl)-6,7-dihydro-5H-cyclopenta-
[d]pyrimidin-7-ol dihydrochloride (0.098 g, 99%). MS (APCI+)
[M+H].sup.+ 249.
[0301] Step 6: To a solution of the
(5R,7R)-5-methyl-4-((S)-2-methylpiperazin-1-yl)-6,7-dihydro-5H-cyclopenta-
[d]pyrimidin-7-ol dihydrochloride (33 mg, 0.10 mmol) and
(R)-2-(tert-butoxycarbonyl)-3-(4-chlorophenyl)propanoic acid (31
mg, 0.10 mmol) in DCM (5 mL) and triethylamine (1 mL) was added
HBTU (39 mg, 0.1 mmol). The mixture was stirred at room temperature
for 1 hour. The solvent was removed and the residue was purified by
silica gel chromatography, eluting with DCM/MeOH (20:1) to give
tert-butyl
(R)-3-(4-chlorophenyl)-1-((S)-4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5-
H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)-1-oxopropan-2-ylcar-
bamate (45 mg, 83%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.53
(s, 1H), 7.25-7.10 (m, 4H), 5.60-5.30 (m, 1H), 5.20-4.60 (m, 3H),
4.50-4.00 (m, 2H), 3.90-3.60 (m, 4H), 3.58-2.90 (m, 3H), 2.17 (m,
1H), 1.46-1.30 (m, 9H), 1.28-0.90 (m, 6H). MS (APCI+) [M+H].sup.+
531.
[0302] Step 7: Treatment of tert-butyl
(R)-3-(4-chlorophenyl)-1-((S)-4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5-
H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)-1-oxopropan-2-ylcar-
bamate with HCl (4M in dioxane, 2 mL) in DCM (5 mL) for 6 hours
gave the
(R)-2-amino-3-(4-chlorophenyl)-1-((S)-4-((5R,7R)-7-hydroxy-5-methyl-6,7-d-
ihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)propan-1-one
dihydrochloride. .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.53-8.40
(m, 1H), 7.40-7.10 (m, 4H), 5.35-5.30 (m, 1H), 4.05-3.95 (m, 1h),
3.70-3.40 (m, 5H), 3.20-2.90 (m, 4H), 2.40-2.20 (m, 2H), 2.04-1.98
(m, 1H), 1.20-0.95 (m, 6H). MS (APCI+) [M+H].sup.+ 431.
Example 3
##STR00101##
[0303] Preparation of
(R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-((S)-4-((5R,7R)-7-hydroxy-5-met-
hyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)pro-
pan-1-one dihydrochloride
[0304] Step 1: To a solution of
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine (2.5
g, 14.8 mmol) in CHCl.sub.3 (60 mL) was added MCPBA (8.30 g, 37.0
mmol) in three portions. The mixture was stirred at room
temperature for 2 days. The mixture was cooled to 0.degree. C. and
to this was added dropwise Na.sub.2S.sub.2O.sub.3 (10 g) in water
(60 mL), followed by Na.sub.2CO.sub.3 (6 g) in water (20 mL). The
reaction mixture was stirred for 20 minutes. The aqueous phase was
extracted with CHCl.sub.3 (2.times.200 mL), and the combined
organic phases were concentrated at low temperature (<25.degree.
C.). The residue was purified by silica gel chromatography, eluting
with ethyl acetate-DCM/MeOH (20:1) to give
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-oxide
(1.45 g, 53%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.66 (s,
1H), 3.50 (m, 1H), 3.20 (m, 2H), 2.44 (m, 1H), 1.90 (m, 1H), 1.37
(d, J=7.2 Hz, 3H).
[0305] Step 2: A solution of
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-oxide
(1.45 g, 7.85 mmol) in acetic anhydride (20 mL) was heated to
110.degree. C. for 2 hours. After cooling, excess solvent was
removed under vacuum. The residue was purified by silica gel
chromatography, eluting with Hexane/ethyl acetate (3:1) to give
(5R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-yl
acetate (1.25 g, 70%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta.
8.92 (m, 1H), 6.30-6.03 (m, 1H), 3.60-3.30 (m, 1H), 2.84 (m, 1H),
2.40-2.20 (m, 1H), 2.15 (d, J=6 Hz, 2H), 1.75 (m, 2H), 1.47 (d,
J=6.8, 2H), 1.38 (d, J=7.2, 1H). MS (APCI+) [M+H].sup.+ 227.
[0306] Step 3: To a solution of
(5R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-yl
acetate (0.75 g, 3.3 mmol) in NMP (10 mL) was added (S)-tert-butyl
3-methylpiperazine-1-carboxylate (1.0 g, 5.0 mmol). The mixture was
heated to 125.degree. C. for 60 hours. After cooling, the mixture
was diluted with ethyl acetate (200 mL) and washed with water
(6.times.100 mL). The organic phase was dried and concentrated. The
residue was purified by silica gel chromatography, eluting with
ethyl acetate to give (5)-tert-butyl
4-((5R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3--
methylpiperazine-1-carboxylate (0.775 g, 60%). .sup.1H NMR
(CDCl.sub.3, 400 MHz) .delta. 8.60-8.59 (d, 1H), 6.07-5.89 (m, 1H),
4.73-4.60 (m, 1H), 4.30-3.80 (m, 3H), 3.60-3.35 (m, 1H), 3.22 (m,
1H), 3.02 (br, 1H), 2.78 (m, 1H), 2.35-1.60 (m, 5H), 1.49 (s, 9H),
1.32-1.20 (m, 6H). MS (APCI+) [M+H].sup.+ 391. The resulting
mixture of diastereomers was purified by chiral separation by HPLC
(Chiralcel ODH column, 250.times.20 mm, 15 mL/min, Hexane/EtOH
50:50). The first peak (RT=3.864 min) gave (S)-tert-butyl
4-((5R,7R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
-3-methylpiperazine-1-carboxylate (0.281 g, 36%) and the second
peak (RT=5.064 min) gave (S)-tert-butyl 4-((5R,7
S)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methy-
lpiperazine-1-carboxylate (0.389 g, 50%). Treatment of the
(S)-tert-butyl
4-((5R,7R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
-3-methylpiperazine-1-carboxylate with HCl in dioxane (4M, 2 ml)
gave the
(5R,7R)-5-methyl-4-((S)-2-methylpiperazin-1-yl)-6,7-dihydro-5H-cyclopenta-
[d]pyrimidin-7-ol dihydrochloride in quantitative yield.
[0307] Step 4: To a solution of
(5R,7R)-5-methyl-4-((S)-2-methylpiperazin-1-yl)-6,7-dihydro-5H-cyclopenta-
[d]pyrimidin-7-ol dihydrochloride (33 mg, 0.10 mmol) and
(R)-2-(tert-butoxycarbonyl)-3-(4-chloro-3-fluorophenyl)propanoic
acid (33 mg, 0.10 mmol) in DCM (5 mL) and triethylamine (1 mL) was
added HBTU (39 mg, 0.1 mmol). The mixture was stirred at room
temperature for 1 hour. The solvent was removed and the residue was
purified by silica gel chromatography, eluting with DCM/MeOH (20:1)
to give tert-butyl
(R)-3-(4-chloro-3-fluorophenyl)-1-((S)-4-((5R,7R)-7-hydroxy-5-methyl-6,7--
dihydro-5Hz-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)-1-oxoprop-
an-2-ylcarbamate (44 mg, 78%). .sup.1H NMR (CDCl.sub.3, 400 MHz)
.delta. 8.53 (s, 1H), 7.31-6.88 (m, 3H), 5.60-5.30 (m, 1H), 5.13
(m, 3H), 4.90-4.70 (m, 2H), 4.60-4.00 (m, 2H), 3.90-2.85 (m, 7H),
2.19 (m, 1H), 1.40 (m, 9H), 1.28-0.98 (m, 6H). MS (APCI+)
[M+H].sup.+ 549.
[0308] Step 5: Treatment of tert-butyl
(R)-3-(4-chloro-3-fluorophenyl)-1-((S)-4-((5R,7R)-7-hydroxy-5-methyl-6,7--
dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)-1-oxopropa-
n-2-ylcarbamate with HCl (4M in dioxane, 2 mL) in DCM (5 mL) for 6
hours gave
(R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-((S)-4-((5R,7R)-7-hydroxy--
5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-y-
l)propan-1-one dihydrochloride. .sup.1H NMR (D.sub.2O, 400 MHz)
.delta. 8.51-8.40 (m, 1H), 7.29-7.24 (m, 1H), 7.08-7.08 (d, J=10
Hz, 1H), 6.95-6.93 (d, J=8.4 Hz, 1H), 5.36-5.32 (m, 1H), 4.18-3.98
(m, 2H), 3.75-3.50 (m, 5H), 3.20-2.97 (m, 4H), 2.60-2.50 (m, 1H),
2.30-2.20 (m, 1H), 2.05-1.98 (m, 1H), 1.14-1.12 (d, J=6.4 Hz, 3H),
0.98-0.96 (d, J=6.8 Hz, 3H). MS (APCI+) [M+H].sup.+ 449.
Example 4
##STR00102##
[0309] Preparation of
(R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-((S)-4-((5R,7R)-7-methoxy-5-met-
hyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)pro-
pan-1-one dihydrochloride
[0310] Step 1: 1,1,3,3-Tetramethylguanidine (2.11 ml, 16.8 mmol)
was added to a 0.degree. C. solution of methyl
2-(tert-butoxycarbonyl)-2-(dimethoxyphosphoryl)-acetate (5.00 g,
16.8 mmol) in DCM (70 mL). The reaction mixture was stirred at
0.degree. C. for 30 minutes. Then a solution of
4-chloro-3-fluorobenzaldehyde (2.67 g, 16.8 mmol) in DCM (10 mL)
was added by syringe. The reaction mixture was stirred for 10
minutes, then warmed to room temperature and stirred for another 1
hour. H.sub.2O was then added, and the mixture was extracted with
DCM. The combined extracts were dried (Na.sub.2SO.sub.4), filtered,
and concentrated. The resulting solids were recrystallized from IPA
to give (Z)-methyl
2-(tert-butoxycarbonyl)-3-(4-chloro-3-fluorophenyl)acrylate (3.76
g, 67.8% yield) as a white powder (2 crops). LCMS (APCI.sup.-) m/z
328 [M-H].sup.-.
[0311] Step 2: (Z)-methyl
2-(tert-butoxycarbonyl)-3-(4-chloro-3-fluorophenyl)acrylate (200
mg) and ca. Rh--(R,R)--[Et-DuPhos(COD)]OTf (4 mg) in 1:1 MeOH:EtOAc
(3 mL; degassed 1 h with N.sub.2 prior to use) was dissolved in 8
Argonaut Endeavor.TM. reaction tubes. The reaction mixtures were
put on the Endeavor.TM. under 40 psi H.sub.2 and stirred for 12
hours at room temperature. All of the reaction mixtures were then
combined and concentrated to give (R)-methyl
2-(tert-butoxycarbonyl)-3-(4-chloro-3-fluorophenyl)propanoate (1.52
g, 94.4% yield) as a pale yellow solid, which was used without
further purification in next step.
[0312] Step 3: LiOH--H.sub.2O (0.6246 g, 14.88 mmol) was added to a
solution of (R)-methyl
2-(tert-butoxycarbonyl)-3-(4-chloro-3-fluorophenyl)propanoate
(1.646 g, 4.961 mmol) in 1:1 THF:H.sub.2O (26 mL). The reaction
mixture was stirred at room temperature for 2 hours, after which it
was diluted with H.sub.2O and washed with EtOAc. The aqueous layer
was then acidified with solid KHSO.sub.4 and extracted with DCM.
The combined extracts were dried (Na.sub.2SO.sub.4), filtered,
concentrated, and then re-concentrated from DCM/hexanes to give
(R)-2-(tert-butoxycarbonyl)-3-(4-chloro-3-fluorophenyl)-propanoic
acid (1.31 g, 83.10% yield) as a white powder. LCMS (APCI) m/z 316
[M-H].sup.-.
[0313] Step 4: To a solution of
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine (2.5
g, 14.8 mmol) in CHCl.sub.3 (60 mL) was added MCPBA (8.30 g, 37.0
mmol) in three portions. The mixture was stirred at room
temperature for 2 days. The mixture was cooled to 0.degree. C. and
to this was added dropwise Na.sub.2S.sub.2O.sub.3 (10 g) in water
(60 mL), followed by Na.sub.2CO.sub.3 (6 g) in water (20 mL). The
reaction mixture was stirred for 20 minutes. The aqueous phase was
extracted with CHCl.sub.3 (2.times.200 mL), and the combined
organic phases were concentrated at low temperature (<25.degree.
C.). The residue was purified by silica gel chromatography, eluting
with ethyl acetate-DCM/MeOH (20:1) to give
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-oxide
(1.45 g, 53%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.66 (s,
1H), 3.50 (m, 1H), 3.20 (m, 2H), 2.44 (m, 1H), 1.90 (m, 1H), 1.37
(d, J=7.2 Hz, 3H).
[0314] Step 5: A solution of
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-oxide
(1.45 g, 7.85 mmol) in acetic anhydride (20 mL) was heated to
110.degree. C. for 2 hours. After cooling, excess solvent was
removed under vacuum. The residue was purified by silica gel
chromatography, eluting with Hexane/ethyl acetate (3:1) to give
(5R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-yl
acetate (1.25 g, 70%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta.
8.92 (m, 1H), 6.30-6.03 (m, 1H), 3.60-3.30 (m, 1H), 2.84 (m, 1H),
2.40-2.20 (m, 1H), 2.15 (d, J=6 Hz, 2H), 1.75 (m, 2H), 1.47 (d,
J=6.8, 2H), 1.38 (d, J=7.2, 1H). MS (APCI+) [M+H].sup.+ 227.
[0315] Step 6: To a solution of
(5R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-yl
acetate (0.75 g, 3.3 mmol) in NMP (10 mL) was added (5)-tert-butyl
3-methylpiperazine-1-carboxylate (1.0 g, 5.0 mmol). The mixture was
heated to 125.degree. C. for 60 hours. After cooling, the mixture
was diluted with ethyl acetate (200 mL) and washed with water
(6.times.100 mL). The organic phase was dried and concentrated. The
residue was purified by silica gel chromatography, eluting with
ethyl acetate to give (5)-tert-butyl
4-((5R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3--
methylpiperazine-1-carboxylate (0.775 g, 60%). .sup.1H NMR
(CDCl.sub.3, 400 MHz) .delta. 8.60-8.59 (d, 1H), 6.07-5.89 (m, 1H),
4.73-4.60 (m, 1H), 4.30-3.80 (m, 3H), 3.60-3.35 (m, 1H), 3.22 (m,
1H), 3.02 (br, 1H), 2.78 (m, 1H), 2.35-1.60 (m, 5H), 1.49 (s, 9H),
1.32-1.20 (m, 6H). MS (APCI+) [M+H].sup.+ 391. The resulting
mixture of diastereomers was purified by chiral separation by HPLC
(Chiralcel ODH column, 250.times.20 mm, 15 mL/min, Hexane/EtOH
50:50). The first peak (RT=3.864 min) gave (S)-tert-butyl
4-((5R,7R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
-3-methylpiperazine-1-carboxylate (0.281 g, 36%) and the second
peak (RT=5.064 min) gave (S)-tert-butyl 4-((5R,7
S)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methy-
lpiperazine-1-carboxylate (0.389 g, 50%).
[0316] Step 7: To a solution of (S)-tert-butyl
4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
-3-methylpiperazine-1-carboxylate (0.098 g, 0.28 mmol) in THF (10
mL) were added NaH (60%, 50 mg, 1.25 mmol) and Mel (0.08 mL, 1.28
mmol). The mixture was stirred at room temperature overnight. The
solution was removed and the residue was purified by silica gel
chromatography, eluting with ethyl acetate to give (S)-tert-butyl
4-((5R,7R)-7-methoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
-3-methylpiperazine-1-carboxylate (0.056 g, 55%). .sup.1H NMR
(CDCl.sub.3, 400 MHz) .delta. 8.56 (s, 1H), 4.66 (m, 2H), 4.30-3.80
(m, 3H), 3.55 (s, 3H), 3.54-2.90 (m, 4H), 2.25 (m, 1H), 1.98 (m,
1H), 1.49 (s, 9H), 1.24 (d, J=12.4 Hz, 3H), 1.13 (d, J=7.2 Hz, 3H).
MS (APCI+) [M+H].sup.+ 363.
[0317] Step 8: Treatment of (5)-tert-butyl
4-((5R,7R)-7-methoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
-3-methylpiperazine-1-carboxylate with HCl (4M in dioxane, 4 mL) in
DCM (20 mL) for 10 hours gave
(5R,7R)-7-methoxy-5-methyl-4-((S)-2-methylpiperazin-1-yl)-6,7-dihydro-5H--
cyclopenta[d]pyrimidine dihydrochloride. MS (APCI+) [M+H].sup.+
263.
[0318] Step 9: To a solution of
(5R,7R)-7-methoxy-5-methyl-4-((S)-2-methylpiperazin-1-yl)-6,7-dihydro-5H--
cyclopenta[d]pyrimidine dihydrochloride (52 mg, 0.16 mmol) and
(R)-2-(tert-butoxycarbonyl)-3-(4-chloro-3-fluorophenyl)propanoic
acid (49 mg, 0.16 mmol) in DCM (20 mL) and triethylamine (2 mL) was
added HBTU (59 mg, 0.16 mmol). The mixture was stirred at room
temperature for 1 hour. The solvent was removed and the residue was
purified by silica gel chromatography, eluting with ethyl acetate
to give tert-butyl
(R)-3-(4-chloro-3-fluorophenyl)-1-((S)-4-((5R,7R)-7-methoxy-5-methyl-6,7--
dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)-1-oxopropa-
n-2-ylcarbamate (70 mg, 80%). .sup.1H NMR (CDCl.sub.3, 400 MHz)
.delta. 8.57 (s, 1H), 7.28 (m, 1H), 7.05-6.90 (m, 2H), 5.40-5.05
(m, 1H), 4.90-4.30 (m, 4H), 4.10-3.60 (m, 3H), 3.55 (s, 3H),
3.53-2.82 (m, 4H), 2.26 (m, 1H), 2.00 (m, 1H). 1.42 (m, 9H),
1.30-1.00 (m, 6H). MS (APCI+) [M+H].sup.+ 563.
[0319] Step 10: Treatment of tert-butyl
(R)-3-(4-chloro-3-fluorophenyl)-1-((S)-4-((5R,7R)-7-methoxy-5-methyl-6,7--
dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)-1-oxopropa-
n-2-ylcarbamate with HCl (4M in dioxane, 2 mL) in DCM (10 mL) for
10 hours gave
(R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-((S)-4-((5R,7R)-7-methoxy--
5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-y-
l)propan-1-one dihydrochloride. .sup.1H NMR (D.sub.2O, 400 MHz)
.delta. 8.51-8.40 (m, 1H), 7.29-7.21 (m, 1H), 7.10-7.00 (m, 1H),
6.98-6.90 (m, 1H), 5.15-5.02 (m, 1H), 4.90 (m, 1H), 4.70-4.67 (m,
1H), 4.08-3.98 (m, 2H), 3.75-3.50 (m, 4H), 3.37 (s, 3H), 3.20-2.97
(m, 4H), 2.60-2.50 (m, 1H), 2.30-2.20 (m, 1H), 2.10-2.01 (m, 1H).
1.25-0.95 (m, 6H). MS (APCI+) [M+H].sup.+ 463.
Example 5
##STR00103##
[0320] Preparation of
(S)-3-amino-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihyd-
ro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride
[0321] Step 1: To a 1 L round-bottom flask were added
(R)-(+)-Pulegone (76.12 g, 0.5 mmol), anhydrous NaHCO.sub.3 (12.5
g) and anhydrous ether (500 mL). The reaction mixture was cooled
with ice-bath under nitrogen. The bromine (25.62 mL, 0.5 mmol) was
added dropwise over 30 minutes. The mixture was filtered and
carefully added to NaOEt (21%, 412 mL, 1.11 mmol) in an ice-cooled
bath. The mixture was stirred at room temperature overnight and
then 1 L of 5% HCl and 300 mL of ether were added. The aqueous
phase was extracted with ether (2.times.300 mL). The combined
organic phase was washed with water, dried and concentrated. The
residue was added to a warmed solution of semicarbazide
hydrochloride (37.5 g) and NaOAc (37.5 g) in water (300 mL), and
then boiling ethanol (300 mL) was added to give a clear solution.
The mixture was refluxed for 2.5 hours and then stirred at room
temperature overnight. The mixture was treated with 1 L of water
and 300 mL of ether. The aqueous phase was extracted with ether
(2.times.300 mL). The combined organic phase was washed with water,
dried and concentrated. The residue was purified by vacuum
distillation (73-76.degree. C. at 0.8 mm Hg) to give (2R)-ethyl
2-methyl-5-(propan-2-ylidene)cyclopentanecarboxylate (63 g, 64%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 4.13 (m, 2H), 3.38 (d,
J=16 Hz, 0.5H), 2.93 (m, 0.5H), 2.50-2.17 (m, 2H), 1.98 (m, 1H),
1.76 (m, 1H), 1.23 (m, 6H), 1.05 (m, 6H).
[0322] Step 2: (2R)-Ethyl
2-methyl-5-(propan-2-ylidene)cyclopentanecarboxylate (24 g, 0.122
mol) in ethyl acetate (100 mL) was cooled to -68.degree. C. with
dry ice/isopropanol. Ozonized oxygen (5-7 ft.sup.3h.sup.-1 of
O.sub.2) was bubbled through the solution for 3.5 hours. The
reaction mixture was flushed with nitrogen at room temperature
until the color disappeared. The ethyl acetate was removed under
vacuum and the residue was dissolved in 150 mL of acetic acid and
cooled by ice water, and zinc powder (45 g) was added. The solution
was stirred for 30 minutes and then filtered. The filtrate was
neutralized with 2N NaOH (1.3 L) and NaHCO.sub.3. The aqueous phase
was extracted with ether (3.times.200 mL). The organic phase was
combined, washed with water, dried and concentrated to afford
(2R)-ethyl 2-methyl-5-oxocyclopentanecarboxylate (20 g, 96%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 4.21 (m, 2H), 2.77 (d,
J=11.2 Hz, 1H), 2.60 (m, 1H), 2.50-2.10 (m, 3H), 1.42 (m, 1H), 1.33
(m, 3H), 1.23 (m, 3H).
[0323] Step 3: To a solution of a mixture of (2R)-ethyl
2-methyl-5-oxocyclopentanecarboxylate (20 g, 117.5 mmol) and
thiourea (9.2 g, 120.9 mmol) in ethanol (100 mL) was added KOH (8.3
g, 147.9 mmol) in water (60 mL). The mixture was refluxed for 10
hours. After cooling, the solvent was removed and the residue was
neutralized with concentrated HCl (12 mL) at 0.degree. C. and then
extracted with DCM (3.times.150 mL). The solvent was removed and
the residue was purified by silica gel chromatography, eluting with
Hexane/ethyl acetate (2:1) to give
(R)-2-mercapto-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol
(12 g, 56%). MS (APCI+) [M+H].sup.+ 183.
[0324] Step 4: To a suspension of
(R)-2-mercapto-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol
(12 g, 65.8 mmol) in distilled water (100 mL) was added Raney
Nickel (15 g) and NH.sub.4OH (20 mL). The mixture was refluxed for
3 hours then filtered, and the filtrate was concentrated to afford
(R)-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol (9.89 g,
99%). MS (APCI+) [M+H].sup.+ 151.
[0325] Step 5: A mixture of
(R)-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol (5.8 g,
38.62 mmol) in POCl.sub.3 (20 mL) was refluxed for 5 minutes.
Excess POCl.sub.3 was removed under vacuum and the residue was
dissolved in DCM (50 mL). The mixture was then added to saturated
NaHCO.sub.3 (200 mL). The aqueous phase was extracted with DCM
(3.times.100 mL), and the combined organic phases were dried and
concentrated. The residue was purified by silica gel
chromatography, eluting with ethyl acetate to give
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine (3.18
g, 49%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.81 (s, 1H),
3.47 (m, 1H), 3.20 (m, 1H), 3.05 (m, 1H), 2.41 (m, 1H), 1.86 (m,
3H), 1.47 (m, 3H).
[0326] Step 6: To a solution of
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine (2.5
g, 14.8 mmol) in CHCl.sub.3 (60 mL) was added MCPBA (8.30 g, 37.0
mmol) in three portions. The mixture was stirred at room
temperature for 2 days. The mixture was cooled to 0.degree. C. and
to this was added dropwise Na.sub.2S.sub.2O.sub.3 (10 g) in water
(60 mL), followed by Na.sub.2CO.sub.3 (6 g) in water (20 mL). The
reaction mixture was stirred for 20 minutes. The aqueous phase was
extracted with CHCl.sub.3 (2.times.200 mL), and the combined
organic phases were concentrated at low temperature (<25.degree.
C.). The residue was purified by silica gel chromatography, eluting
with ethyl acetate-DCM/MeOH (20:1) to give
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-oxide
(1.45 g, 53%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.66 (s,
1H), 3.50 (m, 1H), 3.20 (m, 2H), 2.44 (m, 1H), 1.90 (m, 1H), 1.37
(d, J=7.2 Hz, 3H).
[0327] Step 7: A solution of
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-oxide
(1.45 g, 7.85 mmol) in acetic anhydride (20 mL) was heated to
110.degree. C. for 2 hours. After cooling, excess solvent was
removed under vacuum. The residue was purified by silica gel
chromatography, eluting with Hexane/ethyl acetate (3:1) to give
(5R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-yl
acetate (1.25 g, 70%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta.
8.92 (m, 1H), 6.30-6.03 (m, 1H), 3.60-3.30 (m, 1H), 2.84 (m, 1H),
2.40-2.20 (m, 1H), 2.15 (d, J=6 Hz, 2H), 1.75 (m, 2H), 1.47 (d,
J=6.8, 2H), 1.38 (d, J=7.2, 1H). MS (APCI+) [M+H].sup.+ 227.
[0328] Step 8: To a solution of
(5R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-yl
acetate (0.5 g, 2.2 mmol) in NMP (10 mL) was added 1-Boc-piperazine
(0.9 g, 4.8 mmol). The reaction mixture was heated to 110.degree.
C. for 12 hours. After cooling, the reaction mixture was diluted
with ethyl acetate (200 mL) and washed with water (6.times.100 mL).
The organic phase was dried and concentrated. The residue was
purified by silica gel chromatography, eluting with ethyl acetate
to give tert-butyl
4-45R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pipe-
razine-1-carboxylate (0.6 g, 72%). .sup.1H NMR (CDCl.sub.3, 400
MHz) .delta. 8.60 (d, 1H), 6.05-5.90 (m, 1H), 3.80-3.30 (m, 9H),
2.84 (m, 1H), 2.20 (m, 1H), 1.49 (s, 9H), 1.29-1.20 (m, 3H). MS
(APCI+) [M+H].sup.+ 377. The resulting mixture of the diastereomers
was purified by chiral separation HPLC (Chiralcel ODH column,
250.times.20 mm, Hexane/EtOH 60:40, 21 mL/min). The first peak
(RT=3.73 min) gave the tert-butyl
4-((5R,7R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate (0.144 g, 24%). The second peak (RT=5.66
min) gave the tert-butyl
4-((5R,7S)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate (0.172 g, 29%). MS (APCI+) [M+H].sup.+
377.
[0329] Step 9: To a solution of tert-butyl
4-((5R,7R)-7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate (0.144 g, 0.383 mmol) in THF (4 mL) was
added LiOH (3M, 2 mL). The mixture was stirred at room temperature
for 6 hours and then quenched with 2N HCl (3 mL). The solvent was
removed and the residue was purified by silica gel chromatography,
eluting with ethyl acetate to give tert-butyl
4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate (89 mg, 70%). %). .sup.1H NMR (CDCl.sub.3,
400 MHz) .delta. 8.52 (s, 1H), 5.48 (br, 1H), 5.14 (m, 1H),
3.82-3.40 (m, 9H), 2.20 (m, 2H), 1.49 (s, 9H), 1.19 (d, J=6.8 Hz,
3H). MS (APCI+) [M+H].sup.+ 335.
[0330] Step 10: tert-Butyl
4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate was treated with HCl (4M in dioxane, 2 mL)
in DCM (5 mL) for 6 hours to give
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride. MS (APCI+) [M+H].sup.+ 235.
[0331] Step 11: Tert-butyl 2,4-dimethoxybenzylcarbamate (3.96 g,
14.8 mmol) was dissolved in THF (74 mL) and cooled to -78.degree.
C. The solution was treated with butyl lithium (7.44 mL, 16.3 mmol)
dropwise over a five minute period to afford a pale-yellow
solution. The solution was allowed to stir for 15 minutes before
the chloro(methoxy)methane (1.35 mL, 17.8 mmol) was added dropwise
(neat). The reaction was stirred at -78.degree. C. for 10 minutes,
then allowed to warm slowly to ambient temperature overnight. The
reaction was concentrated in vacuo to afford a yellow gel which was
partitioned between half-saturated NH.sub.4Cl solution and ether.
The aqueous layer was extracted once, and the organics were
combined. The organic layer was washed with water, then brine,
separated, dried over Na.sub.2SO.sub.4, filtered, and concentrated
in vacuo. .sup.1H NMR supports the desired near-pure (>90%)
tert-butyl 2,4-dimethoxybenzyl(methoxymethyl)carbamate (4.81 g,
104% yield) as a pale-yellow oil which was used without
purification.
[0332] Step 12:
(R)-4-benzyl-3-(2-(4-chlorophenyl)acetyl)oxazolidin-2-one (3.00 g,
9.10 mmol) was dissolved in DCM (91 mL) and cooled to -78.degree.
C. A 1M toluene solution of TiCl.sub.4 (11.4 mL, 11.4 mmol) was
added to the solution followed by DIEA (1.66 mL, 9.55 mmol) to
afford a dark purple reaction. This was allowed to stir for 15
minutes before the tert-butyl
2,4-dimethoxybenzyl(methoxymethyl)carbamate (3.40 g, 10.9 mmol) was
added as a solution in DCM (10 mL) dropwise. The reaction was
allowed to stir for 15 minutes at -78.degree. C., then allowed to
warm to -18.degree. C. in a brine-ice bath for one hour. This
reaction was allowed to warm slowly to 0.degree. C. over a 2.5 hour
period. The reaction was then quenched with the addition of
saturated NH.sub.4Cl solution (100 mL). The layers were separated,
and the organic layers was extracted once with DCM. The combined
organic layers were dried over MgSO.sub.4, filtered, and
concentrated in vacuo to afford a yellow oil. The residue was
purified by chromatography (silica gel eluted with 4:1
hexanes:ethyl acetate) to afford the pure material as a colorless
oil tert-butyl
2,4-dimethoxybenzyl((S)-3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chloro-
phenyl)-3-oxopropyl)carbamate (4.07 g, 73.5% yield). This
tert-butyl
2,4-dimethoxybenzyl((S)-3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chloro-
phenyl)-3-oxopropyl)carbamate (680 mg, 1.12 mmol) was dissolved in
DCM (10.6 mL) and water (560 uL; 19:1 DCM:water) at ambient
temperature. The solution was treated with DDQ (380 mg, 1.67 mmol),
and the reaction was allowed to stir for one day to afford reaction
completion by TLC and LCMS analysis. The reaction was diluted with
DCM and washed twice with half saturated NaHCO.sub.3 solution. The
organic layer was dried over MgSO.sub.4, filtered, and concentrated
in vacuo to afford a yellow-orange oil. The residue was purified by
chromatography (silica gel eluted with 9:1 hexanes:ethyl acetate)
to afford a mixture of the aldehyde by-product and tert-butyl
(S)-3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropylc-
arbamate (not separable) as a pale-yellow oil (729 mg combined
mass). LC/MS (APCI+) m/z 359.1 [M-BOC+H].sup.+.
[0333] Step 13: 35% H.sub.2O.sub.2 (0.240 mL, 2.91 mmol) was added
to a solution of LiOH--H.sub.2O (0.0978 g, 2.33 mmol) in 2:1
THF:H.sub.2O (33 mL). The reaction mixture was stirred at room
temperature for 35 minutes, and then cooled to 0.degree. C. A
solution containing a mixture of tert-butyl
(S)-3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropylc-
arbamate (0.535 g, 1.17 mmol) and 2,4-dimethoxybenzaldehyde (0.194
g, 1.17 mmol) in THF (7 mL) was added dropwise by addition funnel.
The ice bath was allowed to slowly warm, and the reaction mixture
was stirred overnight. The reaction mixture was then cooled to
0.degree. C., and 1M Na.sub.2SO.sub.3 (7 mL) was added. The mixture
was stirred for 5 minutes, and then warmed to room temperature and
stirred an additional 20 minutes. The reaction mixture was then
transferred to a separatory funnel and washed with ether
(3.times.). The aqueous layer was acidified with KHSO.sub.4(s), and
the mixture was extracted with DCM (2.times.). The combined
extracts were dried (Na.sub.2SO.sub.4), filtered, and concentrated
to give
(S)-3-(tert-butoxycarbonylamino)-2-(4-chlorophenyl)propanoic acid
(0.329 g, 94.2% yield) as a white residue. LC/MS (APCI+) m/z 200
[M-BOC+H].sup.+.
[0334] Step 14: 4M HCl/dioxane (5.49 ml, 22.0 mmol) was added to a
solution of
(S)-3-(tert-butoxycarbonylamino)-2-(4-chlorophenyl)propanoic acid
(0.329 g, 1.10 mmol) in 2:1 dioxane:DCM (10 mL). The reaction
mixture was stirred at room temperature overnight (16 hours), after
which it was concentrated to 1/3 volume. The resulting cloudy
mixture was diluted with ether, and the mixture was concentrated
again to 1/3 volume. The mixture was diluted again with ether (20
mL), and the solids were isolated by filtration through a medium
frit funnel with nitrogen pressure, rinsed with ether (5.times.10
mL), dried under nitrogen pressure, and dried in vacuo to give
(S)-3-amino-2-(4-chlorophenyl)propanoic acid hydrochloride (0.199
g, 76.8% yield) as a white powder. HPLC >99 area % pure. LC/MS
(APCI+) m/z 200.
[0335] Step 15: Boc.sub.2O (0.368 g, 1.69 mmol) was added to a
solution of (S)-3-amino-2-(4-chlorophenyl)propanoic acid
hydrochloride (0.199 g, 0.843 mmol) and tetramethylammonium
hydroxide pentahydrate (0.382 g, 2.11 mmol) in 10:1 MeCN:H.sub.2O
(7.7 mL). The reaction mixture was stirred overnight at room
temperature (12 hours), after which the MeCN was removed on a
rotary evaporator. The mixture was diluted with water and washed
with ether (2.times.). The aqeuous layer was acidified with
KHSO.sub.4(s), the mixture was extracted with DCM, and the combined
extracts were dried (Na.sub.2SO.sub.4), filtered, and concentrated
to give
(S)-3-(tert-butoxycarbonylamino)-2-(4-chlorophenyl)propanoic acid
(0.229 g, 90.6% yield) as a foam. HPLC >99 area % pure. LC/MS
(APCI+) m/z 200 [M-BOC+H].sup.+.
[0336] Step 16: To a solution of
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride (88 mg, 0.29 mmol) and
(S)-3-(tert-butoxycarbonylamino)-2-(4-chlorophenyl)propanoic acid
(86 mg, 0.29 mmol) in DCM (10 mL) and Diisopropylethylamine (0.22
mL, 1.3 mmol) was added HBTU (110 mg, 0.29 mmol). The reaction
mixture was stirred at room temperature for 1 hour. The solvent was
removed and the residue was dissolved in ethyl acetate (100 mL),
washed with water (6.times.50 ml). The organic phase was dried and
concentrated to give tert-butyl
(S)-2-(4-chlorophenyl)-3-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropylcarbamate (116
mg, 78%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.51 (s, 1H),
7.34-7.20 (m, 4H), 5.15-5.09 (m, 2H), 4.15-4.05 (m, 1H), 3.87-3.85
(m, 2H), 3.78-3.38 (m, 7H), 3.22-3.19 (m, 1H), 2.20-2.10 (m, 2H),
1.48 (s, 9H), 1.41 (s, 9H), 1.14-1.12 (d, J=7.2 Hz, 3H). MS (APCI+)
[M+H].sup.+ 516.
[0337] Step 17: Treatment of tert-butyl
(S)-2-(4-chlorophenyl)-3-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropylcarbamate with
HCl (4M in dioxane, 2 mL) in DCM (5 mL) for 6 hours to give
(S)-3-amino-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihyd-
ro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
dihydrochloride. .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.38 (s,
1H), 7.37-7.35 (d, J=8.4 Hz, 2H), 7.23-7.21 (d, J=8.4 Hz, 2H),
5.29-5.25 (m, 1H), 4.64 (s, 9H), 4.31-4.28 (m, 1H), 4.11 (m, 1H),
3.88-3.79 (m, 2H), 3.70-3.20 (m, 10H), 2.23-2.17 (m, 1H), 2.07-1.99
(m, 1H), 1.22-1.20 (m, 2H), 0.98-0.96 (d, J=6.8 Hz, 2H). MS (APCI+)
[M+H].sup.+ 416.
[0338] The following compounds have also been prepared according to
the above-described methods unless otherwise noted.
Example 6
##STR00104##
[0339]
(R)-2-amino-3-(4-chlorophenyl)-1-((S)-4-((S)-7-hydroxy-6,7-dihydro--
5H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)propan-1-one
[0340] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.60-8.40 (m, 1H),
7.40-7.10 (m, 4H), 5.25-5.10 (m, 1H), 4.00-2.90 (m, 14H), 2.52-2.40
(m, 1H), 1.95-1.80 (m, 1H), 1.20-1.10 (m, 3H). MS (APCI+)
[M+H].sup.+ 416.
Example 7
##STR00105##
[0341]
(R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-((S)-4-((S)-7-hydroxy-6,7-
-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)propan-1-o-
ne
[0342] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.55-8.40 (m, 1H),
7.40-7.10 (m, 3H), 5.25-5.10 (m, 1H), 4.00-2.90 (m, 14H), 2.52-2.40
(m, 1H), 1.95-1.80 (m, 1H), 1.20-1.10 (m, 3H). MS (APCI+)
[M+H].sup.+ 434.
Example 8
##STR00106##
[0343]
(2R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-((3S)-4-((5R)-7-hydroxy--
5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-y-
l)propan-1-one
[0344] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.52-8.50 (m, 1H),
7.44-7.38 (m, 1H), 7.16-7.00 (m, 2H), 5.15-5.10 (m, 1H), 4.22-4.10
(m, 1H), 3.90-3.00 (m, 9H), 2.49-2.30 (m 2H), 1.60-1.50 (m, 1H),
1.18-0.95 (m, 6H). MS (APCI+) [M+H].sup.+ 448.
Example 9
##STR00107##
[0345]
(2R)-2-amino-3-(4-chlorophenyl)-1-(4-(7-hydroxy-6,7-dihydro-5H-cycl-
openta[d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
[0346] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.44 (s, 1H),
7.31-7.10 (m, 4H), 5.20-5.16 (m, 1H), 4.00-3.90 (m, 1H), 3.82-2.90
(m, 12H), 2.60-2.50 (m, 1H), 1.90-1.80 (m, 1H), 1.17-1.10 (m, 3H).
MS (APCI+) [M+H].sup.+ 402.
Example 10
##STR00108##
[0347]
(R)-2-amino-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclope-
nta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(4-methoxyphenyl)propan-1-one
[0348] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.44 (s, 1H),
7.17-7.10 (m, 2H), 6.90-6.80 (m, 2H), 5.31-5.26 (m, 1H), 4.15-4.05
(m, 1H), 3.80-2.90 (m, 11H), 2.68 (s, 3H), 2.26-2.20 (m, 1H),
2.10-2.00 (m, 1H), 1.04-1.00 (m, 3H). MS (APCI+) [M+H].sup.+
412.
Example 11
##STR00109##
[0349]
2-(4-chlorophenyl)-1-((S)-4-((R)-7-hydroxy-6,7-dihydro-5H-cyclopent-
a[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)-3-(isopropylamino)propan-1-one
[0350] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.40-8.25 (m, 1H),
7.45-7.10 (m, 4H), 5.25-5.10 (m, 1H), 4.40-4.19 (m, 1H), 3.80-2.80
(m, 12H), 2.55-2.40 (m, 1H), 1.85-1.70 (m, 1H), 1.22-1.10 (m, 9H).
MS (APCI+) [M+H].sup.+ 458.
Example 12
##STR00110##
[0351] Preparation of
2-(4-chlorophenyl)-1-(4-(7-hydroxy-6,7-dihydro-5H-cyclopenta[d]pyrimidin--
4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
dihydrochloride
[0352] Step 1: To a solution of the methyl
2-oxocyclopentanecarboxylate (40 g, 281 mmol) and thiourea (21 g,
281 mmol) in ethanol (200 ml) was added KOH (20 g, 356 mmol) in
water (120 ml). The mixture was refluxed for 12 hour. The solvent
was removed and the residue was quenched with concentrated HCl (25
mL). The precipitate was filtered, washed with water and dried to
afford the 2-mercapto-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol
(12.5 g, 26%). MS (APCI+) [M+H].sup.+ 168.
[0353] Step 2: To a solution of
2-mercapto-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol (12.2 g, 72.5
mmol) in water (200 ml) was added Raney Ni (8 g, slurry in water)
and followed by concentrated ammonia solution (27 mmol). The
mixture was refluxed for 6 hour. The catalyst was filtered off. The
solvent was removed under vacuum to afford
6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol (9.87 g, 99%). .sup.1H
NMR (CD.sub.3OD, 400 MHz) .delta. 8.07 (s, 1H), 2.89-2.85 (m, 2H),
2.80-2.76 (m, 2H), 2.23 (m, 1H), 2.13-2.05 (m, 2H), 1.64 (m,
1H).
[0354] Step 3: To a solution of
6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol (9.87 g, 72.5 mmol) in
DCE (200 ml) was added DIEA (15 mL, 86.1 mmol). The mixture was
stirred at room temperature for 30 minutes and then added
POCl.sub.3 (15 mL, 163.9 mmol) was added slowly. The mixture was
stirred at room temperature for 1 hour and then refluxed for 12
hour. After cooling, the solvent was removed and the residue was
dissolved in CHCl.sub.3 (200 ml). The mixture was basified by
adding ice-cooled concentrated aqueous ammonia (15 mL). The organic
phase was separated. The aqueous phase was washed with CHCl.sub.3
(3.times.100 mL). The organic phase was combined, dried and
concentrated. The residue was subject to chromatography on silica
gel, eluted by Hexanes/ethyl acetate (4:1) to afford
4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine (5.7 g, 51%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.76 (s, 1H), 3.12-3.01
(m, 4H), 2.23-2.14 (m, 2H).
[0355] Step 4: To a solution of
4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine (5.69 g, 36.8 mmol)
in chloroform (200 mL) was added MCPBA (19 g, 84.8 mmol) in
chloroform (50 mL) dropwise. The mixture was stirred at room
temperature for 16 hour. After cooling with ice-water, the mixture
was quenched with Na.sub.2S.sub.2O.sub.3 (27.5 g) in water (110 mL)
dropwise and followed by Na.sub.2CO.sub.3 (14 g) in water (52 mL)
dropwise. The organic phase was separated and the aqueous phase was
extracted with chloroform (3.times.200 mL). The organic phase was
dried and concentrated at low temperature (<25.degree. C.). The
residue was subject to chromatography on silica gel, eluting by
ethyl acetate to afford
4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine 1-oxide (2.93 g,
47%). MS (APCI+) [M+H].sup.+ 171.
[0356] Step 5: The solution of
4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine 1-oxide (2.93 g,
17.2 mmol) in acetic anhydride (50 mL) was added dropwise to the
acetic anhydride (50 mL) at 50.degree. C. After addition, the
mixture was stirred at 110.degree. C. for 2 hour. After cooling,
the solvent was removed and the residue was treated with toluene
and hexanes (1:1, 200 mL). The mixture was stirred and then the
solvent was removed. The residue was subject to chromatography on
silica gel, eluted by hexanes/ethyl acetate (4:1-3:1) to afford the
4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-yl acetate (2.3 g,
63%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.92 (s, 1H),
6.20-6.16 (m, 1H), 3.20-3.10 (m, 1H), 3.03-2.93 (m, 1H), 2.76-2.67
(m, 1H), 2.20-2.05 (m, 4H).
[0357] Step 6: To a solution of
4-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-yl acetate (1.15
g, 5.4 mmol) in NMP (4 mL) and TEA (0.5 mL) was added
1-Boc-piperazine (1.05 g, 5.64 mmol). The mixture was microwaved at
100.degree. C. for 30 minutes and then diluted with ethyl acetate
(200 mL) and washed with water (6.times.100 mL). The organic phase
was dried and concentrated. The residue was subject to
chromatography on silica gel, eluting by hexanes/ethyl acetate
(2:1-1:1) to afford the tert-butyl
4-(7-acetoxy-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carb-
oxylate (1.47 g, 75%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta.
8.56 (s, 1H), 5.99-5.96 (m, 1H), 3.78-3.73 (m, 2H), 3.53-3.50 (m,
2H), 3.15-3.07 (m, 1H), 2.99-2.92 (m, 1H), 2.63-2.54 (m, 1H),
2.04-1.93 (m, 1H), 1.48 (s, 9H). MS (APCI+) [M+H].sup.+ 363.
[0358] Step 7: To a solution of tert-butyl
4-(7-acetoxy-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carb-
oxylate (0.43 g, 1.2 mmol) in THF (15 mL) was added LiOH (3M, 6
mL). The mixture was stirred at room temperature overnight. The
mixture was quenched with 2N HCl (9 mL) and then extracted with DCM
(3.times.100 mL). The organic phase was dried and concentrated. The
residue was subject to chromatography on silica gel, eluted by
DCM/MeOH (20:1) to afford the tert-butyl
4-(7-hydroxy-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carb-
oxylate (0.37 g, 97%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta.
8.51 (m, 1H), 5.06-5.04 (m, 1H), 3.80-3.69 (m, 4H), 3.56-3.45 (m,
4H), 3.10-3.05 (m, 1H), 2.94-2.86 (m, 1H), 2.51-2.44 (m, 1H),
2.00-1.94 (m, 1H), 1.48 (s, 9H). MS (APCI+) [M+H].sup.+ 321.
[0359] Step 8: To a solution of tert-butyl
4-(7-hydroxy-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carb-
oxylate (0.37 g, 1.2 mmol) in DCM (20 mL) was added HCl in dioxane
(4M, 5 mL). The mixture was stirred at room temperature overnight.
The solvent was removed to afford the
4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-ol
dihydrochloride (0.25 g, 98%). MS (APCI+) [M+H].sup.+ 221.
[0360] Step 9: To a solution of
4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-ol
dihydrochloride (40 mg, 0.14 mmol) in DCM (20 mL) and TEA (2 mL)
was added
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoic
acid (47 mg, 0.14 mmol) and HBTU (52 mg, 0.14 mmol). The mixture
was stirred at room temperature for 1 hour. The solvent was removed
and the residue was subject to chromatography on silica gel, eluted
by ethyl acetate to afford the tert-butyl
2-(4-chlorophenyl)-3-(4-(7-hydroxy-6,7-dihydro-5H-cyclopenta[d]pyrimidin--
4-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate (49 mg, 66%).
MS (APCI+) [M+H].sup.+ 544.
[0361] Step 11: To a solution of tert-butyl
2-(4-chlorophenyl)-3-(4-(7-hydroxy-6,7-dihydro-5H-cyclopenta[d]pyrimidin--
4-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate (49 mg, 0.09
mmol) in DCM (10 mL) was added HCl in dioxane (4M, 2 mL). The
mixture was stirred at room temperature overnight. The solvent was
removed to afford the
2-(4-chlorophenyl)-1-(4-(7-hydroxy-6,7-dihydro-5H-cyclopenta[d]pyrimidin--
4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one dihydrochloride
(46 mg, 99%). .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.38-8.36 (m,
1H), 7.37-7.34 (m, 2H), 7.22-7.19 (m, 2H), 5.18-5.10 (m, 1H),
4.34-4.28 (m, 1H), 4.10-3.00 (m, 12H), 2.50-2.40 (m, 1H), 1.85-1.75
(m, 1H), 1.28-1.26 (m, 6H), 1.20-1.13 (m, 3H). MS (APCI+)
[M+H].sup.+ 444.
Example 13
##STR00111##
[0362]
2-(4-chlorophenyl)-3-(isopropylamino)-1-(4-(7-methoxy-6,7-dihydro-5-
H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
[0363] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.39 (s, 1H),
7.40-7.36 (m, 2H), 7.22-7.16 (m, 2H), 4.90-4.85 (m, 1H), 4.30-4.28
(m, 1H), 4.12-4.00 (m, 1H), 3.92-3.80 (m, 2H), 3.79-3.70 (m, 1H),
3.58-3.18 (m, 7H), 3.15-2.80 (2H), 2.46-2.35 (m, 1H), 1.95-1.83 (M,
1H), 1.20-1.14 (m, 6H). MS (APCI+) [M+H].sup.+ 458.
Example 14
##STR00112##
[0364]
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-
-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-
-one
[0365] Step 1: Ethyl pulegenate (130 g, 662 mmol) in EtOAc (900 mL)
was cooled to -78.degree. C. using a dry ice-isopropanol bath. This
mixture was subjected to ozonolysis until the reaction turned
purple in color. At this point, ozone generation ceased, and the
reaction was removed from the dry-ice bath. Oxygen was bubbled
through the reaction mixture until it turned yellow. The reaction
mixture was concentrated under vacuum, and the resulting residue
was dissolved in glacial acetic acid (400 mL). The solution was
cooled to 0.degree. C., and Zn dust (65 g, 993 mmol) was added
portionwise over 30 minutes. The reaction was then allowed to stir
for 2 hours, at which point the reaction mixture was filtered
through a pad of celite to remove the zinc dust. The acetic acid
was neutralized to pH 7 with aqueous NaOH and NaHCO.sub.3 and
extracted with ether (3.times.800 mL). The combined organics were
dried with brine, MgSO.sub.4 and concentrated to give (2R)-ethyl
2-methyl-5-oxocyclopentanecarboxylate as a brown liquid (107 g,
95%).
[0366] Step 2: Ammonium acetate (240.03 g, 3113.9 mmol) was added
to a solution of (R)-ethyl 2-methyl-5-oxocyclopentanecarboxylate
(106.0 g, 622.78 mmol) in MeOH (1.2 L). The reaction mixture was
stirred at room temperature under nitrogen for 20 hours, after
which it was complete as judged by TLC and HPLC. The reaction
mixture was concentrated to remove MeOH. The resulting residue was
dissolved in DCM, washed twice with H.sub.2O, once with brine,
dried (Na.sub.2SO.sub.4), filtered, and concentrated to give
(R)-ethyl 2-amino-5-methylcyclopent-1-enecarboxylate (102 g, 97%
yield) as an orange oil. LC/MS (APCI+) m/z 170 [M+H]+.
[0367] Step 3: A solution containing (R)-ethyl
2-amino-5-methylcyclopent-1-enecarboxylate (161.61 g, 955.024 mmol)
and ammonium formate (90.3298 g, 1432.54 mmol) in formamide
(303.456 ml, 7640.19 mmol) was heated to an internal temperature of
150.degree. C. and stirred for 17 hours. The reaction mixture was
cooled, and transferred to a 2 L single neck flask. Then excess
formamidine was removed by high vacuum distillation. Once
formamidine stopped coming over, the remaining oil in the still pot
was dissolved in DCM and washed with brine (3.times.200 mL). The
combined aqueous washes were extracted with DCM. The combined
organic extracts were dried (Na.sub.2SO.sub.4), filtered, and
concentrated. The resulting brown oil was dissolved in minimal DCM,
and this solution was added using a separatory funnel to a stirred
solution of ether (ca. 5 vol of ether vs. DCM solution), causing
some brown precipitate to form. This brown precipitate was removed
by filtration through a medium frit funnel which was rinsed with
ether and disposed. The filtrate was concentrated, the trituration
from ether repeated two more times and then dried on high vacuum
line to give
(R)-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol (93.225 g,
65.00% yield) as a brown-yellow pasty solid. LC/MS (APCI-) m/z
149.2.
[0368] Step 4: Neat POCl.sub.3 (463.9 ml, 5067 mmol) was added
slowly by addition funnel to a 0.degree. C. solution of
(R)-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol (152.2 g,
1013 mmol) in DCE (1.2 L). After the addition was complete, the
reaction mixture was warmed to room temperature, then heated to
reflux and stirred for 70 minutes. The reaction was complete as
determined by HPLC. The reaction mixture was cooled to room
temperature, and the excess POCl.sub.3 was quenched in 4 portions
as follows: Reaction mixture transferred to separatory funnel and
dripped into a beaker containing ice and saturated NaHCO.sub.3
solution cooled in an ice bath. Once the addition of each portion
of the reaction mixture was completed, the quenched mixture was
stirred 30 minutes to ensure complete destruction of POCl.sub.3
prior to transfer to separatory funnel. The mixture was transferred
to the separatory funnel and extracted twice with DCM. The combined
extracts were dried (Na.sub.2SO.sub.4), filtered, and concentrated.
The crude was purified on silica gel as follows: silica gel (1 kg)
was slurried in 9:1 hexane:ethyl acetate onto a 3 L fritted funnel,
silica settled under vacuum, topped with sand. The crude was loaded
with a DCM/hexane mixture, and the compound was eluted using 1 L
sidearm flasks under vacuum. High Rf byproducts eluted first, then
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine (104.4
g, 61.09% yield) as a brown oil. Triethylamine (93.0 ml, 534 mmol)
and tert-butyl piperazine-1-carboxylate (34.8 g, 187 mmol) was
added to a solution of
(R)-4-chloro-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine (30.0
g, 178 mmol) in n-BuOH (250 mL). The reaction mixture was heated to
reflux under nitrogen and stirred overnight (17 hours), after which
it was concentrated on a rotavap. The resulting oil was dissolved
in DCM, washed with H.sub.2O, dried (Na.sub.2SO.sub.4), filtered,
and was concentrated. The resulting brown oil was purified on
silica gel eluting first with 2:1 hexanes:ethyl acetate until
product eluting cleanly, then gradient 1:1 to 1:5 DCM:ethyl acetate
to give (R)-tertbutyl
4-(5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carbo-
xylate (42.0 g, 74.1% yield) as a beige powder. LC/MS (APCI+) m/z
319.1 [M+H].sup.+.
[0369] Step 5: Solid 77% max. MCPBA (23.9 g, 107 mmol) was added
portionwise to a 0.degree. C. solution of (R)-tert-butyl
4-(5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carbo-
xylate (20.0 g, 62.8 mmol) in CHCl.sub.3 (310 mL). The reaction
mixture was stirred 5 for minutes, then warmed to room temperature
and stirred for 90 minutes. HPLC looked similar after 7.5 hours.
The reaction mixture was cooled to 0.degree. C., then NaHCO.sub.3
(13.2 g, 157 mmol) and another 0.5 equivalents of m-CPBA were
added. The reaction mixture was stirred overnight (14 hours). The
reaction mixture was cooled to 0.degree. C., and a solution of
Na.sub.2S.sub.2O.sub.3 (29.8 g, 188 mmol) in H.sub.2O (50 mL) was
added dropwise by addition funnel. This was followed by a solution
of Na.sub.2CO.sub.3 (24.6 g, 232 mmol) in H.sub.2O (70 mL) by
addition funnel (mixture turns homogeneous). The reaction mixture
was stirred for 30 minutes, then the mixture was extracted with
CHCl.sub.3 (3.times.150 mL). The combined extracts were dried
(Na.sub.2SO.sub.4), filtered, and concentrated to give the N-oxide.
LC/MS (APCI+) m/z 335.1 [M+H]+.
[0370] Step 6: Ac.sub.2O (77.0 ml, 816 mmol) was added to the
N-oxide (21.0 g, 62.8 mmol) from Step 5. The reaction mixture was
heated under nitrogen in a 90.degree. C. sand bath and stirred for
100 minutes. The reaction mixture was cooled to room temperature,
and excess acetic anhydride was removed by rotary evaporation. The
resulting oil was dissolved in DCM, which was then poured carefully
into ice saturated Na.sub.2CO.sub.3. The mixture was extracted with
DCM, and the combined extracts were dried (Na.sub.2SO.sub.4),
filtered, and concentrated to give (5R)-tert-butyl
4-(7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[
d]pyrimidin-4-yl)piperazine-1-carboxylate (23.6 g, 100%) as a brown
foam. LC/MS (APCI+) m/z 377.1 [M+H].sup.+.
[0371] Step 7: LiOH--H.sub.2O (6.577 g, 156.7 mmol) was added to a
0.degree. C. solution of (5R)-tert-butyl
4-(7-acetoxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazi-
ne-1-carboxylate (23.6 g, 62.69 mmol) in 2:1 THF:H.sub.2O (320 mL).
The reaction mixture was stirred for 10 minutes, and then warmed to
room temperature. LC/MS looked the same at 3 hours and 4.5 hours.
The reaction mixture was cooled to 0.degree. C., and then saturated
NH.sub.4Cl was added to the mixture. The mixture was stirred for 5
minutes, and most of the THF was removed by rotary evaporation. The
mixture was extracted with EtOAc (3.times.250 mL), and the combined
extracts were dried (Na.sub.2SO.sub.4), filtered, and concentrated.
The crude was flashed on Biotage 65M: 4:1 DCM:ethyl acetate, then
gradient to 1:1 to 1:4 DCM:ethyl acetate. Once the product was
eluting, then ethyl acetate was flushed through the column. Then
30:1 DCM:MeOH eluted the rest of the product (8.83 g). The mixed
fractions were re-flashed with Biotage 40M using the same
conditions to give another 2.99 g which gave a combined yield of
(5R)-tert-butyl
4-(7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazi-
ne-1-carboxylate (11.82 g, 56.38% yield) as a brown foam. LC/MS
(APCI+) m/z 335.1 [M+H]+.
[0372] Step 8: A solution of DMSO (5.45 ml, 76.8 mmol) in DCM (50
mL) was added dropwise by addition funnel to a -78.degree. C.
solution of oxalyl chloride (3.35 ml, 38.4 mmol) in DCM (150 mL).
The reaction mixture was stirred for 35 minutes, and then a
solution of (5R)-tert-butyl
4-(7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazi-
ne-1-carboxylate (9.17 g, 27.4 mmol) in DCM (80 mL) was added
slowly by addition funnel. The reaction mixture was stirred another
1 hour at -78.degree. C., after which neat triethylamine (18.0 ml,
129 mmol) was added to the mixture. The reaction mixture was then
allowed to warm to room temperature, and then it was stirred for 30
minutes. H.sub.2O was added. The mixture was extracted with DCM
(3.times.200 mL), and the combined extracts were dried
(Na.sub.2SO.sub.4), filtered, and concentrated in vacuo. The crude
was purified on silica gel (Biotage 65M): the column was flushed
with ca. 800 mL 4:1 DCM:EtOAc, then gradient to 1:1 DCM:ethyl
acetate until product eluting, then 1:4 DCM:EtOAc eluted product to
give (R)-tert-butyl
4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-
-carboxylate (7.5 g, 82.3% yield) as a brown foam. The foam was
concentrated (3.times.) from DCM/hexanes, which gave a very light
brown foam. HPLC >95% area. LC/MS (APCI+) m/z 333 [M+H]+.
[0373] Step 9: Triethylamine (4.33 ml, 31.1 mmol; degassed with
nitrogen 30 minutes prior to use) and formic acid (1.36 ml, 36.1
mmol; degassed with nitrogen 30 minutes prior to use) were added to
a solution of (R)-tert-butyl
4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-
-carboxylate (9.75 g, 29.3 mmol) in DCM (210 mL; degassed with
nitrogen 30 minutes prior to use). The mixture was stirred for 5
minutes, then a Ru catalyst (0.0933 g, 0.147 mmol) was added. The
reaction was stirred under positive nitrogen pressure overnight (18
hours). The reaction mixture was concentrated to dryness and dried
on high vacuum. The impure material was flashed on Biotage 65M
loaded 1:1 DCM:ethyl acetate 500 mL flushed, then 1:4 DCM:ethyl
acetate until product (2nd spot), then gradient to neat ethyl
acetate, then 25:1 DCM:MeOH eluted rest of product. The fractions
were combined and concentrated on a rotary evaporator. The residue
was concentrated again from DCM/hexanes to give a mixture of
tert-butyl
4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate (major) and tert-butyl
4-((5R,7S)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate (minor) (9.35 g, 95.3% yield) as a beige
foam. LC/MS (APCI+) m/z 335 [M+H]+. 1H NMR (CDCl.sub.3) shows 88%
de by integration of carbinol methine.
[0374] Step 10: 4-Nitrobenzoyl chloride (4.27 g, 23.0 mmol) was
added to a 0.degree. C. solution of tert-butyl
4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate (7.0 g, 20.9 mmol) and triethylamine (4.38
ml, 31.4 mmol) in DCM (110 mL). The reaction mixture was stirred at
room temperature overnight, after which saturated NaHCO.sub.3 was
added. The mixture was stirred 10 minutes, and then extracted with
DCM. The combined extracts were dried (Na.sub.2SO.sub.4), filtered,
and concentrated. The crude was flashed on Biotage 65M (3:1
hexanes:ethyl acetate loaded crude, then 2:1 hexanes:ethyl acetate
eluted tert-butyl
4-((5R,7R)-5-methyl-7-(4-nitrobenzoyloxy)-6,7-dihydro-5H-cyclopenta[d]pyr-
imidin-4-yl)piperazine-1-carboxylate and a few mixed fractions).
Then tert-butyl
4-((5R,7S)-5-methyl-7-(4-nitrobenzoyloxy)-6,7-dihydro-5H-cyclopenta[d]pyr-
imidin-4-yl)piperazine-1-carboxylate was eluted using 1:2
hexanes:ethyl acetate. The fractions with product were concentrated
by rotary evaporation to give tert-butyl
4-((5R,7R)-5-methyl-7-(4-nitrobenzoyloxy)-6,7-dihydro-5H-cyclopenta[d]pyr-
imidin-4-yl)piperazine-1-carboxylate (8.55 g, 84.5% yield) as a
yellow foam. LC/MS (APCI+) m/z 484 [M+H]+. 1H NMR (CDCl.sub.3)
shows single diastereomer). The fractions with other diastereomer
were concentrated by rotary evaporation to give tert-butyl 4-((5R,7
S)-5-methyl-7-(4-nitrobenzoyloxy)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-
-yl)piperazine-1-carboxylate (0.356 g, 3.52% yield) as a brown
foam. LC/MS (APCI+) m/z 484 [M+H]+.
[0375] Step 11: LiOH--H.sub.2O (0.499 g, 11.9 mmol) was added to a
0.degree. C. solution of tert-butyl
4-((5R,7R)-5-methyl-7-(4-nitrobenzoyloxy)-6,7-dihydro-5H-cyclopenta[d]pyr-
imidin-4-yl)piperazine-1-carboxylate (2.30 g, 4.76 mmol) in 2:1
THF:H.sub.2O (40 mL). The reaction mixture was warmed to room
temperature and stirred for 1 hour. The THF was removed by rotary
evaporation, saturated NaHCO.sub.3 was added, and the mixture was
extracted with ethyl acetate. The combined extracts were washed
(1.times.) with saturated NaHCO.sub.3, dried (Na.sub.2SO.sub.4),
filtered, and concentrated to give tert-butyl
4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-
piperazine-1-carboxylate (1.59 g, 100.0% yield) as a yellow foam.
HPLC after workup just product>98 area % pure. LC/MS (APCI+) m/z
335 [M+H]+. The tert-butyl 4-((5R,7
S)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazi-
ne-1-carboxylate was prepared using an analogous method.
[0376] Step 12: 4M HCl/dioxane (11.2 ml, 44.9 mmol) was added to a
solution of tert-butyl
4-05R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)p-
iperazine-1-carboxylate (0.600 g, 1.79 mmol) in dioxane (15 mL).
The reaction mixture was stirred at room temperature under nitrogen
overnight (20 hours). The mixture was concentrated to dryness and
dried on high vacuum line. The crude was suspended in ether,
sonicated, and stirred for 5 minutes. The solids were isolated by
filtration through a medium frit funnel with nitrogen pressure,
rinsed with ether, dried under nitrogen pressure, and dried further
on a hi vacuum line to give
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride (0.440 g, 79.8% yield) as a yellow powder.
LC/MS (APCI+) m/z 235. The (5R,7
S)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-ol
dihydrochloride was prepared using an analogous method.
[0377] Step 13: Methyl 2-(4-chlorophenyl)acetate (36.7 g, 199 mmol)
and paraformaldehyde (6.27 g, 209 mmol) were dissolved/suspended in
DMSO (400 mL) and treated with NaOMe (537 mg, 9.94 mmol). The
mixture was allowed to stir at room temperature for 2 hours to
completion by TLC analysis of the crude. The reaction was poured
into ice-cold water (700 mL; white emulsion) and neutralized with
the addition of 1M HCl solution. The aqueous layer was extracted
with ethyl acetate (3.times.), and the organics were combined. The
organic layer was washed with water (2.times.), brine (1.times.),
separated, dried over MgSO.sub.4, filtered, and concentrated in
vacuo to afford the crude product as a yellow oil. The residue was
loaded onto a large fritted filtered with silica gel and eluted
with 9:1 hexanes:ethyl acetate until the starting material/olefin
were collected. The plug was then eluted with 1:1 hexanes: ethyl
acetate until the pure desired product was eluted completely. The
concentrated pure fractions yielded methyl
2-(4-chlorophenyl)-3-hydroxypropanoate as a colorless oil (39.4 g,
92%).
[0378] Step 14: Methyl 2-(4-chlorophenyl)-3-hydroxypropanoate (39.4
g, 184 mmol) was dissolved in DCM (500 mL) and treated with TEA
(64.0 mL, 459 mmol). The solution was cooled to 0.degree. C. and
slowly treated with MsCl (15.6 mL, 202 mmol), then allowed to stir
for 30 minutes to completion by TLC analysis. The solution was
partitioned with 1N HCl solution, and the aqueous layer was
extracted once with DCM. The combined organic layer was washed once
more with 1N HCl solution, separated, washed with diluted
NaHCO.sub.3 solution, and separated. The organic layer was dried
over MgSO.sub.4, filtered, and concentrated in vacuo to afford an
orange oil. The residue was loaded onto a large fritted filter with
a plug of silica gel and eluted with 9:1 hexanes:ethyl acetate
affording the pure desired product by TLC analysis. The
concentrated pure fractions yielded the methyl
2-(4-chlorophenyl)acrylate as a colorless oil (30.8 g, 85%). This
methyl 2-(4-chlorophenyl)acrylate (500 mg, 2.54 mmol) was added as
a solution in THF (1.35 mL) to a stirring solution of i-PrNH.sub.2
(217 uL, 2.54 mmol) in THF (5.0 mL) at 0.degree. C. The reaction
was allowed to stir at room temperature overnight to completion by
LCMS analysis. The Boc2O (584 uL, 2.54 mmol) was added to the
stirring amine via pipet. The reaction was allowed to stir
overnight to completion by LCMS and TLC analysis of the mixture.
The solution was concentrated in vacuo to afford methyl
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoate
as a colorless oil (854 mg, 94%). LC/MS (APCI+) m/z 256.1
[M-Boc]+.
[0379] Step 15: Methyl
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoate
(133 g, 374 mmol) was dissolved in THF (1.0 L) and treated with
KOTMS (56.0 g, 392 mmol) at room temperature. The mixture was
allowed to stir overnight to completion by LCMS analysis of the
crude. The mixture was concentrated in vacuo to afford a wet foam,
which was allowed to dry under vacuum overnight to afford potassium
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoate
as a white solid (148.7 g, 105%). LC/MS (APCI+) m/z 242.1
[M-Boc-K]+.
[0380] Step 16: Potassium
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoate
(77.2 g, 203 mmol) was dissolved in THF (515 mL) and treated with
pivaloyl chloride (26.3 mL, 213 mmol) at room temperature. The
mixture was allowed to stir for 3 hours to form the mixed
anhydride. (S)-4-benzyloxazolidin-2-one (46.1 g, 260 mmol) was
dissolved in THF (600 mL) and cooled to -78.degree. C. in a
separate flask. The solution was treated with n-BuLi (102 mL of a
2.50M solution in hexanes, 254 mmol) and allowed to stir for one
hour. The prepared anhydride solution was added to the stirring
Li-oxazolidinone via cannula, and the mixture was allowed to warm
to room temperature overnight. The mixture was quenched with the
addition of saturated ammonium chloride solution, then partitioned
between more water and ethyl acetate. The aqueous layer was
extracted several times, and the organics were combined. The
organic layer was washed with water, then brine, separated, dried
over MgSO.sub.4, filtered, and concentrated in vacuo. The residue
was purified/separated (diastereomers) via chromatography (silica
gel eluted with 4:1 hexanes:ethyl acetate) to afford the completely
separated diastereomers as viscous oils: tert-butyl
(R)-3-((S)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl(-
isopropyl)carbamate (12.16 g, 24% based on 1/2 of acid racemate)
and tert-butyl
(S)-3-((S)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl(-
isopropyl)carbamate (39.14 g, 77% based on 1/2 of acid racemate).
LC/MS (APCI+) m/z 401.2 [M-Boc]+.
[0381] Step 17: LiOH--H.sub.2O (168 mg, 4.00 mmol) was added to a
stirring solution of THF (30 mL) and water (15 mL) at room
temperature until it was dissolved. The mixture was treated with
hydrogen peroxide (658 uL of a 35% wt. solution in water, 8.00
mmol) and allowed to stir at room temperature for 10 minutes. The
reaction was cooled to 0.degree. C. in an ice bath, and the
tert-butyl
(S)-3-((S)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl(-
isopropyl)carbamate (1.00 g, 2.00 mmol) was added dropwise via
addition funnel as a solution in THF (15 mL) over a 10 minutes. The
mixture was allowed to stir overnight at room temperature to
completion by LCMS analysis of the crude. The reaction was cooled
to 0.degree. C., and then treated with 1M Na.sub.2SO.sub.3 (9.00
mL) solution via addition funnel over a ten minute period. After
the addition was complete, the mixture was allowed to warm to room
temperature for 10 minutes. The mixture was concentrated to remove
the THF, and then diluted with water. The aqueous layer was washed
twice with ethyl acetate (discarded). The aqueous layer was
partitioned with ethyl acetate, then treated dropwise while
stirring with 1M HCl until pH 2-3 was attained. The aqueous layer
was extracted twice with ethyl acetate, and the organics were
combined. The organic was washed with brine, separated, dried over
MgSO.sub.4, filtered, and concentrated in vacuo. The colorless oil
product was dried under high vacuum for one hour to afford
(S)-3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoic
acid as a viscous oil/foam (685 mg, 100%). LC/MS (APCI+) m/z 242.1
[M-Boc]+.
[0382] Step 18: A solution of
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride (2.92 g, 9.51 mmol) and
(S)-3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoic
acid (3.25 g, 9.51 mmol) in DCM (40 mL) and DIEA (5.0 mL, 28.7
mmol) was stirred at room temperature for 10 minutes. HBTU (3.61 g,
9.51 mmol) was added to the mixture. The mixture was stirred at
room temperature for 1 hour. The solvent was removed, and the
residue was dissolved in ethyl acetate (500 mL) and washed with
water (6.times.100 mL). The organic phase was dried and
concentrated. The residue was subject to column chromatography,
eluted by EtOAc-DCM/MeOH (20:1) to give tert-butyl
(S)-2-(4-chlorophenyl)-3-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate
(3.68 g, 69%.) LC/MS (APCI+) m/z 558.2 [M+H]+.
[0383] Step 19: The tert-butyl
(S)-2-(4-chlorophenyl)-3-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropyl (isopropyl)
carbamate (2.50 g, 4.48 mmol) was dissolved in dioxane (22.4 mL)
and treated with 4M HCl in dioxane (22.4 mL, 89.6 mmol) at room
temperature. The resulting solution was allowed to stir overnight
to completion by LCMS analysis of the crude. The solution was
concentrated in vacuo to afford a gel that was dissolved in a
minimal amount of methanol (10 mL). The solution was transferred
via pipette to stirred ether (300 mL) to afford a white precipitate
of desired product. The addition was about half when the white
precipitate melted into a yellow gel. The material was concentrated
in vacuo to afford a yellow gel which was allowed to stand under
reduced pressure overnight to yield
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
dihydrochloride as a light yellow powder (2.14 g, 90%).
[0384] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.39 (s, 1H),
7.37-7.35 (d, J=8.4 Hz, 2H), 7.23-7.20 (d, J=8.4 Hz, 2H), 5.29-5.25
(m, 1H), 4.33-4.29 (m, 1H), 4.14-4.10 (m, 1H), 3.89-3.19 (m, 11H),
2.23-2.17 (m, 1H), 2.08-1.99 (m, 1H), 1.20-1.18 (m, 6H), 0.98-0.96
(d, J=6.8 Hz, 3H). MS (APCI+) [M+H].sup.+ 458.
Example 15
##STR00113##
[0385]
2-(4-fluorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H--
cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
[0386] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.39 (m, 1H),
7.27-7.25 (m, 2H), 7.11-7.07 (m, 2H), 5.29-5.25 (m, 1H), 4.33-4.30
(m, 1H), 4.20-3.00 (m, 12H), 2.22-2.18 (m, 1H), 2.06-2.00 (m, 1H),
1.20-1.10 (m, 6H), 1.08-0.96 (m, 3H). MS (APCI+) [M+H].sup.+
442.
Example 16
##STR00114##
[0387]
2-(3,4-difluorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-
-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-
-one
[0388] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.37-8.25 (m, 1H),
7.36-7.16 (m, 9H), 5.37-5.22 (m, 1H), 4.33-4.30 (m, 1H), 4.25-3.00
(m, 13H), 2.22-2.18 (m, 1H), 2.06-1.98 (m, 1H), 1.29-1.22 (m, 3H),
1.20-0.96 (m, 3H). MS (APCI+) [M+H].sup.+ 550.
Example 17
##STR00115##
[0389]
2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H--
cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(pyri
din-3-ylmethylamino)propan-1-one
[0390] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.84 (m, 1H), 8.75
(m, 1H), 8.68-8.54 (m, 1H), 8.39 (m, 1H), 8.03-8.01 (m, 1H),
7.36-7.33 (m, 2H), 7.22-7.19 (m, 2H), 5.28-5.22 (m, 1H), 4.50-4.40
(m, 1H), 4.20-3.05 (m, 12H), 2.21-2.15 (m, 1H), 1.20-1.10 (m, 2H),
1.08-0.95 (m, 3H). MS (APCI+) [M+H].sup.+ 507.
Example 18
##STR00116##
[0391]
2-(2,4-dichlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-
-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-
-one
[0392] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.41-8.38 (m, 1H),
7.58 (s, 1H), 7.40-7.26 (m, 1H), 7.12-7.10 (m, 1H), 5.36-5.27 (m,
1H), 4.18-3.10 (m, 13H), 2.23-2.18 (m, 1H), 2.08-2.00 (m, 1H),
1.30-1.20 (m, 6H), 1.08-0.98 (m, 3H). MS (APCI+) [M+H].sup.+
492.
Example 19
##STR00117##
[0393]
2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H--
cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(pentan-3-ylamino)propan-1-o-
ne
[0394] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.39-8.37 (d, J=7.2
Hz, 1H), 7.36-7.34 (m, 2H), 7.22-7.20 (d, J=8.4 Hz, 2H), 5.30-5.25
(m, 1H), 4.33-4.29 (m, 1H), 4.18-3.00 (m, 12H), 2.24-2.15 (m, 4H),
2.10-2.00 (m, 1H), 1.30-1.20 (m, 4H), 1.12-0.95 (m, 3H), 0.90-0.86
(m, 6H). MS (APCI+) [M+H].sup.+ 486.
Example 20
##STR00118##
[0395]
2-(4-chlorophenyl)-3-((1S,2R)-1-hydroxy-1-phenylpropan-2-ylamino)-1-
-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl-
)piperazin-1-yl)propan-1-one
[0396] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.39 (m, 1H),
7.27-7.16 (m, 2H), 7.06-7.04 (m, 1H), 5.25-5.22 (m, 1H), 4.33-4.30
(m, 1H), 4.25-3.00 (m, 14H), 2.22-2.18 (m, 1H), 2.06-1.98 (m, 1H),
1.20-1.10 (m, 6H), 1.08-0.96 (m, 3H). MS (APCI+) [M+H].sup.+
460.
Example 21
##STR00119##
[0397]
2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H--
cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-((1R,4R)-4-hydroxycyclohexyl-
amino)propan-1-one
[0398] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.30 (m, 1H),
7.38-7.33 (m, 2H), 7.22-7.19 (m, 2H), 5.30-5.20 (m, 1H), 4.40-4.33
(m, 1H), 4.20-3.05 (m, 12H), 2.21-2.15 (m, 1H), 1.80-1.10 (m, 9H),
1.08-0.95 (m, 3H). MS (APCI+) [M+H].sup.+ 514.
Example 22
##STR00120##
[0399] ((3
S,4R)-4-(3,4-dichlorophenyl)pyrrolidin-3-yl)(4-((5R,7R)-7-hydro-
xy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)meth-
anone and
((3R,4S)-4-(3,4-dichlorophenyl)pyrrolidin-3-yl)(4-((5R,7R)-7-hyd-
roxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)me-
thanone
[0400] Step 1: TFA (0.2 mL, 2.63 mmol) was added to a solution of
(E)-methyl 3-(3,4-dichlorophenyl)acrylate (2.6 g, 11.7 mmol) in DCM
(40 mL). The mixture was cooled to 0.degree. C. Then
benzylmethoxytrimethylsilanyl methylamine (6.0 mL, 23.5 mmol) was
added dropwisely while maintaining the temperature between
-5.degree. C. and +5.degree. C. After the addition was complete,
the mixture was stirred at room temperature overnight. The solvent
was removed, and the residue was dissolved in ether and treated
with 1N HCl. The mixture was shaken to agitate, and a three layer
solution formed. The lower two layers were collected and basified
with 2N NaOH to a pH of 14, extracted with CHCl.sub.3 (3.times.100
mL). The organic phase was dried, filtered and concentrated. The
residue was subjected to column chromatography, eluted by
hexane/ethyl acetate (4:1) to give (3 S,4R)-methyl
1-benzyl-4-(3,4-dichlorophenyl)pyrrolidine-3-carboxylate (4.2 g,
99%.) (LCMS (APCI+) [M+H].sup.+ 364.2; Rt: 2.63 min.)
[0401] Step 2: 1-Chloroethyl chloroformate (1.5 mL, 13.9 mmol) was
added to a solution of (3 S,4R)-methyl
1-benzyl-4-(3,4-dichlorophenyl)pyrrolidine-3-carboxylate (4.20 g,
11.5 mmol) in DCE (50 mL) at 0.degree. C. The mixture was refluxed
for 1 hour. After cooling, the solvent was removed under vacuum at
65.degree. C. for 1 hour. MeOH (50 mL) was added to the residue and
refluxed for 1 hour. The MeOH was removed. The solid was
redissolved in CHCl.sub.3 and treated with saturated
Na.sub.2CO.sub.3. The aqueous layer was separated and extracted
with CHCl.sub.3 (2.times.30 mL). The organic phase was combined and
dried. The solvent was removed to afford (3 S,4R)-methyl
4-(3,4-dichlorophenyl)pyrrolidine-3-carboxylate (3.1 g, 98%). (LCMS
(APCI+) [M+H].sup.+ 274.1; Rt: 2.25 min.).
[0402] Step 3: Boc anhydride (3.0 g, 13.7 mmol) was added to a
solution of (3S,4R)-methyl
4-(3,4-dichlorophenyl)pyrrolidine-3-carboxylate (3.10 g, 11.3 mmol)
in THF (100 mL) and TEA (4 mL). The mixture was stirred at room
temperature overnight. The solvent was removed, and the residue was
subject to column chromatography, eluted by hexane/ethyl acetate
(8:1) to give (3 S,4R)-1-tert-butyl 3-methyl
4-(3,4-dichlorophenyl)pyrrolidine-1,3-dicarboxylate (LCMS (APCI+)
[M-Boc+H].sup.+ 274.1; Rt: 4.17 min). The (3S,4R)-1-tert-butyl
3-methyl 4-(3,4-dichlorophenyl)pyrrolidine-1,3-dicarboxylate was
redissolved in MeOH (50 mL), and LiOH (3M, 10 mL) was added. The
mixture was stirred at room temperature for 6 hours. 2N HCl (15 mL)
was added to the mixture. The solvent was removed, and the residue
was subject to column chromatography, eluted by DCM/MeOH
(40:1-10:1) to give
(3S,4R)-1-(tert-butoxycarbonyl)-4-(3,4-dichlorophenyl)pyrrolidine-3-carbo-
xylic acid (1.95 g). (LCMS (APCI+) [M-Boc+H].sup.+260.1; Rt: 3.67
min.)
[0403] Step 4: HBTU (37 mg, 0.098 mmol) was added to a solution of
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride (30 mg, 0.098 mmol) and
1-(tert-butoxycarbonyl)-4-(3,4-dichlorophenyl)pyrrolidine-3-carboxylic
acid (35 mg, 0.098 mmol) in DCM (5 mL) and TEA (1 mL). The mixture
was stirred at room temperature for 1 hour. The solvent was
removed, and the residue was dissolved in ethyl acetate (50 mL) and
washed with brine (5.times.50 mL). The organic phase was dried and
concentrated to afford tert-butyl
3-(3,4-dichlorophenyl)-4-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazine-1-carbonyl)pyrrolidine-1-carboxylate
(LCMS (APCI+) [M+H].sup.+ 576.1; Rt: 2.90 min). The product was
treated with 4N HCl in dioxane to afford
(4-(3,4-dichlorophenyl)pyrrolidin-3-yl)(4-((5R,7R)-7-hydroxy-5-methyl-6,7-
-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)methanone as
the HCl salt (30 mg, 64%).
[0404] Obtained as a 1:1 mixture of diastereomers. .sup.1H NMR
(D.sub.2O, 400 MHz) .delta. 8.44-8.10 (m, 1H), 7.48-7.40 (m, 2H),
7.24-7.12 (m, 1H), 5.33-5.28 (m, 1H), 4.00-3.85 (m, 1H), 3.80-3.00
(m, 11H), 2.26-2.20 (m, 1H), 2.10-2.00 (m, 1H), 1.08-1.00 (m, 3H).
MS (APCI+) [M+H].sup.+ 476.
Example 23
##STR00121##
[0405]
2-(4-chlorophenyl)-2-hydroxy-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-d-
ihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)pr-
opan-1-one
[0406] Step 1: MCPBA (35 g, 77%, 156 mmol) was added to a solution
of methyl 2-(4-chlorophenyl)-acrylate (20 g, 102 mmol) in
CHCl.sub.3 (200 mL). The mixture was refluxed for 24 hours. The
reaction was cooled to room temperature, diluted with chloroform
(200 mL) and washed with 10% Na.sub.2S.sub.2O.sub.3, 10%
NaHCO.sub.3 and water. The organic phase was dried and
concentrated. The residue was subject to column chromatography,
eluted by hexane/ethyl acetate (9:1) to give methyl
2-(4-chlorophenyl)oxirane-2-carboxylate. Methyl
2-(4-chlorophenyl)oxirane-2-carboxylate (2 g, 9.4 mmol) and ethanol
(10 mL) and isopropylamine (1 mL, 11.7 mmol) were added to a 50 mL
high pressure bomb. The mixture was heated to 90.degree. C. for 12
hours in the bomb. After cooling, the solvent was removed, and the
residue was dissolved in DCM (20 mL) and TEA (2 mL). (Boc)2O (4 g,
23.0 mmol) was added to it. The mixture was stirred at room
temperature for 48 hours. The solvent was removed, and the residue
was dissolved in THF (20 mL). LiOH (3M, 14 mL) was added to the
mixture. The mixture was stirred at room temperature for 16 hours
and refluxed for 2 hours. After cooling, the mixture was quenched
with 2N HCl (21 mL). The solvent was removed and the residue was
subject to column chromatography, eluted by hexane/ethyl acetate
(1:1) to give
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)-2-hydroxyprop
an oi c acid. LCMS (APCI+) [M-Boc+H].sup.+ 258.1; Rf: 3.66 min.
[0407] Step 2: HBTU (37 mg, 0.098 mmol) was added to a solution of
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride (30 mg, 0.098 mmol) and
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)-2-hydroxypropa-
noic acid (35 mg, 0.098 mmol) in DCM (5 mL) and TEA (1 mL). The
mixture was stirred at room temperature for 1 hour. The solvent was
removed, and the residue was subject to column chromatography,
eluted by DCM/MeOH (40:1). The resulting product was treated with
HCl (4M, 2 mL) to afford
2-(4-chlorophenyl)-2-hydroxy-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-
-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-
-one as HCl salt (22 mg, 48%).
[0408] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.35-8.34 (m, 1H),
7.41-7.36 (m, 4H), 5.26-5.18 (m, 1H), 4.18-3.00 (m, 12H), 2.20-2.14
(m, 1H), 2.08-1.98 (m, 1H), 1.20-1.10 (m, 6H), 1.08-0.98 (m, 3H).
MS (APCI+) [M+H].sup.+ 474.
Example 24
##STR00122##
[0409]
4-amino-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dih-
ydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-4-methylpentan-1-one
[0410] Step 1: 1,8-Diazabicyclo[5.4.0]undec-7-ene (33.68 mL, 225.2
mmol) was added to a solution of methyl 2-(4-chlorophenyl)acrylate
(36.9 g, 187.7 mmol) and 2-nitropropane (20.23 mL, 225.2 mmol) in
CH.sub.3CN (500 mL) at 0.degree. C. under nitrogen. The mixture was
warmed to room temperature and stirred overnight. The solution was
concentrated in vacuo and subjected to column chromatography (20%
EtOAc/hexanes) to give methyl
2-(4-chlorophenyl)-4-methyl-4-nitropentanoate (52.9 g, 98.66%
yield) as a colourless oil. .sup.1H NMR (CDCl.sub.3, 400 MHz)
.delta. 7.31-7.29 (m, 2H), 7.21-7.19 (m, 2H), 3.66 (s, 3H),
3.60-3.57 (m, 1H), 2.87-2.81 (dd, 1H), 2.39-2.34 (dd, 1H), 1.56 (s,
3H), 1.55 (s, 3H).
[0411] Step 2: Zn dust (128 g, 1.960 mol) was treated with a
solution of methyl 2-(4-chlorophenyl)-4-methyl-4-nitropentanoate
(28 g, 98.0 mmol) dissolved in ethanol (490 mL). Concentrated HCl
(26.9 mL, 323 mmol) was added slowly, and then the reaction was
heated to 70.degree. C. for 2 hours. The reaction mixture was
filtered through a plug of SiO.sub.2 and celite. The filter pad was
washed with ethyl acetate, and the filtrate was concentrated in
vacuo. The residue was dissolved in a minimum amount of ethanol and
then treated with water.
3-(4-Chlorophenyl)-5,5-dimethylpyrrolidin-2-one precipitated from
the solution and was collected by filtration. The solid was washed
with water and air-dried, (11.2 g, 51% yield). .sup.1H NMR
(CD.sub.3OD, 400 MHz) .delta. 7.35-7.32 (m, 2H), 7.26-7.24 (m, 2H),
3.94-3.90 (m, 1H), 2.50-2.44 (m, 1H), 1.99-1.93 (m, 1H), 1.36 (s,
3H), 1.34 (s, 3H).
[0412] Step 3: Lithium bis(trimethylsilyl)amide (36 mL, 36 mmol)
was added to a stirred solution of
3-(4-chlorophenyl)-5,5-dimethylpyrrolidin-2-one (6.7 g, 30 mmol) in
THF (200 mL) at -78.degree. C. under nitrogen. The solution was
stirred at -78.degree. C. for 30 minutes. Then a solution of
di-tert-butyl dicarbonate (7.6 mL, 33 mmol) in THF (30 mL) was
added in a single portion. The solution was warmed to room
temperature and allowed to stir at room temperature overnight. The
reaction was poured into 0.5M HCl solution and extracted with ethyl
acetate twice. The combined organic layer was washed with water,
separated, dried over MgSO.sub.4, filtered, and concentrated in
vacuo to afford the near-pure product (excess Boc2O) as a colorless
oil. Column chromatography (20% EtOAc/hexanes) to give pure
tert-butyl
4-(4-chlorophenyl)-2,2-dimethyl-5-oxopyrrolidine-1-carboxylate.
LCMS (APCI+) [M-Boc+H]+224.1; Rt: 3.68 min. .sup.1H NMR
(CDCl.sub.3, 400 MHz) .delta. 7.32-7.30 (m, 2H), 7.22-7.20 (m, 2H),
3.80-3.74 (m, 1H), 2.33-2.28 (m, 1H), 2.05-1.97 (m, 1H), 1.58 (s,
3H), 1.55 (s, 9H), 1.53 (s, 3H).
[0413] Step 4: Lithium hydroxide hydrate (6.44 mL, 232 mmol) was
added to a stirred solution of tert-butyl
4-(4-chlorophenyl)-2,2-dimethyl-5-oxopyrrolidine-1-carboxylate (7.5
g, 23.2 mmol) in THF/MeOH/H.sub.2O (30 mL/30 mL/30 mL) at room
temperature. The mixture was stirred at room temperature overnight
and concentrated in vacuo. The mixture was taken up into water (200
mL), washed with EtOAc (100 mL), acidified with concentrated HCl
and extracted into EtOAc (2.times.200 mL). The mixture was dried
over Na.sub.2SO.sub.4 and concentrated in vacuo. Residual HCl was
removed by evaporating from toluene to give
4-(tert-butoxycarbonylamino)-2-(4-chlorophenyl)-4-methylpentanoic
acid (5.0 g, 63.2% yield) as a white solid. LCMS (APCI.sup.+)
[M-Boc+H].sup.+ 242.0; Rt: 2.8 min.
[0414] Step 5: HBTU (37 mg, 0.098 mmol) was added to a solution of
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride (30 mg, 0.098 mmol) and
4-(tert-butoxycarbonylamino)-2-(4-chlorophenyl)-4-methylpentanoic
acid (33 mg, 0.098 mmol) in DCM (5 mL) and TEA (1 mL). The mixture
was stirred at room temperature for 1 hour. The solvent was
removed, and the residue was dissolved in ethyl acetate (50 mL) and
washed with brine (5.times.50 mL). The organic phase was dried and
concentrated to afford the product. The product was treated with
HCl to afford
4-amino-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5-
H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-4-methylpentan-1-one
as HCl salt (22 mg, 49%).
[0415] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.40-8.37 (m, 1H),
7.32-7.29 (m, 2H), 7.25-7.19 (m, 2H), 5.29-5.25 (m, 1H), 4.12-4.09
(m, 1H), 4.06-3.18 (m, 9H), 2.58-2.48 (m, 1H), 2.24-1.98 (m, 1H),
2.08-2.00 (m, 1H), 1.90-1.80 (m, 1H), 1.26-1.09 (m, 6H), 1.08-0.98
(m, 3H). MS (APCI+) [M+H].sup.+ 458.
Example 25
##STR00123##
[0416]
4-amino-2-(3,4-difluorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-
-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-4-methylpentan-1-o-
ne
[0417] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.40 (m, 1H),
7.32-7.29 (m, 2H), 7.06-7.00 (m, 1H), 5.29-5.25 (m, 1H), 4.19-3.22
(m, 10H), 2.58-2.48 (m, 1H), 2.24-1.98 (m, 1H), 2.08-2.00 (m, 1H),
1.90-1.80 (m, 1H), 1.26-1.09 (m, 6H), 1.08-0.98 (m, 3H). MS (APCI+)
[M+H].sup.+ 460.
Example 26
##STR00124##
[0418]
(4-(4-chloro-3-fluorophenyl)piperidin-4-yl)(4-((5R,7R)-7-hydroxy-5--
methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)methanone
[0419] Step 1: KCN (1.25 g, 19.2 mmol) was added to a solution of
4-(bromomethyl)-1-chloro-2-fluorobenzene (3.90 g, 17.5 mmol) in
DMSO (60 mL). Several milliliters of H.sub.2O were added to help
dissolve the KCN. After 1 hour, the reaction mixture was diluted
with H.sub.2O and extracted with EtOAc. The extracts were dried
(Na.sub.2SO.sub.4), filtered, and concentrated. The crude product
was flashed on silica (Biotage 40M, 9:1 to 4:1 hex:EtOAc) to give
2-(4-chloro-3-fluorophenyl)acetonitrile (1.81 g, 61.2% yield) as a
yellow crystalline solid.
[0420] Step 2: 60% NaH (1.07 g, 26.7 mmol) was added in 2 portions
to a 0.degree. C. solution of
2-(4-chloro-3-fluorophenyl)acetonitrile (1.81 g, 10.7 mmol) and
15-crown-5 (0.235 g, 1.07 mmol) in DMF (45 mL). The reaction
mixture was warmed to room temperature and stirred for 35 minutes.
The reaction mixture was then cooled to 0.degree. C. NaI (1.60 g,
10.7 mmol) was added, and then a solution of freshly prepared
tert-butyl bis(2-chloroethyl)carbamate (2.58 g, 10.7 mmol) in DMF
(10 mL) was added by syringe. The reaction mixture was warmed to
room temperature and stirred overnight (19 hours). The reaction
mixture was poured into ice saturated NH.sub.4Cl, and the mixture
was extracted with EtOAc. The combined extracts were dried
(Na.sub.2SO.sub.4), filtered, and concentrated. The crude was
flashed on silica (Biotage 40 L, 9:1 hex:EtOAc until product
eluted, then 6:1 hex:EtOAc to elute product) to give tert-butyl
4-(4-chloro-3-fluorophenyl)-4-cyanopiperidine-1-carboxylate (1.96
g, 54.2% yield) as a yellow oil. LC/MS (APCI+) m/z 239
[M-Boc+H]+.
[0421] Step 3: Tert-butyl
4-(4-chloro-3-fluorophenyl)-4-cyanopiperidine-1-carboxylate (1.96
g, 5.785 mmol) was dissolved in concentrated HCl (48.21 mL, 578.5
mmol), heated to reflux, and then stirred over the weekend
(approximately 60 hours). The reaction mixture was cooled to room
temperature, transferred to a separatory funnel, and washed with
ether. The aqueous layer was concentrated on a rotary evaporator
and dried on a high vacuum line. The resulting solids were
dissolved in 10% NaOH (9.255 g, 23.14 mmol), dioxane (40 mL) was
added, followed by a Boc2O addition (1.326 g, 6.074 mmol). The
reaction mixture was stirred at room temperature overnight (16
hours). The reaction mixture was then diluted with H.sub.2O and
washed with ether. The aqueous layer was acidified with solid
KHSO.sub.4, and then extracted with DCM. The combined extracts were
dried (Na.sub.2SO.sub.4), filtered, concentrated and dried on a
high vacuum line to give
1-(tert-butoxycarbonyl)-4-(4-chloro-3-fluorophenyl)piperidine-4-carboxyli-
c acid (0.910 g, 43.96% yield) as a foam. LC/MS (APCI-) m/z 713
[2M-H]-.
[0422] Step 4:
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride (35.0 mg, 0.114 mmol) and
1-(tert-butoxycarbonyl)-4-(4-chloro-3-fluorophenyl)piperidine-4-carboxyli-
c acid (40.8 mg, 0.114 mmol) were dissolved in DCM (1.1 mL) and
treated with DIEA (0.0595 ml, 0.342 mmol) at ambient temperature.
The mixture was allowed to homogenize before the HBTU (47.5 mg,
0.125 mmol) was added in one lot. The reaction was allowed to stir
for four hours to completion by LCMS analysis of the crude. The
reaction was diluted with DCM, washed with diluted NaHCO.sub.3
solution, washed with water, washed with brine, and separated. The
organic layer was dried over Na.sub.2SO.sub.4, filtered, and
concentrated in vacuo. The residue was purified by chromatography
(silica gel eluted with 5% methanol in ethyl acetate) to afford the
pure tert-butyl
4-(4-chloro-3-fluorophenyl)-4-(1-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro--
5H-cyclopenta[d]pyrimidin-4-yl)piperazine-4-carbonyl)piperidine-1-carboxyl-
ate (15.0 mg, 22.9% yield) as a pale yellow oil. MS (APCI+)
[M+H].sup.+ 574; Rf: 2.92.
[0423] Step 5: The tert-butyl
4-(4-chloro-3-fluorophenyl)-4-(1-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro--
5H-cyclopenta[d]pyrimidin-4-yl)piperazine-4-carbonyl)piperidine-1-carboxyl-
ate (15.0 mg, 0.0261 mmol) was dissolved in dioxane (131 uL) and
treated with 4M HCl (0.131 ml, 0.523 mmol) in dioxane. The mixture
was allowed to stir overnight to afford the pure product as a gel
precipitate. The solvent was removed under reduced pressure, and
the foam was triturated with ether (sonicated) to afford a white
suspension. The ether was removed under reduced pressure to afford
the pure
(4-(4-chloro-3-fluorophenyl)piperidin-4-yl)(4-((5R,7R)-7-hydroxy-5-methyl-
-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)methanone
dihydrochloride (12.0 mg, 84.0% yield) as a white powder. Rf:
1.96.
[0424] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.36 (m, 1H),
7.25-7.00 (m, 3H), 5.28-5.20 (m, 1H), 4.00-3.00 (m, 14H), 2.50-2.38
(m, 2H), 2.26-2.00 (m, 2H), 1.04-1.00 (m, 3H). MS (APCI+)
[M+H].sup.+ 474.
Example 27
##STR00125##
[0425]
(3-(4-chlorophenyl)pyrrolidin-3-yl)(4-((5R,7R)-7-hydroxy-5-methyl-6-
,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)methanone
[0426] Step 1: TFA (0.34 ml, 4.41 mmol) was added to a solution of
N-(methoxymethyl)(phenyl)-N-((trimethylsilyl)methyl)methanamine
(3.9 g, 19.8 mmol) in DCM (40 mL). The mixture was cooled to
0.degree. C. The benzylmethoxytrimethylsilanyl methylamine (10.5
mL, 41 mmol) was added dropwise at 0.degree. C. The mixture was
stirred at room temperature for 2 hours. The solvent was removed,
and the residue was dissolved in ether and treated with 1N HCl. The
mixture was shaken, and the aqueous layer was separated and
basified with 2N NaOH to a pH of 14. The aqueous layer was
extracted with CHCl.sub.3 (3.times.100 mL). The organic phase was
dried and concentrated. The residue was subjected to column
chromatography, eluted by hexanes/ethyl acetate (10:1) to give
methyl 1-benzyl-3-(4-chlorophenyl)pyrrolidine-3-carboxylate (LCMS
(APCI+) [M-Boc+H].sup.+ 330.2; Rt: 2.46 min).
[0427] Step 2: 1-Chloroethylformate (1.0 mL, 9.27 mmol) was added
to a solution of methyl
1-benzyl-3-(4-chlorophenyl)pyrrolidine-3-carboxylate (3.05 g, 9.25
mmol) in toluene (40 mL) at 0.degree. C. The mixture was refluxed
for 10 hours. After cooling, the solvent was removed under vacuum.
The residue was treated with MeOH (20 mL) and refluxed for 1 hour.
The solvent was removed, and the residue was dissolved in ethyl
acetate (200 mL). The residue was washed with 1N NaOH (50 mL) and
then washed with water. The organic phase was dried and
concentrated. The residue was subjected to column chromatography,
eluted by EtOAc-DCM/MeOH (10:1). The resulting methyl
3-(4-chlorophenyl)pyrrolidine-3-carboxylate (LCMS (APCI+)
[M-Boc+H].sup.+ 240.1; Rt: 2.06 min) was dissolved in DCM (20 mL)
and TEA (1 mL). Then is was treated with Boc anhydride (1 g, 4.58
mmol). After stirring for 2 hours, the solvent was removed, and the
1-tert-butyl 3-methyl
3-(4-chlorophenyl)pyrrolidine-1,3-dicarboxylate (LCMS (APCI+)
[M-Boc+H].sup.+ 240.1; Rt: 3.78 min) was dissolved in THF (50 mL).
LiOH (3M, 6 mL) was added to the mixture. The mixture was stirred
at room temperature overnight. The mixture was quenched with 2N HCl
(9 mL). The solvent was removed and the residue was subjected to
column chromatography, eluted by Hex/EtOAc(4:1)-DCM/MeOH (20:1) to
give
1-(tert-butoxycarbonyl)-3-(4-chlorophenyl)pyrrolidine-3-carboxylic
acid. LCMS (APCI+) [M-Boc+H].sup.+ 224.1; Rt: 2.90 min.
[0428] Step 3: HBTU (37 mg, 0.098 mmol) was added to a solution of
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride (30 mg, 0.098 mmol) and
1-(tert-butoxycarbonyl)-3-(4-chlorophenyl)pyrrolidine-3-carboxylic
acid (32 mg, 0.098 mmol) in DCM (5 mL) and TEA (1 mL). The mixture
was stirred at room temperature for 10 hours. The solvent was
removed, and the residue was subjected to column chromatography,
eluted by ethyl acetate-DCM/MeOH (20:1). The product was treated
with HCl (4M, 2 mL) in DCM (5 mL) to afford
(3-(4-chlorophenyl)pyrrolidin-3-yl)(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dih-
ydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)methanone as the
HCl salt (35 mg, 81%).
[0429] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.39-8.37 (d, J=2.8
Hz, 1H), 7.40-7.38 (d, J=8.4 Hz, 2H), 7.27-7.25 (d, J=8.4 Hz, 2H),
5.28-5.24 (m, 1H), 4.18-4.10 (m, 1H), 4.08-2.98 (m, 12H), 2.83-2.78
(m, 1H), 2.59-2.50 (m, 1H), 2.24-2.15 (m, 1H), 2.10-2.00 (m, 1H),
1.20-0.95 (m, 7H). MS (APCI+) [M+H].sup.+ 442.
Example 28
##STR00126##
[0430]
1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimi-
din-4-yl)piperazin-1-yl)-3-(isopropylamino)-2-p-tolylpropan-1-one
[0431] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.40-8.39 (m, 1H),
7.20-7.10 (m, 4H), 5.30-5.25 (m, 1H), 4.30-4.26 (m, 1H), 4.19-3.00
(m, 12H), 2.24-2.15 (m, 4H), 2.10-2.00 (m, 1H), 1.30-1.10 (m, 6H),
1.08-0.95 (m, 3H). MS (APCI+) [M+H].sup.+ 438.
Example 29
##STR00127##
[0432]
1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimi-
din-4-yl)piperazin-1-yl)-3-(isopropylamino)-2-(4-methoxyphenyl)propan-1-on-
e
[0433] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.38 (m, 1H),
7.18-7.16 (m, 2H), 6.95-6.92 (d, J=8.8 Hz, 2H), 5.29-5.25 (m, 1H),
4.29-4.25 (m, 1H), 4.20-3.00 (m, 15H), 2.23-2.17 (m, 1H), 2.07-1.98
(m, 1H), 1.30-0.95 (m, 9H). MS (APCI+) [M+H].sup.+ 454.
Example 30
##STR00128##
[0434]
3-(ethylamino)-2-(4-fluorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl--
6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
[0435] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.39 (m, 1H),
7.28-7.25 (m, 2H), 7.10-7.07 (m, 2H), 5.28-5.25 (m, 1H), 4.39-4.37
(m, 1H), 4.20-2.95 (m, 13H), 2.22-2.18 (m, 1H), 2.06-1.98 (m, 1H),
1.22-1.14 (m, 3H), 1.04-0.96 (m, 3H). MS (APCI+) [M+H].sup.+
428.
Example 31
##STR00129##
[0436]
2-(4-fluorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H--
cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(methylamino)propan-1-one
[0437] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.40 (m, 1H),
7.28-7.24 (m, 2H), 7.12-7.08 (m, 2H), 5.29-5.25 (m, 1H), 4.39-4.37
(m, 1H), 4.20-3.00 (m, 11H), 2.62 (s, 3H), 2.22-2.18 (m, 1H),
2.06-1.98 (m, 1H), 1.17-1.14 (m, 1H), 1.04-0.96 (m, 3H). MS (APCI+)
[M+H].sup.+ 414.
Example 32
##STR00130##
[0438]
(S)-3-amino-2-(3,4-dichlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-
-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
[0439] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.40-8.39 (d, J=5.2
Hz, 1H), 7.50-7.43 (m, 2H), 7.19-7.16 (d, J=8.0 Hz, 2H), 5.30-5.25
(m, 1H), 4.32-4.29 (m, 1H), 4.15-3.00 (m, 11H), 2.26-2.20 (m, 1H),
2.10-2.00 (m, 1H), 1.30-0.98 (m, 3H), MS (APCI+) [M+H].sup.+
450.
Example 33
##STR00131##
[0440]
2-(4-chlorophenyl)-3-(cyclopropylmethylamino)-1-(4-((5R,7R)-7-hydro-
xy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)prop-
an-1-one
[0441] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.16-8.14 (d, J=7.6
Hz, 1H), 7.18-7.16 (m, 2H), 7.02-7.00 (d, J=8.0 Hz, 2H), 5.02-4.95
(m, 1H), 4.14-4.10 (m, 1H), 3.98-3.00 (m, 11H), 2.89-2.84 (m, 1H),
2.65-2.62 (m, 1H), 1.98-1.90 (m, 1H), 1.85-1.77 (m, 1H), 1.05-0.70
(m, 6H), 0.35-0.33 (m, 2H), 0.02-0.00 (m, 2H). MS (APCI+)
[M+H].sup.+ 470.
Example 34
##STR00132##
[0442]
2-(4-chloro-3-fluorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-di-
hydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)pro-
pan-1-one
[0443] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.40 (m, 1H),
7.47-7.43 (m, 1H), 7.16-7.14 (d, J=9.6 Hz, 1H), 7.06-7.04 (d, J=8.4
Hz, 1H), 5.30-5.25 (m, 1H), 4.38-4.35 (m, 1H), 4.20-3.65 (m, 4H),
3.60-3.20 (m, 7H), 3.10-3.04 (m, 1H), 2.22-2.18 (m, 1H), 2.10-1.98
(m, 1H), 1.20-1.10 (m, 6H), 1.08-0.96 (m, 3H). MS (APCI+)
[M+H].sup.+ 476.
Example 35
##STR00133##
[0444]
2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H--
cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(pyrrolidin-1-yl)propan-1-on-
e
[0445] Step 1: Methyl 2-(4-chlorophenyl)acrylate (500 mg, 2.54
mmol) was diluted in THF (6.0 mL) and treated with pyrrolidine (233
uL, 2.80 mmol) at 0.degree. C. After 1 hour, the crude LCMS
indicated that the reaction was complete (LCMS (APCI+) [M+H].sup.+
268.1; Rf: 2.13 min). The solution was treated with water (2.0 mL)
and LiOH--H.sub.2O (320 mg, 7.63 mmol), respectively, and the
reaction was allowed to stir overnight to completion by LCMS
analysis. The mixture was partitioned between water and ethyl
acetate. The aqueous layer was washed again with ethyl acetate, and
the organics were discarded. The aqueous layer was treated with
excess 3N HCl solution (3.82 mL) and washed with ethyl acetate. The
separated aqueous layer was concentrated in vacuo to afford the
pure product (as a HCl-3LiCl salt) as a white solid (1.15 g). MS
(APCI+) [M+H].sup.+ 254.1; Rf: 1.30 min.
[0446] Step 2: HBTU (37 mg, 0.098 mmol) was added to a solution of
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride (30 mg, 0.098 mmol) and
2-(4-chlorophenyl)-3-(pyrrolidin-1-yl)propanoic acid
hydrochloride-3LiCl complex (83 mg) in DCM (4 mL) and TEA (1 mL).
The mixture was stirred at room temperature for 2 hours. The
solvent was removed, and the residue was subject to column
chromatography, eluted by EtOAc-DCM/MeOH (10:1). The product was
treated with HCl to afford
2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclop-
enta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(pyrrolidin-1-yl)propan-1-one
as the HCl salt (12 mg, 26%).
[0447] .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.46 (s, 1H),
7.83-7.81 (d, J=8.4 Hz, 1H), 7.63-7.61 (d, J=8.0 Hz, 1H), 7.31-7.23
(m, 2H), 5.11-4.98 (m, 2H), 3.95-3.90 (m, 1H), 3.80-3.00 (m, 10H),
2.20-1.90 (m, 7H), 1.32-1.20 (m, 3H), 1.12-1.08 (m, 4H). MS (APCI+)
[M+H].sup.+ 470.
Example 36
##STR00134##
[0449]
(R)-2-amino-3-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-
-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
[0450] MS (APCI+) [M+H].sup.+ 416.
Example 37
##STR00135##
[0451]
2-(4-chlorophenyl)-1-((S)-4-((S)-7-hydroxy-6,7-dihydro-5H-cyclopent-
a[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)-3-(isopropylamino)propan-1-one
[0452] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.10-8.00 (m, 1H),
7.10-6.85 (m, 2H), 6.80-6.70 (m, 2H), 4.82-4.70 (m, 1H), 4.00-2.50
(m, 12H), 2.10-1.90 (m, 1H), 1.50-1.40 (m, 1H), 0.90-0.70 (m, 9H).
MS (APCI+) [M+H].sup.+ 458.
Example 38
##STR00136##
[0453]
(R)-2-amino-3-(4-chlorophenyl)-1-((S)-44R)-7-hydroxy-6,7-dihydro-5H-
-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)propan-1-one
[0454] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.50-8.40 (m, 1H),
7.40-7.10 (m, 4H), 5.25-5.10 (m, 1H), 4.00-2.90 (m, 14H), 2.52-2.40
(m, 1H), 1.95-1.80 (m, 1H), 1.20-1.10 (m, 3H). MS (APCI+)
[M+H].sup.+ 416.
Example 39
##STR00137##
[0455]
(R)-2-amino-3-(4-chloro-3-fluorophenyl)-1-((S)-4-((R)-7-hydroxy-6,7-
-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)propan-1-o-
ne
[0456] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.55-8.40 (m, 1H),
7.40-6.90 (m, 3H), 5.25-5.10 (m, 1H), 4.00-2.90 (m, 14H), 2.52-2.40
(m, 1H), 1.95-1.80 (m, 1H), 1.20-1.10 (m, 3H). MS (APCI+)
[M+H].sup.+ 434.
Example 40
##STR00138##
[0457]
2-(4-chlorophenyl)-1-(4-((5R)-7-hydroxy-5,7-dimethyl-6,7-dihydro-5H-
-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-on-
e
[0458] Step 1: A solution of (R)-tert-butyl
4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-
-carboxylate (40 mg, 0.120 mmol) in THF (4 mL) was added to a 1.5M
solution of methyllithium in diethyl ether (0.088 mL, 0.132 mmol)
at -78.degree. C. The resulting mixture was stirred at -78.degree.
C. for 1 hour and quenched by saturated aqueous NH.sub.4Cl. The
aqueous layer was extracted with EtOAc (2.times.). The organic
layer was dried (MgSO.sub.4) and concentrated. The residue was
purified by a silica cartridge (5.0 g) eluted by EtOAc to give
tert-butyl
4-((5R)-7-hydroxy-5,7-dimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl-
)piperazine-1-carboxylate as an off-white solid (29 mg, 69%). LCMS
(APCI+) [M-Boc+H]+349.1; Rt: 2.49 min.
[0459] Step 2: A solution of tert-butyl
4-((5R)-7-hydroxy-5,7-dimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl-
)piperazine-1-carboxylate (28 mg, 0.080 mmol) in DCM (6 mL) was
added to a 4.0M HCl solution in dioxane (1.4 mL, 5.63 mmol). The
mixture was stirred at room temperature for 4 hours. A 4.0M HCl
solution in dioxane (1.4 mL, 5.63 mmol) from a different bottle was
added. The resulting mixture was stirred for 18 hours. The solvents
were removed in vacuo to give
(5R)-5,7-dimethyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidi-
n-7-ol dihydrochloride. DIPEA (41.5 mg, 0.321 mmol) was added to a
suspension of this
(5R)-5,7-dimethyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidi-
n-7-ol dihydrochloride (25.8 mg, 0.0803 mmol),
3-(tert-butoxycarbonyl(isopropyl)amino)-2-(4-chlorophenyl)propanoic
acid (32.9 mg, 0.0964 mmol), and
O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (36.6 mg, 0.0964 mmol) in CH.sub.2Cl.sub.2 (6
mL) at room temperature. The resulting mixture was stirred for 1
hour. The solvent was removed in vacuo. The residue was purified by
a silica cartridge (5.0 g) eluted by EtOAc to give tert-butyl
2-(4-chlorophenyl)-3-(4-((5R)-7-hydroxy-5,7-dimethyl-6,7-dihydro-5H-cyclo-
penta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropyl(isopropyl)carbamate
(46 mg, 100%) as a gel. LCMS (APCI+) [M-Boc+H].sup.+ 472.2; Rt:
3.51 min.
[0460] Step 3: A solution of tert-butyl
2-(4-chlorophenyl)-3-(4-((5R)-7-hydroxy-5,7-di
methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopr-
opyl(isopropyl)carbamate (46 mg, 0.080 mmol) in DCM (6 mL) was
added to a 4.0M HCl solution in dioxane (1.4 mL, 5.63 mmol). The
mixture was stirred at room temperature for 16 hours. The solvents
were removed in vacuo to give
2-(4-chlorophenyl)-1-(4-((5R)-7-hydroxy-5,7-dimethyl-6,7-dihydro-5H--
cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
dihydrochloride (49 mg, 100%) as a mixture of diastereomers. Rt:
2.05 and 2.18 min.
[0461] LCMS (APCI+) [M+H].sup.+ 472.
Example 41
##STR00139##
[0462]
(R)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-
-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-
-one
[0463] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.39 (s, 1H),
7.38-7.36 (d, J=8.0 Hz, 2H), 7.23-7.20 (d, J=8.4 Hz, 2H), 5.29-5.25
(m, 1H), 4.33-4.29 (m, 1H), 4.09-3.90 (m, 2H), 3.82-3.10 (m, 10H),
2.23-2.17 (m, 1H), 2.07-1.98 (m, 1H), 1.20-1.18 (m, 6H), 1.03-1.01
(d, J=6.8 Hz, 3H). MS (APCI+) [M+H].sup.+ 458.
Example 42
##STR00140##
[0464]
(4-(3,4-dichlorophenyl)piperidin-4-yl)(4-((5R,7R)-7-hydroxy-5-methy-
l-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)methanone
dihydrochloride
[0465] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.36 (m, 1H),
7.25-7.00 (m, 3H), 5.28-5.20 (m, 1H), 4.00-3.00 (m, 14H), 2.50-2.38
(m, 2H), 2.26-2.00 (m, 2H), 1.04-1.00 (m, 3H). MS (APCI+)
[M+H].sup.+ 490.
Example 43
##STR00141##
[0466]
4-(3,4-dichlorophenyl)pyrrolidin-3-yl)(4-((5R,7R)-7-hydroxy-5-methy-
l-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)methanone
dihydrochloride
[0467] .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.44-8.10 (m, 1H),
7.48-7.40 (m, 2H), 7.24-7.12 (m, 1H), 5.33-5.28 (m, 1H), 4.00-3.85
(m, 1H), 3.80-3.00 (m, 11H), 2.26-2.20 (m, 1H), 2.10-2.00 (m, 1H),
1.08-1.00 (m, 3H). MS (APCI+) [M+H].sup.+ 476.
Example 44
##STR00142##
[0468]
1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimi-
din-4-yl)piperazin-1-yl)-2-(4-methoxyphenyl)-3-(pyrrolidin-1-yl)propan-1-o-
ne
[0469] .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 8.46 (s, 1H),
7.83-7.81 (d, J=8.4 Hz, 1H), 7.63-7.61 (d, J=8.0 Hz, 1H), 7.31-7.23
(m, 2H), 5.11-4.98 (m, 2H), 3.95-3.90 (m, 1H), 3.80-3.00 (m, 10H),
2.20-1.90 (m, 7H), 1.32-1.20 (m, 3H), 1.12-1.08 (m, 4H). MS (APCI+)
[M+H].sup.+ 466.
Example 45
##STR00143##
[0470]
2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H--
cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(2,2,2-trifluoroethyl
amino)propan-1-one
[0471] Step 1: A solution of 2-(4-chlorophenyl)acetic acid (20.0 g,
117 mmol) in dry methanol (235 mL) was treated with 5 drops of
concentrated H.sub.2SO.sub.4 (cat.) at room temperature. The
mixture was stirred overnight to completion, and then concentrated
in vacuo to about 40 milliliters. The concentrate was partitioned
between ether and half saturated NaHCO.sub.3 solution. The aqueous
portion was back-extracted once with ether, and the organics were
combined. The organic portion was washed with water, then brine,
dried over MgSO.sub.4, and concentrated in vacuo. The material was
placed under high vacuum for one hour to afford the pure methyl
2-(4-chlorophenyl)acetate as a pale yellow oil (19.8 g, 92%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 7.30 (d, J=8.4 Hz, 2H),
7.21 (d, J=8.4 Hz, 2H), 3.70 (s, 3H), 3.60 (2, 2H).
[0472] Step 2: n-BuLi (1.60M in hexanes, 35.6 mL, 56.9 mmol) was
added to a 0.degree. C. solution of diisopropylamine (8.35 mL, 59.6
mmol) in THF (200 mL). The mixture was allowed to stir at 0.degree.
C. for 30 minutes, and was then cooled to -78.degree. C. A solution
of methyl 2-(4-chlorophenyl)acetate (10.0 g, 54.2 mmol) in THF (10
mL) was added to the -78.degree. C. LDA solution by syringe, which
was then stirred for 45 minutes. Neat tert-butyl bromoacetate (9.60
mL, 65.0 mmol) was added by syringe, and the reaction was stirred
for 15 minutes at -78.degree. C. The bath was removed, and the
reaction was allowed to warm to room temperature. After stirring an
additional 5 hours, the reaction mixture was quenched with
saturated NH.sub.4Cl solution, and the solvent(s) were removed in
vacuo. The oily mixture was extracted with ethyl acetate, and the
organics were combined. The organic portion was dried over
MgSO.sub.4, filtered, and concentrated in vacuo. The crude oil was
purified on silica gel (95:5 hexanes:EtOAc) to afford the
4-tert-butyl 1-methyl 2-(4-chlorophenyl)succinate as a pale yellow
oil (14.3 g, 88%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 7.29
(d, J=7.2 Hz, 2H), 7.22 (d, J=7.2 Hz, 2H), 4.00 (dd, J=9.6, 5.6 Hz,
1H), 3.67 (s, 3H), 3.07 (dd, J=16.4, 9.6 Hz, 1H), 2.58 (dd, J=16.8,
6.0 Hz, 1H), 1.40 (m, 3H).
[0473] Step 3: A solution of 4-tert-butyl 1-methyl
2-(4-chlorophenyl)succinate (14.3 g, 47.7 mmol) in DCM (75 mL) was
treated with neat TFA (75 mL) at room temperature. The mixture was
stirred for five hours to completion, after which the reaction
mixture was concentrated and dried in vacuo overnight to afford a
white solid. The solid was suspended in toluene (160 mL), cooled to
0.degree. C., and treated successively with diphenylphosphoryl
azide (11.2 mL, 52.1 mmol) and triethylamine (13.2 mL, 94.7 mmol).
The reaction mixture (homogeneous) was allowed to warm to room
temperature and stirred for four hours to completion. The solution
was quenched with 1% citric acid solution and extracted with EtOAc
(3.times.). The combined organic portion was washed with brine,
dried over Na.sub.2SO.sub.4, filtered, and concentrated in vacuo to
give a light brown oil. The crude azide was dissolved in
tert-butanol (160 mL), treated with neat SnCl.sub.4 (1.0M solution,
2.37 mL, 2.37 mmol), and carefully heated to 90.degree. C. with
evolution of nitrogen. The mixture was stirred at 90.degree. C. for
2.5 hours and cooled to room temperature. The solution was quenched
with saturated NaHCO.sub.3 solution and then concentrated. The oily
mixture was extracted with EtOAc (3.times.), and the combined
organic portion was washed with brine, dried over MgSO.sub.4,
filtered, and concentrated in vacuo. The residue was purified by on
silica gel (4:1 hexanes:EtOAc) to afford the methyl
3-(tert-butoxycarbonylamino)-2-(4-chlorophenyl)propanoate as a pale
yellow oil (11.7 g, 79%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta.
7.31 (d, J=8.0 Hz, 2H), 7.20 (d, J=8.0 Hz, 2H), 4.86 (br s, 1H),
3.88 (m, 1H), 3.69 (s, 3H), 3.58 (m, 1H), 3.49 (m, 1H), 1.42 (s,
9H).
[0474] Step 4: A solution of methyl
3-(tert-butoxycarbonylamino)-2-(4-chlorophenyl)propanoate (451 mg,
1.44 mmol) in dioxane (6.0 mL) was treated with 4M HCl in dioxane
(about 6.0 mL, 23.0 mmol) at room temperature. The mixture was
stirred for 18 hours to completion, after which the reaction
mixture was diluted with ether to afford a precipitate. The slurry
was filtered under nitrogen to afford a white solid, which was
washed with ether. The solid was dried under vacuum to afford the
methyl 3-amino-2-(4-chlorophenyl)propanoate hydrochloride as a
white solid (321 mg, 89%). LCMS (APCI+) m/z 214.0 [M+H].sup.+.
[0475] Step 5: A solution of methyl
3-amino-2-(4-chlorophenyl)propanoate hydrochloride (215 mg, 0.86
mmol) in 1:1 THF:DMF (3.0 mL) was treated with DIEA (389 uL, 2.23
mmol) at room temperature. Trifluoroethyl triflate (299 mg, 1.29
mmol) was added to the mixture, and the reaction was stirred for 20
hours to completion. The mixture was partitioned between ethyl
acetate and diluted NaHCO.sub.3 solution. The aqueous portion was
extracted twice, and the combined organic portions were washed with
water (3.times.). The organic portion was washed with brine,
separated, dried over MgSO.sub.4, filtered, and concentrated in
vacuo. The residue was purified by chromatography (silica gel
eluted with 4:1 hexanes:ethyl acetate, Rf=0.18) to afford the pure
methyl 2-(4-chlorophenyl)-3-(2,2,2-trifluoroethylamino)propanoate
(235 mg, 93%) as a colorless oil. LCMS (APCI+) m/z 296.0
[M+H].sup.+.
[0476] Step 6: A solution of methyl
2-(4-chlorophenyl)-3-(2,2,2-trifluoroethylamino)propanoate (235 mg,
0.795 mmol) in THF (3.0 mL) was treated with KOTMS (153 mg, 1.19
mmol) at room temperature. The reaction was allowed to stir 18
hours to completion, and the mixture was diluted with ether. The
resulting precipitate was isolated by filtration and placed under
high vacuum for two hours to afford the potassium
2-(4-chlorophenyl)-3-(2,2,2-trifluoroethylamino)propanoate (299 mg,
118%, excess salts) as a white solid. LCMS (APCI+) m/z 282.0
[M+H].sup.+.
[0477] Step 7: A solution of
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride (30 mg, 98 umol) and potassium
2-(4-chlorophenyl)-3-(2,2,2-trifluoroethylamino)propanoate (31.2
mg, 98 umol) in DME (1.0 mL) was treated with with DIEA (36 uL, 205
umol) and HBTU (41 mg, 107 umol), respectively, at room
temperature. The mixture was allowed to stir for 18 hours to
completion, and the solution was partitioned between ethyl acetate
and water. The aqueous portion was extracted twice, and the
organics were combined. The organic portion was washed with water
(3.times.), then brine, separated, dried over MgSO.sub.4, filtered,
and concentrated in vacuo. The residue was purified by
chromatography (silica gel eluted with 9:1 ethyl acetate:MeOH) to
afford the pure free-base as a colorless oil. This material was
dissolved in ether (1.0 mL), then treated with excess 2.0M HCl in
ether. The suspension was concentrated in vacuo to afford the pure
2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclop-
enta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(2,2,2-trifluoroethylamino)propan--
1-one dihydrochloride (31 mg, 99%) as a white solid. LCMS (APCI+)
m/z 498.2 [M+H]+.
Example 46
##STR00144##
[0478]
3-(tert-butylamino)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-me-
thyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)propan-1-on-
e
[0479] Step 1: A stirring solution of methyl
2-(4-chlorophenyl)acetate (36.7 g, 199 mmol) (From Example 1, Step
1) and paraformaldehyde (6.27 g, 209 mmol) in DMSO (400 mL) was
treated with sodium methoxide (537 mg, 9.94 mmol) at room
temperature. The mixture was allowed to stir for two hours to
completion and then poured into ice-cold water (700 mL) forming a
white emulsion. The quench was neutralized with the addition of 1M
HCl solution, and the aqueous was extracted with ethyl acetate
(3.times.). The combined organic portions were washed with water
(2.times.), then brine, dried over MgSO.sub.4, and concentrated in
vacuo. The residue was filtered through a plug of silica gel eluted
stepwise with 9:1 to 1:1 hexanes:ethyl acetate to afford the pure
methyl 2-(4-chlorophenyl)-3-hydroxypropanoate (39.4 g, 92%) as a
colorless oil.
[0480] .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 7.32 (d, J=8.4 Hz,
2H), 7.21 (d, J=8.4 Hz, 2H), 4.10 (m, 1H), 3.82 (m, 2H), 3.72 (s,
3H), 2.25 (m, 1H).
[0481] Step 2: A solution of methyl
2-(4-chlorophenyl)-3-hydroxypropanoate (39.4 g, 184 mmol) in DCM
(500 mL) was treated with triethylamine (64.0 mL, 459 mmol) and
cooled to 0.degree. C. The solution was treated with
methanesulfonyl chloride (15.6 mL, 202 mmol) slowly, then allowed
to stir for 30 minutes to completion. The solution was partitioned
with 1N HCl solution, and the aqueous portion was back-extracted
once with DCM. The combined organic portions were washed again with
1N HCl solution, separated, then washed with a half saturated
NaHCO.sub.3 solution. The organic portion was dried over MgSO.sub.4
and concentrated in vacuo to afford an orange oil. The residue was
filtered through a plug of silica gel eluted with 9:1 hexanes:ethyl
acetate to afford the pure methyl
2-(4-chlorophenyl)-3-hydroxypropanoate (30.8 g, 85%) as a colorless
oil. .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 7.36 (d, J=8.4 Hz,
2H), 7.32 (d, J=8.4 Hz, 2H), 6.38 (s, 1H), 5.90 (s, 1H), 3.82 (s,
3H).
[0482] Step 3: A solution of methyl 2-(4-chlorophenyl)acrylate
(2.00 g, 10.2 mmol) in 1:1 THF:ethanol (20 mL) was treated with
tert-butyl amine (389 uL, 2.23 mmol) at 60.degree. C. The reaction
stirred for 20 hours to completion, and the solvent/excess amine
were removed in vacuo. The residue was purified by chromatography
on silica gel (eluted with 1:1 hexanes:ethyl acetate) to afford the
pure methyl 3-(tert-butylamino)-2-(4-chlorophenyl)propanoate (2.54
g, 93%) as a colorless oil. LCMS (APCI+) m/z 270.0 [M+H].sup.+.
[0483] Step 4: A solution of methyl
3-(tert-butylamino)-2-(4-chlorophenyl)propanoate (1.00 g, 3.71
mmol) in THF (15 mL) was treated with KOTMS (555 mg, 3.89 mmol) at
room temperature. The reaction was allowed to stir 18 hours to
completion, and the mixture was concentrated in vacuo. The residue
was placed under high vacuum for three hours to afford the
near-pure potassium
3-(tert-butylamino)-2-(4-chlorophenyl)propanoate (1.06 g, 97%) as a
white solid. This material was used without purification. LCMS
(APCI+) m/z 256.0 [M+H].sup.+.
[0484] Step 5: A solution of
(5R,7R)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride (31.7 mg, 0.103 mmol) and potassium
3-(tert-butylamino)-2-(4-chlorophenyl)propanoate (30.3 mg, 0.103
mmol) in DMF (1.0 mL) was treated with with DIEA (38 uL, 0.217
mmol) and HBTU (43 mg, 114 mmol), respectively, at room
temperature. The mixture was allowed to stir for 18 hours to
completion, and the solution was partitioned between ethyl acetate
and water. The aqueous was extracted twice, and the organics were
combined. The organic portion was washed with water (3.times.),
then brine, separated, dried over MgSO.sub.4, filtered, and
concentrated in vacuo. The residue was purified by reverse phase
chromatography (eluted with water: acetonitrile gradients modified
with 1% ammonium acetate) to afford the pure
3-(tert-butylamino)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6-
,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one
(20 mg, 41%) as a white solid. LCMS (APCI+) m/z 472.2
[M+H].sup.+.
Example 47
##STR00145##
[0485]
S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro--
5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(methyl(tetrahydro-2H-pyr-
an-4-yl)amino)propan-1-one
[0486] 37% w/w formaldehyde/H.sub.2O (0.1489 ml, 2.000 mmol) was
added to a solution of
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(tetrahydro-2H-pyran-4-ylamino-
)propan-1-one dihydrochloride (0.115 g, 0.2000 mmol) and DIEA
(0.105 mL, 0.600 mmol) in DCE (1.5 mL) and THF (0.5 mL), followed
by addition of Na(OAc).sub.3BH (0.08477 g, 0.4000 mmol). The
reaction mixture was stirred for 2 hours, and 1 equivalent of
Na(OAc).sub.3BH was added. The reaction mixture was stirred for 14
hours. Another 5 equivalents of formaldehyde solution and 1.5
equivalents of Na(OAc).sub.3BH were added, and the reaction mixture
was stirred another 3 hours. Saturated NaHCO.sub.3 was added, the
mixture was extracted with DCM, and the combined extracts were
dried (Na.sub.2SO.sub.4), filtered, and concentrated. The crude was
purified on silica using Biotage 12M (1:1 DCM:EtOAc loaded and 125
mL flushed, then 25:1 to 10:1 DCM:MeOH gradient), and fractions
with product were concentrated. The resulting residue was dissolved
in minimal DCM/ether, and excess 2M HCl/ether was added, causing
precipitation. The mixture was stirred for 5 minutes, then
concentrated to dryness and dried in vacuo. The solids were
suspended in ether and isolated by filtration through 20 .mu.m
nylon filter paper with nitrogen pressure, rinsed with ether, and
dried in vacuo to give
(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(methyl(tetrahydro-2H-pyran-4--
yl)amino)propan-1-one dihydrochloride (0.080 g, 68.15% yield) as a
white powder. LCMS (APCI.sup.+) m/z 514 [M+H].sup.+.
Example 48
##STR00146##
[0487]
(S)-2-(4-chlorophenyl)-3-(cyclopropylmethylamino)-1-(4-((5R,7S)-7-h-
ydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-
propan-1-one
[0488] Step 1: Tert-butyl cyclopropylmethylcarbamate (11.2 g, 65.4
mmol) was dissolved into THF (60 mL) and set to stir at -78.degree.
C. BuLi (2.5M, 28.8 mL) was then added portionwise over 10 minutes.
The reaction was allowed to stir while warming to -20.degree. C.
for 10 minutes, and continued stirring at that temperature for
another 10 minutes. The reaction was then recooled to -78.degree.
C. at which point chloro(methoxy)methane (5.79 g, 72.0 mmol) was
added via syringe. The reaction was then allowed to stir overnight
with warming. The reaction was then quenched with 1 N HCl and the
organic layer separated. The aqeuous layer was then extracted with
DCM (2.times.), and the combined organic portions were dried with
MgSO.sub.4, filtered and concentrated. The crude material was
purified by passing through a silica plug eluting 10:1 Hex/EtOAc to
give tert-butyl cyclopropylmethyl(methoxymethyl)carbamate (12.8 g,
91%) as a clear liquid.
[0489] Step 2:
(R)-4-Benzyl-3-(2-(4-chlorophenyl)acetyl)oxazolidin-2-one (2.0 g,
6.06 mmol) was added to a flask in DCM (75 ml) followed by
TiCl.sub.4 (1.38 g, 7.28 mmol) and DIEA (0.823 g, 6.37 mmol). The
reaction was allowed to stir for about 15 to about 20 minutes at
-78.degree. C. at which point tert-butyl
cyclopropylmethyl(methoxymethyl)carbamate (1.57 g, 7.28 mmol) was
added. The reaction allowed to stir for 5 minutes, and the
-78.degree. C. bath was replaced with a 0.degree. C. bath. The
reaction was then allowed to stir for 3 hours at room temperature.
After the reaction was determined to be complete by HPLC, the
reaction was cooled to 0.degree. C. and quenched by the slow
addition of aqueous NaHCO.sub.3 while stirring for 10 minutes. The
organic layer was separated, and the aqueous layer was re-extracted
(3.times. EtOAc). The combined organics were dried with MgSO.sub.4,
filtered and concentrated. The crude residue was purified by column
chromatography, eluting 6:1 to 2:1 hexane/EtOAc to give tert-butyl
(S)-3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl(-
cyclopropylmethyl)carbamate (2.70 g, 87%) as light brown oil. (LCMS
(APCI+) [M-Boc+H].sup.+ 412.9; Rt: 4.42 min)
[0490] Step 3: LiOH (1.41 g, 33.5 mmol) was added to a flask
containing THE (360 mL) and H.sub.2O (120 mL), which was stirred
until dissolved. At this point, the reaction was cooled to
0.degree. C. with ice, and hydrogen peroxide (35 wt. %, 6.52 g) was
added. This solution was stirred for minutes, at which point
tert-butyl
(S)-3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl(-
cyclopropylmethyl)carbamate (8.6 g, 16.8 mmol) was added as a
solution in THF (20 mL). The reaction was stirred overnight with
warming. The reaction was quenched by the addition of 10% aqueous
Na.sub.2SO.sub.3 (1 mL) and saturated aqueous NaHCO.sub.3 (1 mL)
and stirred for 10 minutes. The reaction was concentrated to remove
THF and the aqueous layer extracted with ether (3.times.). The
aqueous layer was diluted with EtOAc and acidified with 1N HCl. The
organic layer was removed, and the aqueous layer was extracted with
EtOAc (2.times.). The combined organics were dried with MgSO.sub.4
and concentrated to give the crude product,
(S)-3-(tert-butoxycarbonyl(cyclopropylmethyl)amino)-2-(4-chlorophenyl)pro-
panoic acid as a clear oil (LCMS (APCI+) [M-Boc+H].sup.+ 254.1; Rt:
3.03 min).
[0491] Step 4: Crude
(S)-3-(tert-butoxycarbonyl(cyclopropylmethyl)amino)-2-(4-chlorophenyl)pro-
panoic acid (4.6 g, 13 mmol) was dissolved into DCM (130 mL) and
excess 4N HCl was added. The reaction was allowed to stir
overnight, after which it was concentrated. The resulting white
solid was taken up into EtOAC and filtered. The resulting solid was
washed with EtOAc (4.times.) to give pure
(S)-2-(4-chlorophenyl)-3-(cyclopropylmethylamino)propanoic acid
hydrochloride (3.60 g, 95%). This
(S)-2-(4-chlorophenyl)-3-(cyclopropylmethylamino)propanoic acid
(0.57 g, 2.24 mmol) was dissolved into 10:1 CH.sub.3CN:H.sub.2O (50
mL) and tetramethylammonium hydroxide pentahydrate (1.00 g) was
added followed by Boc2O (0.73 g, 3.36 mmol). The reaction mixture
was allowed to stir at room temperature overnight, and the reaction
was quenched by the addition of 1N HCl. The reaction was
concentrated, and the residue was diluted with EtOAc. The organics
were separated, and the aqueous portion was extracted with EtOAc.
The combined organics were dried with MgSO.sub.4, filtered and
concentrated. The crude residue was purified by silica plug eluting
Hex to 1:1 Hex/EtOAc to give
(S)-3-(tert-butoxycarbonyl(cyclopropylmethyl)amino)-2-(4-chlorophenyl)pro-
panoic acid (0.58 g, 73%) as a clear oil. (LCMS (APCI+)
[M-Boc+H].sup.+ 254.0)
[0492] Step 5:
(5R,7S)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-
-7-ol dihydrochloride (0.0444 g, 0.1445 mmol) and
(S)-3-(tert-butoxycarbonyl(cyclopropylmethyl)amino)-2-(4-chlorophenyl)pro-
panoic acid (0.05114 g, 0.1445 mmol) were combined in methylene
chloride (1.25 mL). They were then treated with
diisopropylethylamine (0.07552 ml, 0.4336 mmol), followed by HBTU
(0.05495 g, 0.1445 mmol). The reaction was stirred at ambient
temperature for 16 hours. The reaction was quenched with 10%
Na.sub.2CO.sub.3, diluted with methylene chloride and separated.
The aqueous portion was washed with methylene chloride (2.times.),
and the combined organic layers were dried over Na.sub.2SO.sub.4
and concentrated in vacuo. The material was chromatographed on
SiO.sub.2 (Biotage 12M) and eluted with 4% MeOH/MC. The material
was concentrated in vacuo to give tert-butyl
(S)-2-(4-chlorophenyl)-3-(4-((5R,7
S)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazi-
n-1-yl)-3-oxopropyl (cyclopropylmethyl)carbamate as a white solid
(67.4 mg, 82%). LCMS (APCI+) [M+H].sup.+ 570.0.
[0493] Step 6: Tert-butyl
(S)-2-(4-chlorophenyl)-3-(4-((5R,7S)-7-hydroxy-5-methyl-6,7-dihydro-5H-cy-
clopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropyl(cyclopropylmethyl)ca-
rbamate (0.0674 g, 0.1182 mmol) was dissolved in dioxane (0.5 mL)
and treated with HCl in dioxane (0.7389 ml, 2.956 mmol) (4M). The
reaction was stirred at ambient temperature for 48 hours. The
reaction mixture was concentrated in vacuo. The residue was
redissolved in MeOH and re-concentrated three times. This residue
was resuspended in MeOH (0.2+0.1 mL) and added dropwise to a
stirred flask of Et.sub.2O (10 mL). After stirring for 30 minutes,
the solids were filtered, washed with Et.sub.2O, and dried under a
blanket of nitrogen to give
(S)-2-(4-chlorophenyl)-3-(cyclopropylmethylamino)-1-(4-((5R,7
S)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazi-
n-1-yl)propan-1-one as a white solid (60.2 mg, 94%.) LCMS (APCI+)
[M+H].sup.+ 470.2.
Example 49
##STR00147##
[0494]
(S)-2-(5-chlorothiophen-2-yl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7--
dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)p-
ropan-1-one
[0495] Step 1: Triethylamine (7.32 mL, 52.5 mmol) was added to a
solution of 5-chlorothiophene-2-acetic acid (8.83 g, 50.0 mmol) in
ether (200 mL) at -78.degree. C., followed by 2,2-dimethylpropanoyl
chloride (6.46 mL, 52.5 mmol). The resulting mixture was stirred at
0.degree. C. for 2 hours, and then re-cooled to -78.degree. C.
Meanwhile, a solution of (R)-4-benzyl-2-oxazolidinone (9.30 g, 52.5
mmol) in THF (100 mL) in a separated flask was cooled to
-78.degree. C. 2.5M of n-butyllithium in hexane (22.0 mL) was added
dropwise. The resulting solution was stirred at -78.degree. C. for
1 hour, and then added via cannula into the solution of the mixed
anhydride. The reaction mixture was stirred at -78.degree. C. for
15 minutes, at 0.degree. C. for 30 minutes, then at room
temperature overnight. Saturated NHCl (300 mL) was added to quench
the reaction. The mixture was extracted with EtOAc (3.times.200
mL). The combined organics were dried (Na.sub.2SO.sub.4), filtered
and concentrated. The crude product was purified by silica gel
chromatography, eluting with EtOAc/hexane (0-25%) to give
(R)-4-benzyl-3-(2-(5-chlorothiophen-2-yl)acetyl)oxazolidin-2-one
(9.43 g, 56%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 7.33-7.25
(m, 3H), 7.16-7.13 (m, 2H), 6.79-6.76 (m, 2H), 4.70-4.65 (m, 1H),
4.38 (q, J=17.2 Hz, 2H), 4.25-4.18 (m, 2H), 3.27 (dd, J=13.6 Hz,
J=3.6 Hz, 1H), 2.77 (dd, J=13.6 Hz, J=3.6 Hz, 1H).
[0496] Step 2: 1.0M of titanium tetrachloride in DCM (30.9 mL, 30.9
mmol) was added dropwise to a solution of
(R)-4-benzyl-3-(2-(5-chlorothiophen-2-yl)acetyl)oxazolidin-2-one
(9.43 g, 28.1 mmol) in DCM (170 mL) at -78.degree. C., followed by
N,N-diisopropylethylamine (9.78 mL, 56.2 mmol). The resulting dark
blue mixture was stirred at -78.degree. C. for 1 hour. tert-Butyl
isopropyl(methoxymethyl)carbamate (11.4 g, 56.2 mmol) was then
added. The mixture was stirred at -78.degree. C. for 1 hour, and
then allowed to warm up to room temperature. The mixture was
stirred at room temperature for 2 hours, quenched with saturated
NH.sub.4Cl (300 mL), and extracted with DCM (3.times.200 mL). The
combined organics were dried (Na.sub.2SO.sub.4), filtered and
concentrated. The crude product was purified by silica gel
chromatography eluting with EtOAc/hexane (0-20%) to give tert-butyl
(S)-3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-(5-chlorothiophen-2-yl)-3-oxo-
propyl (isopropyl)carbamate (10.2 g, 72%). MS (APCI+) [M+H].sup.+
507.2. .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 7.36-7.22 (m, 5H),
6.79 (d, J=4.0 Hz, 1H), 6.75 (d, J=4.0 Hz, 1H). 4.67-4.62 (m, 1H),
4.15-4.09 (m, 4H), 3.45-3.38 (m, 2H), 2.80-2.72 (m, 1H), 1.49 (s,
9H), 1.12 (d, J=6.0 Hz, 3H), 1.05 (d, J=6.0 Hz, 3H).
[0497] Step 3: A mixture solution of lithium hydroxide (374 mg,
15.6 mmol) in H.sub.2O (60 mL) and 30% hydrogen peroxide (1.60 mL,
15.6 mmol) was added dropwise to a solution of tert-butyl
(S)-3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-(5-chlorothiophen-2-yl)-3-oxo-
propyl(isopropyl)carbamate (7.54 g, 14.9 mmol) in THF (150 mL) at
-5.degree. C. The mixture was stirred at -5.degree. C. After 10
minutes, the reaction was quenched with 10% Na.sub.2SO.sub.3 (16
mL) at -5.degree. C. and stirred at room temperature for 30
minutes. The THF was removed in vacuo. The aqueous layer was
acidified with 1M NaH.sub.2PO.sub.4 and extracted with DCM
(3.times.100 mL). The combined organics were dried
(Na.sub.2SO.sub.4), filtered and concentrated to give
(S)-3-(tert-butoxycarbonyl(isopropyl)amino)-2-(5-chlorothiophen-2-yl)prop-
anoic acid which was used in the next step without purification. MS
(APCI+) [M+H]+ 348.2.
[0498] Step 4: A solution of
(5R,7R)-5-methyl-4-((S)-piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrim-
idin-7-ol ditrifluoroacetic acid (351 mg, 1.50 mmol) and
N,N-diisopropylethylamine (2.61 mL, 15.0 mmol) in DCM (5 mL) was
added to a solution of
(S)-3-(tert-butoxycarbonyl(isopropyl)amino)-2-(5-chlorothiophen-2-yl)prop-
anoic acid (0.522 g, 1.50 mmol) in DCM (5 mL) and DMF (1 mL),
followed by O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (0.597 g, 1.57 mmol). The mixture was stirred
at room temperature for 1 hour. The reaction was quenched with
saturated NH.sub.4Cl (20 mL) and extracted with DCM (2.times.20
mL). The combined organics were dried (Na.sub.2SO.sub.4), filtered
and concentrated. The crude product was purified by silica gel
chromatography eluting first with EtOAc/hexane (0-100%), then with
MeOH/DCM (0-6%) to give tert-butyl
(S)-2-(5-chlorothiophen-2-yl)-3-(4-((5R,7R)-6,7-dihydro-7-hydroxy-5-methy-
l-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropylisopropylcarba-
mate (535 mg, 63%). MS (APCI+) [M+H].sup.+ 564.0. .sup.1H NMR
(CDCl.sub.3, 400 MHz) .delta..quadrature.8.53 (s, 1H), 6.75 (d,
J=4.0 Hz, 1H), 6.68 (d, J=4.0 Hz, 1H), 5.11 (t, J=6.8 Hz, 1H), 4.94
(brs, 1H), 3.83-3.35 (m, 13H), 2.24-2.12 (m, 2H), 1.49 (s, 9H),
1.18 (d, J=7.2 Hz, 3H), 1.01 (d, J=6.0 Hz, 3H), 0.82 (d, J=6.0 Hz,
3H).
[0499] Step 5: 4.0M hydrogen chloride in 1,4-dioxane (2.508 mL) was
added to a solution of tert-butyl
(S)-2-(5-chlorothiophen-2-yl)-3-(4-((5R,7R)-6,7-dihydro-7-hydroxy-5-methy-
l-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropylisopropylcarba-
mate (283 mg, 0.502 mmol) in 1,4-dioxane (2.5 mL) and methylene
chloride (2.5 mL) at 0.degree. C. The mixture was allowed to warm
up to room temperature and stirred for 1 hour. The mixture was
concentrated in vacuo. The residue was then dissolved in a minimum
volume of DCM (1 mL) and added dropwise to ether (10 mL) at
0.degree. C. with stirring. A white solid precipitated. The
solvents were evaporated with a rotovap in a 25.degree. C. bath.
The off-white solid was dried under high vacuum overnight to give
(S)-2-(5-chlorothiophen-2-yl)-1-(4-((5R,7R)-6,7-dihydro-7-hydroxy-5-methy-
l-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan--
1-one dihydrochloride (537 mg, 99.9%). MS (APCI+) [M+H].sup.+
464.1. .sup.1H NMR (D.sub.2O, 400 MHz) .delta. 8.53 (s, 1H), 6.97
(d, J=4.0 Hz, 1H), 6.96 (d, J=4.0 Hz, 1H), 5.40 (t, J=8.0 Hz, 1H),
4.78-4.71 (m, 1H), 4.31-4.27 (m, 1H), 4.09-3.97 (m, 2H), 3.84-3.42
(m, 10H), 2.36-2.30 (m, 1H), 2.21-2.13 (M, 1H), 1.33 (d, J=6.4 Hz,
3H), 1.32 (d, J=6.4 Hz, 3H), 1.14 (d, J=6.4 Hz, 3H).
[0500] Examples 50-324 shown in Table 1 can also be made according
to the above-described methods.
TABLE-US-00001 TABLE 1 Example Structure Name LCMS or .sup.1H NMR
50 ##STR00148## (R)-2-amino-3-(4-chlorophenyl)-
1-(4-((5R,7S)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 416.2 51
##STR00149## 1-(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
(isopropylamino)-2-(4- (trifluoromethyl)phenyl) propan-1-one 492.2
52 ##STR00150## 4-(1-(4-((5R,7R)-7-hydroxy-5-
methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3- (isopropylamino)-1-oxopropan-2-
yl)benzonitrile 449.2 53 ##STR00151## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 458.3 54
##STR00152## 3-(azetidin-1-yl)-2-(4-chlorophenyl)-
1-(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 456.2 55
##STR00153## 2-(4-chlorophenyl)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3-(3- hydroxyazetidin-1-yl)propan-1-one 472.2 56
##STR00154## 2-(4-chlorophenyl)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3- (neopentylamino)propan-1-one 486.3 57
##STR00155## 2-(4-bromophenyl)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 504.2 58
##STR00156## 2-(4-chlorophenyl)-3-(4-
fluoropiperidin-1-yl)-1-(4-((5R,7R)-
7-hydroxy-5-methyl-6,7-dihydro- 5H-cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 502.2 59 ##STR00157##
2-(4-chlorophenyl)-3-((S)-3- fluoropyrrolidin-1-yl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)propan-1-one 488.2 60 ##STR00158##
2-(4-chlorophenyl)-3-(ethylamino)-
1-(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 444.3 61
##STR00159## 2-(4-chlorophenyl)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3- (isopropyl(methyl) amino)propan-1-one 472.2
62 ##STR00160## 2-(4-chlorophenyl)-3-(4,4-
difluoropiperidin-1-yl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
520.2 63 ##STR00161## 2-(4-chlorophenyl)-3-(3,3-
difluoropyrrolidin-1-yl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
506.2 64 ##STR00162## 2-(4-bromo-3-fluorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 520.2 65
##STR00163## (R)-2-amino-3-(4-fluorophenyl)-1-
(4-((5R,7S)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 400.2 66
##STR00164## (R)-2-amino-3-(3,4-dichlorophenyl)-
1-(4-((5R,7S)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 450.2 67
##STR00165## (R)-2-amino-3-(3,4-difluorophenyl)-
1-(4-((5R,7S)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 418.2 68
##STR00166## (R)-2-(4-chlorophenyl)-3-
(cyclopropylmethylamino)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
m/z 470 [M + H]+ 69 ##STR00167## (S)-2-(4-chlorophenyl)-3-
(cyclopropylmethylamino)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
m/z 470 [M + H]+ 70 ##STR00168## 2-(4-chlorophenyl)-3-((R)-3-
fluoropyrrolidin-1-yl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
488.2 71 ##STR00169## (S)-1-(4-((5R,7R)-7-hydroxy-5-
methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3- (isopropylamino)-2-(4- (trifluoromethoxy)
phenyl)propan-1-one 508.3 72 ##STR00170## (S)-2-(4-chlorophenyl)-3-
(cyclopropylamino)-1-(4-((5R,7R)- 7-hydroxy-5-methyl-6,7-dihydro-
5H-cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 456.2
73 ##STR00171## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(3- hydroxyazetidin-1-yl)propan-1-one 472.1
74 ##STR00172## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(3- hydroxyazetidin-1-yl)propan-1-one 472.1
75 ##STR00173## (R)-4-amino-2-(4-chlorophenyl)-1-
(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-4- methylpentan-1-one
.sup.1H NMR(CD.sub.3OD), 400 MHz, 8.51 (s, 1H), 7.40-7.33 (m, 4H),
5.17 (dd, J = 14.9, 7.04 Hz, 1H), 4.26 (dd, J = 9.4, 3.1 Hz, 1H),
4.06 (m, 1H), 3.85-3.60 (bm, 7H), 3.42 (m, 1H), 2.76 (dd, J = 14.9,
10.1 Hz, 1H), 2.2 (m, 2H), 1.81 (dd, J = 14.1, 3.1 Hz, 1H), 1.35
(s, 3H), 1.32 (s, 3H), 1.15 (d, J = 7.04 Hz, 3H). 76 ##STR00174##
(S)-4-amino-2-(4-chlorophenyl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-4-
methylpentan-1-one .sup.1H NMR(CD.sub.3OD), 400 MHz, 8.51 (s, 1H),
7.40-7.32 (m, 4H), 5.17 (dd, J = 14.9, 7.04 Hz, 1H), 4.25 (dd, J =
9.4, 3.1 Hz, 1H), 4.03- 3.52 (bm, 8H), 3.30 (m, 1H), 2.75 (dd, J =
14.9, 9.4 Hz, 1H), 2.18 (m, 2H), 1.82 (dd, J = 14.1, 3.1 Hz, 1H),
1.35 (s, 3H), 1.32 (s, 3H), 1.18 (d, J = 6.3 Hz, 3H) 77
##STR00175## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-((R)- pyrrolidin-3-ylamino)propan-1-one
485.2 78 ##STR00176## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-((S)- pyrrolidin-3-ylamino)propan-1-one
485.2 79 ##STR00177## (S)-3-((R)-1-acetylpyrrolidin-3-
ylamino)-2-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
527.2 80 ##STR00178## (S)-3-((S)-1-acetylpyrrolidin-3-
ylamino)-2-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
527.2 81 ##STR00179## (S)-2-(4-bromophenyl)-3-
(cyclopropylmethylamino)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
514.0 82 ##STR00180## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(piperidin-4- ylamino)propan-1-one m/z 499
[M + H]+ 83 ##STR00181## (S)-3-(1-acetylpiperidin-4-ylamino)-
2-(4-chlorophenyl)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one m/z 541 [M + H]+ 84 ##STR00182##
(S)-2-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-(2-
methoxyethylamino)propan-1-one m/z 474 [M + H]+ 85 ##STR00183##
(R)-2-(4-chlorophenyl)-4- (dimethylamino)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)butan-1-one 458.1 86 ##STR00184##
(S)-2-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
m/z 500 [M + H]+ 87 ##STR00185## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-((1r,4S)-4- hydroxycyclohexylamino)
propan-1-one 514.3 88 ##STR00186## (S)-3-(azetidin-1-yl)-2-(4-
chlorophenyl)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 456.3 89
##STR00187## (R)-3-(azetidin-1-yl)-2-(4-
chlorophenyl)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 456.3 90
##STR00188## 2-((S)-2-(4-chlorophenyl)-3-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- oxopropylamino)acetamide 473.2 91
##STR00189## 2-((S)-2-(4-chlorophenyl)-3-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- oxopropylamino)-N,N- dimethylacetamide
501.3 92 ##STR00190## 2-((S)-2-(4-chlorophenyl)-3-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- oxopropylamino)-N- methylacetamide 487.2 93
##STR00191## (R)-2-(4-bromophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-4- (isopropylamino)butan-1-one 516.2/518.1 94
##STR00192## (R)-2-(4-bromophenyl)-4-
(dimethylamino)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)butan-1-one 502.1/504.1
95 ##STR00193## (R)-2-(4-bromophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-4- (isobutylamino)butan-1-one 530.2 96
##STR00194## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-4-((2- methoxyethyl)(methyl)amino) butan-1-one
502.1 97 ##STR00195## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-4- (isopropylamino)butan-1-one 472.2 98
##STR00196## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-4-(3- hydroxyazetidin-1-yl)butan-1-one 486.2
99 ##STR00197## 2-((R)-3-(4-bromophenyl)-4-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-4- oxobutylamino)-N,N- dimethylacetamide 559.1
100 ##STR00198## (R)-2-(4-bromophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-4-(2- hydroxyethylamino)butan-1-one
518.2/520.1 101 ##STR00199## (2R)-2-(4-bromophenyl)-4-(2-
hydroxy-1-(tetrahydro-2H-pyran-4- yl)ethylamino)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)butan-1-one 604.2 102 ##STR00200##
(R)-2-amino-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-(4-
iodophenyl)propan-1-one 508.1 103 ##STR00201##
4-((R)-2-amino-3-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
oxopropyl)benzonitrile 407.2 104 ##STR00202##
(R)-2-amino-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-(4-
(trifluoromethyl)phenyl) propan-1-one 450.2 105 ##STR00203##
(S)-3-(4-acetylpiperazin-1-yl)-2-(4- chlorophenyl)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 527.2
106 ##STR00204## (R)-3-(4-acetylpiperazin-1-yl)-2-(4-
chlorophenyl)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 527.2 107
##STR00205## (R)-3-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-2- (methylamino)propan-1-one 430.2 108
##STR00206## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4-(2- hydroxyethyl)piperazin-1-yl)propan-
1-one 529.4 109 ##STR00207## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4-(2- hydroxyethyl)piperazin-1-yl)
propan-1-one 529.4 110 ##STR00208##
2-(4-chlorophenyl)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3-(3- methoxyazetidin-1-yl)propan-1-one 486.2
111 ##STR00209## (R)-2-(4-chlorophenyl)-4-
(cyclohexylamino)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)butan-1-one 512.3 112
##STR00210## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-4-(tetrahydro- 2H-pyran-4-ylamino)butan-1-one
514.2 113 ##STR00211## (2R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-4-(2- hydroxypropylamino)butan-1-one 488.2 114
##STR00212## (2R)-2-(4-chlorophenyl)-4-(2-
hydroxy-1-(tetrahydro-2H-pyran-4- yl)ethylamino)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)butan-1-one 558.2 115 ##STR00213##
(2R)-2-(4-chlorophenyl)-4-(2- hydroxy-1-phenylethylamino)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)butan-1-one 550.2 116 ##STR00214##
(S)-2-(4-chlorophenyl)-3- (ethyl(tetrahydro-2H-pyran-4-
yl)amino)-1-(4-((5R,7R)-7-hydroxy- 5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one m/z 528 [M
+ H]+ 117 ##STR00215## (R)-2-(4-bromophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-4-(2- methoxyethylamino)butan-1-one 534.1 118
##STR00216## (2R)-2-(4-bromophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-4-(3,3,3- trifluoro-2-
hydroxypropylamino)butan-1-one 586.2 119 ##STR00217##
(R)-2-(4-bromophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-4-((1-
hydroxycyclopropyl)methylamino) butan-1-one 544.2/546.2 120
##STR00218## 2-((R)-3-(4-bromophenyl)-4-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-4- oxobutylamino)acetamide 531.1/533.1 121
##STR00219## (R)-2-(4-bromophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-4-(tetrahydro- 2H-pyran-4-ylamino)butan-1-one
558.2 122 ##STR00220## (R)-4-(3-(1H-imidazol-1-
yl)propylamino)-2-(4-bromophenyl)-
1-(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)butan-1-one 584.2 123
##STR00221## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- morpholinopropan-1-one 486.3 124
##STR00222## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- morpholinopropan-1-one 486.3 125
##STR00223## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- methylpiperazin-1-yl)propan-1-one 499.4
126 ##STR00224## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- methylpiperazin-1-yl)propan-1-one 499.4
127 ##STR00225## (S)-3-(3-aminoazetidin-1-yl)-2-(4-
chlorophenyl)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 471.2 128
##STR00226## (R)-3-(3-aminoazetidin-1-yl)-2-(4-
chlorophenyl)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 471.2 129
##STR00227## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- thiomorpholinopropan-1-one 502.2 130
##STR00228## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(piperazin-1- yl)propan-1-one 485.3 131
##STR00229## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(piperazin-1- yl)propan-1-one 485.3 132
##STR00230## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- thiomorpholinopropan-1-one 502.2 133
##STR00231## (R)-2-(4-chlorophenyl)-3-(4-
fluoropiperidin-1-yl)-1-(4-((5R,7R)-
7-hydroxy-5-methyl-6,7-dihydro- 5H-cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 502.2 134 ##STR00232##
(S)-2-(4-chlorophenyl)-3-(4- fluoropiperidin-1-yl)-1-(4-((5R,7R)-
7-hydroxy-5-methyl-6,7-dihydro- 5H-cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 502.2 135 ##STR00233##
(R)-2-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-(3-
methoxyazetidin-1-yl)propan-1-one 486.2 136 ##STR00234##
(S)-2-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-(3-
methoxyazetidin-1-yl)propan-1-one 486.2 137 ##STR00235##
(S)-2-(3,4-dichlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one 492.2 138 ##STR00236##
(S)-2-(4-chlorophenyl)-3- (dimethylamino)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 444.1 139 ##STR00237##
(S)-2-(4-fluoro-3- (trifluoromethyl)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 510.2 140
##STR00238## (S)-2-(3-fluoro-4- (trifluoromethyl)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 510.4 141
##STR00239## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (methoxyamino)propan-1-one 446.2 142
##STR00240## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- methoxypiperidin-1-yl)propan-1-one 514.3
143 ##STR00241## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- methoxypiperidin-1-yl)propan-1-one 514.3
144 ##STR00242## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- hydroxypiperidin-1-yl)propan-1-one 500.3
145 ##STR00243## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- hydroxypiperidin-1-yl)propan-1-one 500.3
146 ##STR00244## (S)-3-(4-aminopiperidin-1-yl)-2-(4-
chlorophenyl)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 499.3 147
##STR00245## (R)-3-(4-aminopiperidin-1-yl)-2-(4-
chlorophenyl)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 499.3 148
##STR00246## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
500.2 149 ##STR00247## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (methyl(tetrahydro-2H-pyran-4-
yl)amino)propan-1-one m/z 514 [M + H]+ 150 ##STR00248##
(S)-2-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-
(isopropyl(methyl)amino) propan-1-one 472.3 151 ##STR00249##
(R)-2-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-(4-
(methylsulfonyl)piperazin-1- yl)propan-1-one 563.2 152 ##STR00250##
(S)-2-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-(4-
(methylamino)piperidin-1- yl)propan-1-one 513.3 153 ##STR00251##
(R)-2-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-(4-
(methylamino)piperidin-1- yl)propan-1-one 513.3 154 ##STR00252##
(S)-2-(4-chloro-3- (trifluoromethoxy)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 542.2 155
##STR00253## (S)-2-(3-fluoro-4- (trifluoromethoxy)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 526.3 156
##STR00254## (S)-2-(4-chloro-3- (trifluoromethyl)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 526.2 157
##STR00255## (R)-2-(4-chlorophenyl)-3-(4-
ethylpiperazin-1-yl)-1-(4-((5R,7R)- 7-hydroxy-5-methyl-6,7-dihydro-
5H-cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 513.3
158 ##STR00256## (S)-2-(4-chlorophenyl)-3-(4-
ethylpiperazin-1-yl)-1-(4-((5R,7R)- 7-hydroxy-5-methyl-6,7-dihydro-
5H-cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 513.3
159 ##STR00257## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- isopropylpiperazin-1-yl)propan-1- one
527.6 160 ##STR00258## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- isopropylpiperazin-1-yl) propan-1-one
527.6 161 ##STR00259## (R)-2-(4-chlorophenyl)-3-((S)-3-
(dimethylamino)pyrrolidin-1-yl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 513.6 162 ##STR00260##
(S)-2-(4-chlorophenyl)-3-((S)-3- (dimethylamino)pyrrolidin-1-yl)-1-
(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 513.6 163
##STR00261## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-((R)- tetrahydrofuran-3-ylamino)
propan-1-one 486.2 164 ##STR00262## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-((R)- tetrahydrofuran-3-ylamino)
propan-1-one
486.2 165 ##STR00263## (S)-2-(4-chlorophenyl)-3-(2-
fluoroethylamino)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 462.2 166
##STR00264## (S)-2-(4-fluoro-3- (trifluoromethoxy)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 526.4 167
##STR00265## (S)-2-(3,5-bis (trifluoromethyl)phenyl)-1-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 560.3 168
##STR00266## (S)-2-(3-fluoro-4-methoxyphenyl)-1-
(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one 472.5 169 ##STR00267##
4-((R)-2-(4-chlorophenyl)-3-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-
oxopropyl)piperazin-2-one 499.3 170 ##STR00268##
(R)-2-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-((R)-3-
hydroxypyrrolidin-1-yl) propan-1-one 486.3 171 ##STR00269##
(S)-2-(4-chlorophenyl)-3-(4- (dimethylamino)piperidin-1-yl)-1-
(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 527.3 172
##STR00270## (R)-2-(4-chlorophenyl)-3-(4-
(dimethylamino)piperidin-1-yl)-1- (4-((5R,7R)-7-hydroxy-5-
methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 527.3 173 ##STR00271##
(S)-2-(3-chloro-5-fluorophenyl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one 476.2 174 ##STR00272##
(S)-2-(3-bromo-4-methoxyphenyl)- 1-(4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one 532.2 175 ##STR00273##
(R)-3-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-2-(piperidin-4- ylamino)propan-1-one 499.3 176
##STR00274## (R)-2-(1-acetylpiperidin-4-ylamino)-
3-(4-chlorophenyl)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 541.3 177 ##STR00275##
2-((R)-3-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-1-oxopropan-2- ylamino)-N-isopropylacetamide
515.3 178 ##STR00276## (R)-3-(4-chlorophenyl)-2-
(dimethylamino)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 444.2 179
##STR00277## (R)-3-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-2-(2- morpholinoethylamino)propan-1-one 529.3
180 ##STR00278## (R)-3-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-2- (isopropylamino)propan-1-one 458.2 181
##STR00279## (R)-3-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-2-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
500.3 182 ##STR00280## (R)-3-(4-chlorophenyl)-1-((S)-4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)-3-methylpiperazin-1-yl)-2- (isopropylamino)propan-1-one 472.3
183 ##STR00281## 2-((R)-3-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-1-oxopropan-2- ylamino)-N,N-dimethylacetamide
501.2 184 ##STR00282## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(1,4- oxazepan-4-yl)propan-1-one 500.3 185
##STR00283## (R)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(1,4- oxazepan-4-yl)propan-1-one 500.3 186
##STR00284## (R)-2-(4-chloro-2-fluorophenyl)-1-
(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one 476.2 187 ##STR00285##
(S)-2-(4-chloro-2-fluorophenyl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one 476.2 188 ##STR00286##
(S)-2-(2-fluoro-4- (trifluoromethyl)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 510.2 189
##STR00287## (S)-2-(4-chlorophenyl)-3-
(cyclohexylamino)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 498.3 190
##STR00288## (S)-2-(4-chlorophenyl)-3-
(cyclohexylamino)-1-(4-((5R,7S)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 498.3 191
##STR00289## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- methoxycyclohexylamino) propan-1-one
528.4 192 ##STR00290## (S)-2-(3-fluoro-4-
(trifluoromethoxy)phenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
568.3 193 ##STR00291## (S)-2-(3-fluoro-4-
(trifluoromethyl)phenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
552.2 194 ##STR00292## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-((S)- tetrahydrofuran-3-ylamino)
propan-1-one 486.3 195 ##STR00293## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- methyltetrahydro-2H-pyran-4-
ylamino)propan-1-one 513.2 196 ##STR00294##
(R)-3-(4-chlorophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-2-(2-
(tetrahydro-2H-pyran-4- yl)ethylamino)propan-1-one 528.3 197
##STR00295## (R)-3-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-2-(3,3,3- trifluoropropylamino)propan-1-one
512.2 198 ##STR00296## (R)-3-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-2-((tetrahydro- 2H-pyran-4-yl)methylamino)
propan-1-one 514.2 199 ##STR00297## (R)-3-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-2- (isopropyl(methyl)amino) propan-1-one 472.3
200 ##STR00298## (S)-3-(tert-butylamino)-2-(4-
chlorophenyl)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 472.1 201
##STR00299## (R)-3-(tert-butylamino)-2-(4-
chlorophenyl)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 472.1 202
##STR00300## (S)-2-(4-chloro-3-fluorophenyl)-1-
(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-(4-
methylpiperazin-1-yl)propan-1-one 517.2 203 ##STR00301##
(R)-2-(4-chloro-3-fluorophenyl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-(4-
methylpiperazin-1-yl)propan-1-one 517.2 204 ##STR00302##
(S)-2-(4-chloro-3-fluorophenyl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-(4-
hydroxypiperidin-1-yl)propan-1-one 518.2 205 ##STR00303##
(R)-2-(4-chloro-3-fluorophenyl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
morpholinopropan-1-one 504.2 206 ##STR00304##
(R)-2-(4-chloro-3-fluorophenyl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-(4-
hydroxypiperidin-1-yl)propan-1-one 518.2 207 ##STR00305##
(S)-2-(3-fluoro-4- (trifluoromethoxy)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- methylpiperazin-1-yl)propan-1-one 567.2
208 ##STR00306## (R)-2-(3-fluoro-4- (trifluoromethoxy)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- methylpiperazin-1-yl)propan-1-one 567.2
209 ##STR00307## (S)-3-(cyclopropylmethylamino)-2-
(3-fluoro-4-(trifluoromethyl)phenyl)-
1-(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 522.2 210
##STR00308## (S)-3-(cyclopropylmethylamino)- 2-(3-fluoro-4-
(trifluoromethoxy)phenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
538.2 211 ##STR00309## (S)-1-(4-((5R,7R)-7-hydroxy-5-
methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3- (isopropylamino)-2-(4-
(trifluoromethyl)phenyl) propan-1-one 492.3 212 ##STR00310##
(S)-3-amino-2-(4-bromophenyl)-1- (4-((5R,7S)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one m/z 460/462 (Br isotope) [M + H]+
213 ##STR00311## (S)-3-amino-2-(4-chloro-3-
fluorophenyl)-1-(4-((5R,7S)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one m/z 434 [M
+ H]+ 214 ##STR00312## (S)-2-(4-bromophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
546.2 215 ##STR00313## 3-((S)-2-(4-chlorophenyl)-3-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- oxopropylamino)propanamide 487.2 216
##STR00314## 3-((S)-2-(4-chlorophenyl)-3-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- oxopropylamino)propanamide 487.2 217
##STR00315## (4-(4-chlorophenyl)piperidin-4-
yl)(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)methanone 456.2 218
##STR00316## (S)-2-(4-bromophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 504.2 219
##STR00317## (S)-3-amino-2-(4-chloro-3-
fluorophenyl)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 434.3 220
##STR00318## (S)-3-amino-2-(4-bromophenyl)-1-
(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 462.2 221
##STR00319## (S)-2-(4-bromophenyl)-1-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
m/z 544/546 (Br isotope) [M + H]+ 222 ##STR00320##
(S)-2-(4-chloro-3-fluorophenyl)-1- (4-((5R,7S)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3-(tetrahydro-2H- pyran-4-ylamino)propan-1-one
m/z 518 [M + H]+
223 ##STR00321## (S)-2-(3,4-dichlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
534.2 224 ##STR00322## (S)-3-amino-2-(3,4-dichlorophenyl)-
1-(4-((5R,7S)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 450.3 225
##STR00323## (R)-2-(3,4-dichlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- hydroxypiperidin-1-yl)propan-1-one 534.2
226 ##STR00324## (S)-2-(3,4-dichlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- isopropylpiperazin-1-yl) propan-1-one
561.3 227 ##STR00325## (S)-2-(3-fluoro-4-
(trifluoromethoxy)phenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-(4-
hydroxypiperidin-1-yl)propan-1-one 568.2 228 ##STR00326##
(R)-2-(3-fluoro-4- (trifluoromethoxy)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- hydroxypiperidin-1-yl)propan-1-one 568.2
229 ##STR00327## (S)-2-(3-fluoro-4- (trifluoromethoxy)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- isopropylpiperazin-1-yl) propan-1-one
595.3 230 ##STR00328## (S)-2-(3,5-difluorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 460.3 231
##STR00329## (S)-3-((R)-3-aminopyrrolidin-1-yl)-
2-(4-chlorophenyl)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 485.3 232 ##STR00330##
(R)-3-((R)-3-aminopyrrolidin-1-yl)-
2-(4-chlorophenyl)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 485.3 233 ##STR00331##
(S)-2-(4-chloro-3-fluorophenyl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-(4-
isopropylpiperazin-1-yl) propan-1-one 545.3 234 ##STR00332##
(S)-2-(3-fluoro-4- (trifluoromethoxy)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- morpholinopropan-1-one 554.3 235
##STR00333## (R)-2-(3-fluoro-4- (trifluoromethoxy)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- morpholinopropan-1-one 554.3 236
##STR00334## (S)-3-(4-ethylpiperazin-1-yl)-2-(3-
fluoro-4-(trifluoromethoxy)phenyl)-
1-(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 581.3 237
##STR00335## (R)-3-(4-ethylpiperazin-1-yl)-2-(3-
fluoro-4-(trifluoromethoxy)phenyl)-
1-(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 581.3 238
##STR00336## (S)-3-(4-acetylpiperazin-1-yl)-2-(3-
fluoro-4-(trifluoromethoxy)phenyl)-
1-(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 595.3 239
##STR00337## (R)-3-(4-acetylpiperazin-1-yl)-2-(3-
fluoro-4-(trifluoromethoxy)phenyl)-
1-(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 595.3 240
##STR00338## (S)-2-(3,4-dichlorophenyl)-1-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
534.2 241 ##STR00339## (S)-2-(4-bromophenyl)-1-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one m/z 502/504
(Br isotope) [M + H]+ 242 ##STR00340##
(S)-2-(4-chloro-3-fluorophenyl)-1- (4-((5R,7S)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one m/z 476 [M + H]+ 243 ##STR00341##
(S)-2-(4-chloro-3-fluorophenyl)-3- (cyclopropylmethylamino)-1-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)propan-1-one m/z 488 [M + H]+ 244 ##STR00342##
(S)-3-(bis (cyclopropylmethyl)amino)-2-(4-
chloro-3-fluorophenyl)-1-(4- ((5R,7S)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
m/z 542 [M + H]+ 245 ##STR00343## (S)-2-(4-bromophenyl)-3-
(cyclopropylmethylamino)-1-(4- ((5R,7S)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
m/z 514/516 (Br isotope) [M + H]+ 246 ##STR00344##
(S)-2-(4-chloro-3-fluorophenyl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3-(tetrahydro-2H- pyran-4-ylamino)propan-1-one
LCMS (APCI+) m/z 518, 520 [M + H]+ 247 ##STR00345##
(S)-2-(4-chloro-3-fluorophenyl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one LCMS (APCI+) m/z 476, 478 [M + H]+ 248
##STR00346## (S)-2-(4-bromophenyl)-3-
((cyclopropylmethyl)(methyl)amino)-
1-(4-((5R,7S)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one m/z
528/530 (Br isotope) [M + H]+ 249 ##STR00347##
(S)-2-(4-chloro-3-fluorophenyl)-3- (cyclopropylmethylamino)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)propan-1-one LCMS (APCI+) m/z 488, 490 [M + H]+
250 ##STR00348## (S)-3-(cyclopropylmethylamino)-2-
(3,4-dichlorophenyl)-1-(4-((5R,7R)- 7-hydroxy-5-methyl-6,7-dihydro-
5H-cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 504.3
251 ##STR00349## (S)-1-(4-((5R,7R)-7-hydroxy-5-
methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3-(tetrahydro-2H- pyran-4-ylamino)-2-(4-
(trifluoromethoxy)phenyl) propan-1-one 550.3 252 ##STR00350##
(R)-2-(4-chlorophenyl)-3-((3S,5R)-
3,5-dimethylpiperazin-1-yl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
513.3 253 ##STR00351## (R)-2-(4-chlorophenyl)-3-((2S,6R)-
2,6-dimethylmorpholino)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
514.3 254 ##STR00352## (S)-2-(4-chlorophenyl)-3-((2S,6R)-
2,6-dimethylmorpholino)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
514.3 255 ##STR00353## (S)-2-(4-chlorophenyl)-3-((3S,5R)-
3,5-dimethylpiperazin-1-yl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
513.3 256 ##STR00354## (S)-2-(3-fluoro-4-
(trifluoromethyl)phenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-(4-
hydroxypiperidin-1-yl)propan-1-one 552.3 257 ##STR00355##
(R)-2-(3-fluoro-4- (trifluoromethyl)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- hydroxypiperidin-1-yl)propan-1-one 552.3
258 ##STR00356## (S)-2-(3-fluoro-4- (trifluoromethyl)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- methylpiperazin-1-yl)propan-1-one 551.3
259 ##STR00357## (R)-2-(3-fluoro-4- (trifluoromethyl)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- methylpiperazin-1-yl)propan-1-one 551.3
260 ##STR00358## (S)-2-(3-fluoro-4- (trifluoromethyl)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(4- isopropylpiperazin-1-yl) propan-1-one
579.3 261 ##STR00359## (R)-2-(3-fluoro-4-
(trifluoromethyl)phenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-(4-
isopropylpiperazin-1-yl) propan-1-one 579.3 262 ##STR00360##
(S)-3-(cyclopropylmethylamino)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-2-(4-
(trifluoromethoxy)phenyl) propan-1-one 520.3 263 ##STR00361##
(S)-3-amino-2-(4-bromo-3- fluorophenyl)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 480.2 264 ##STR00362##
(S)-3-amino-2-(4-bromo-3- fluorophenyl)-1-(4-((5R,7S)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 480.1 265 ##STR00363##
(S)-2-(3,4-dichlorophenyl)-1-(4- ((5R,7S)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one 492.3 266 ##STR00364##
(S)-2-(4-bromo-3-fluorophenyl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one m/z 520, 522 [M + H]+ 267 ##STR00365##
(S)-2-(4-bromo-3-fluorophenyl)-1- (4-((5R,7S)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one m/z 520, 522 [M + H]+ 268 ##STR00366##
(S)-2-(4-bromo-3-fluorophenyl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3-(tetrahydro-2H- pyran-4-ylamino)propan-1-one
m/z 562, 564 [M + H]+ 269 ##STR00367##
(S)-2-(4-bromo-3-fluorophenyl)-1- (4-((5R,7S)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3-(tetrahydro-2H- pyran-4-ylamino)propan-1-one
m/z 562, 564 [M + H]+ 270 ##STR00368##
(S)-2-(4-bromo-3-fluorophenyl)-3- (cyclopropylmethylamino)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)propan-1-one m/z 532, 534 [M + H]+ 271
##STR00369## (S)-2-(4-bromo-3-fluorophenyl)-3-
(cyclopropylmethylamino)-1-(4- ((5R,7S)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
m/z 532, 534 [M + H]+ 272 ##STR00370## (S)-2-(3-fluoro-4-
(trifluoromethyl)phenyl)-1-(4- ((5R,7S)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one 510.3 273 ##STR00371##
(S)-2-(4-bromophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-(4-
isopropylpiperazin-1-yl) propan-1-one 571.3 274 ##STR00372##
(S)-2-(4-bromophenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-(4-
hydroxypiperidin-1-yl)propan-1-one 546.2 275 ##STR00373##
(S)-3-(cyclopropylmethylamino)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-2-(4-
(trifluoromethyl)phenyl) propan-1-one 504.3 276 ##STR00374##
(S)-1-(4-((5R,7R)-7-hydroxy-5- methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-(tetrahydro-2H-
pyran-4-ylamino)-2-(4- (trifluoromethyl)phenyl) propan-1-one 534.3
277 ##STR00375## (S)-3-(cyclopropylmethylamino)-2-
(2-fluoro-4-(trifluoromethyl)phenyl)-
1-(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 522.3 278
##STR00376## (R)-2-(4-bromo-3-fluorophenyl)-1-
(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-(4-
hydroxypiperidin-1-yl) propan-1-one 562.2 279 ##STR00377##
(S)-2-(4-bromophenyl)-1-(4- ((5R,7S)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-
(isopropyl(methyl)amino) propan-1-one 518.2
280 ##STR00378## (S)-3-amino-2-(4-bromo-2-
fluorophenyl)-1-(4-((5R,7R)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 478.2 281
##STR00379## (S)-3-amino-2-(4-bromo-2-
fluorophenyl)-1-(4-((5R,7S)-7- hydroxy-5-methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 478.2 282
##STR00380## (S)-2-(4-bromophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropyl(methyl)amino) propan-1-one 443.2
283 ##STR00381## (S)-2-(4-bromo-2-fluorophenyl)-1-
(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one 520.2 284 ##STR00382##
(S)-2-(4-bromo-2-fluorophenyl)-1- (4-((5R,7S)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one 520.2 285 ##STR00383##
(S)-3-amino-2-(4-chloro-2- fluorophenyl)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 434.2 286 ##STR00384##
2-(4-chlorophenyl)-3-((3S,4R)-4- (dimethylamino)-3-fluoropiperidin-
1-yl)-1-(4-((5R,7R)-7-hydroxy-5- methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 545.3 287
##STR00385## (S)-2-(4-bromo-2-fluorophenyl)-3-
(cyclopropylmethylamino)-1-(4- ((5R,7S)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
532.2 288 ##STR00386## (S)-3-(tert-butylamino)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-2-(4- (trifluoromethyl)phenyl) propan-1-one
506.3 289 ##STR00387## (S)-2-(3-fluoro-4-
(trifluoromethoxy)phenyl)-1-(4- ((5R,7S)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
567.6 290 ##STR00388## (S)-2-(3-fluoro-4-
(trifluoromethyl)phenyl)-1-(4- ((5R,7S)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
552.3 291 ##STR00389## (S)-2-(4-chloro-2-fluorophenyl)-3-
(cyclopropylmethylamino)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
488.3 292 ##STR00390## (S)-2-(4-bromo-2-fluorophenyl)-1-
(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-(tetrahydro-2H-
pyran-4-ylamino)propan-1-one 562.2 293 ##STR00391##
(S)-2-(4-chloro-2-fluorophenyl)-1- (4-((5R,7S)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3-(tetrahydro-2H- pyran-4-ylamino)propan-1-one
518.2 294 ##STR00392## (S)-2-(4-chloro-2-fluorophenyl)-1-
(4-((5R,7R)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-(tetrahydro-2H-
pyran-4-ylamino)propan-1-one 518.3 295 ##STR00393##
(S)-1-(4-((5R,7S)-7-hydroxy-5- methyl-6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-(tetrahydro-2H-
pyran-4-ylamino)-2-(4- (trifluoromethyl)phenyl) propan-1-one 534.2
296 ##STR00394## (S)-3-(cyclopropylmethylamino)-1-
(4-((5R,7S)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-2-(4-
(trifluoromethyl)phenyl) propan-1-one 504.2 297 ##STR00395##
(S)-2-(4-bromophenyl)-3-(tert- butylamino)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one 516.2 298 ##STR00396##
(S)-2-(4-chloro-3-fluorophenyl)-1- (4-((5R,7R)-7-hydroxy-5-methyl-
6,7-dihydro-5H- cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)-3-
(isobutylamino)propan-1-one m/z 490, 492 [M + H]+ 299 ##STR00397##
(S)-2-(4-chloro-3-fluorophenyl)-3- (cyclopentylmethylamino)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)propan-1-one m/z 516, 518 [M + H]+ 300
##STR00398## (S)-2-(4-chloro-3-fluorophenyl)-3-
(cyclopentylamino)-1-(4-((5R,7R)-7-
hydroxy-5-methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)propan-1-one m/z 502, 504 [M + H]+ 301
##STR00399## (S)-2-(2-fluoro-4- (trifluoromethyl)phenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropyl(methyl)amino) propan-1-one 524.2
302 ##STR00400## (S)-2-(4-chlorophenyl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-((2- hydroxyethyl)(isopropyl)amino)
propan-1-one 502.3 303 ##STR00401## (S)-2-(2-fluoro-4-
(trifluoromethyl)phenyl)-1-(4- ((5R,7S)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one 510.2 304 ##STR00402##
(S)-2-(2-fluoro-4- (trifluoromethyl)phenyl)-1-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
552.3 305 ##STR00403## (S)-3-amino-2-(2-fluoro-4-
(trifluoromethyl)phenyl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
467.2 306 ##STR00404## (S)-3-(cyclopropylmethylamino)-2-
(3-fluoro-4-(trifluoromethyl)phenyl)-
1-(4-((5R,7S)-7-hydroxy-5-methyl- 6,7-dihydro-5H-
cyclopenta[d]pyrimidin-4- yl)piperazin-1-yl)propan-1-one 552.2 307
##STR00405## (S)-3-(cyclopropylmethylamino)- 2-(3-fluoro-4-
(trifluoromethoxy)phenyl)-1-(4- ((5R,7S)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
538.2 308 ##STR00406## (S)-2-(4-bromophenyl)-3-(4,4-
dimethylcyclohexylamino)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
572.3 309 ##STR00407## (S)-2-(4-bromophenyl)-3-(3,3-
dimethylcyclohexylamino)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
570.3 310 ##STR00408## (S)-2-(4-chlorophenyl)-3-(4,4-
dimethylcyclohexylamino)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
526.4 311 ##STR00409## (S)-2-(4-chlorophenyl)-3-(3,3-
dimethylcyclohexylamino)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
526.3 312 ##STR00410## (S)-1-(4-((5R,7R)-7-hydroxy-5-
methyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-
yl)piperazin-1-yl)-3- (isopropylamino)-2-(thiophen-2-
yl)propan-1-one 430.3 313 ##STR00411##
(S)-2-(5-bromothiophen-2-yl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one 508.2 314 ##STR00412##
(S)-2-(5-bromothiophen-2-yl)-1-(4- ((5R,7S)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)-3-
(isopropylamino)propan-1-one 508.2 315 ##STR00413##
(S)-2-(5-bromothiophen-2-yl)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
550.2 316 ##STR00414## (R)-2-(5-bromopyridin-2-yl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 503.2 317
##STR00415## (S)-2-(5-bromopyridin-2-yl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 503.2 318
##STR00416## (S)-2-(5-bromothiophen-2-yl)-1-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
550.2 319 ##STR00417## (S)-2-(5-bromothiophen-2-yl)-3-
(cyclopropylmethylamino)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
520.2 320 ##STR00418## (S)-2-(5-chlorothiophen-2-yl)-1-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
506.2 321 ##STR00419## (S)-2-(5-chlorothiophen-2-yl)-1-(4-
((5R,7S)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3- (isopropylamino)propan-1-one 464.2 322
##STR00420## (S)-2-(5-chlorothiophen-2-yl)-1-(4-
((5R,7R)-7-hydroxy-5-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-
4-yl)piperazin-1-yl)-3-(tetrahydro- 2H-pyran-4-ylamino)propan-1-one
506.2 323 ##STR00421## (S)-2-(5-chlorothiophen-2-yl)-3-
(cyclopropylmethylamino)-1-(4- ((5R,7R)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
476.2 324 ##STR00422## (S)-2-(5-chlorothiophen-2-yl)-3-
(cyclopropylmethylamino)-1-(4- ((5R,7S)-7-hydroxy-5-methyl-6,7-
dihydro-5H-cyclopenta[d]pyrimidin- 4-yl)piperazin-1-yl)propan-1-one
476.2
[0501] The foregoing description is considered as illustrative only
of the principles of the invention. Further, since numerous
modifications and changes will be readily apparent to those skilled
in the art, it is not desired to limit the invention to the exact
construction and process shown as described above. Accordingly, all
suitable modifications and equivalents may be considered to fall
within the scope of the invention as defined by the claims that
follow.
[0502] The words "comprise," "comprising," "include," "including,"
and "includes" when used in this specification and in the following
claims are intended to specify the presence of stated features,
integers, components, or steps, but they do not preclude the
presence or addition of one or more other features, integers,
components, steps, or groups.
* * * * *